The codes were arranged into 3 main themes that describe the nuanced factors involving technologies, interactions, and tasks essential for health information management and communication in the complex home care environment for older adults ( Figure 1 ; Table 2 ): (1) updating the caregiver team (binder-based health documentation, digital health documentation, and communication practices beyond the binder), (2) learning to improve care and decision-making (developing expertise as a family caregiver and tailoring expertise as a hired caregiver), and (3) conflicts within caregiver teams (2-way communication and trusting the caregiver team).
Themes and subthemes | Codes | ||||
Family caregivers | Hired caregivers | ||||
— | |||||
— | |||||
— |
a Not applicable.
Many of the codes overlapped between family and hired caregivers within the overarching themes of updating the caregiver team and learning to improve care and decision-making ( Table 2 ). There was a reliance on binder-based health documentation, which was a physical burden for some, and there was a desire for digitalizing home care information for everyone involved, while highlighting the importance of capturing holistic care information. Family and hired caregiver participants developed communication and documentation practices beyond the binder by keeping personal notes to support safer home care, managing information exchange with other caregivers via calling and texting, leaving colocated notes as reminders, and handing off information to other caregivers. They also learned from each other but had different learning needs. Their experiences diverged more prominently in their conflicts regarding information communication, coordination, and control stemming from a lack of 2-way communication, the impacts of the COVID-19 pandemic, and trust issues. The experiences relating to the similarities and differences between family and hired caregiver roles are further explained in the following subsections.
This theme captured the ways in which health information was shared between family and hired caregivers involved in the home, including their communication motivations and intentions. While all participants in this study discussed updating the caregiver team with pertinent health information about an older adult’s care, their methods and reasons for communicating information varied, depending on the context of their home care situation and their caregiving role as a family or hired caregiver.
Overall, every participant in this study described creating written notes maintained in a central location in the home; for example, a family caregiver participant documented medications and recorded details about their spouse’s reactions:
[The hired caregivers] made written notes to all the people in their company that were coming to see [my spouse]...They would have written notes that they kept on top of the refrigerator...I would keep some notes, and there were times when I would make detailed notes about [my spouse’s] reaction to the medication...I had times when I would write things down every day. [Participant 10, family caregiver]
While hired caregivers may have more structured in-home documentation, recordkeeping by family caregiver participants varied, depending on the need for tracking information. A hired caregiver participant strongly expressed the need for caregivers of older adults to maintain paper-based records in their homes:
In the home, it’s still very basic now, as much as you can roll your eyes with that...We find it’s also helpful because if every agency has their own electronic information, that’s great for keeping their records, but remember, there’s all these different people coming into the home. Sometimes you need an old-fashioned 3-ring binder to keep everybody straight. [Participant 5, hired caregiver (home care nurse)]
Paper records were seen as important for their transparency of documentation and for providing the ability to have information stored in a single location for the family caregiver, or any other caregiver, to review. However, while documenting health information was important in our participants’ complex home care environments, there was a lack of tools to support documentation; for example, family caregiver participants sometimes designed their own detailed recordkeeping forms to organize health information that others in the caregiver team were required to use for documentation and communication during caregiver handoffs:
I just do a nice log sheet and [my hired caregivers] write down if [they] take [their] meds, did you have a bowel movement, [are they] sleeping or not? I’m pretty good at creating a form. They have to fill this in, and that’s how we communicate. One person comes, 1 person leaves, and they just look at the notes. [Participant 8, family caregiver]
A hired caregiver participant expressed that they were required to record all details, such as the ones described by participant 8, during their shifts at specific time intervals. This volume of needed paper-based documentation may be one of the most time-demanding aspects for hired caregiver participants to balance with providing physical care tasks. A hired caregiver participant commented on the compounding nature of this burden with the number of clients in their care:
If you work with 10 people, you have to care for them, and you have to document whatever happens to these 10 people. That is why the PSW job is so hard. [Participant 9, hired caregiver (PSW)]
The context for which caregivers documented information varied, depending on the severity of the patient’s conditions, such as monitoring for the effects of a new medication, and the caregiver’s recordkeeping motivations. Family caregivers expressed that they were only documenting information when they felt it was necessary to share progress updates or noticeable patterns with health care professionals. Hired caregiver participants strongly believed that updating others in the caregiver team about the health of their clients, including not only their vital signs but also a holistic picture of the patient, was a critically important factor:
But what about that person? What about how they’re feeling that day? What they’re thinking that day? I get tired of reading documents that say, “changed the sheets, toileted them twice...” But how about asking them, “How do you really feel today? I don’t want to hear ‘good.’ I want to know how you really feel. What are your thoughts?” Like, really get into it and document that. None of this “oh, every day, same document” big deal. What’s the point of even documenting? [Participant 4, hired caregiver (PSW)]
The holistic information they captured may be less structured than objective measures about a client in their home, which may be more challenging to share but essential for providing quality care.
In some complex home care situations, digital methods were used to share information with other caregivers. When recordkeeping was completed and transferred digitally, this information was used to update health care professionals about changes or updates regarding the patient’s care. Other caregivers in a supervisory role on the team used this information to monitor the events during another caregiver’s shift. A hired caregiver participant who was also a nurse described a web-based system that they used to communicate with PSWs in the home:
[The online system is] between the person who’s in the home as the PSW and the delegating nurse. I can go in to see that information through our system. There’s an additional link where I can log in and see how their night was. [Participant 5, hired caregiver (home care nurse)]
The family caregiver participants in this study did not have access to, or know how to use, any potential technologies to see these details other than texting or leaving a voicemail. Systems such as the one used by participant 5 may provide opportunities for family caregivers to see health information updates without physically being in the home. Despite the lack of access, family caregiver participants who controlled the home care recordkeeping were interested in developing digital documentation methods for their caregiver team but did not know how to accomplish this:
I would like to be able to make that easier for [other caregivers]. I don’t know how, but I understand that in some institutions, they do the recordkeeping on computers. [Participant 8, family caregiver]
With limited access to technologies that can support communication to update caregivers, there was creativity beyond using physical notes kept in 1 area of the home. Caregivers sometimes implemented more prominent written notes and posted them around their client’s houses. The posted messages aimed to provide context-specific information in the locations where actions needed to be taken by other caregivers and as a salient reminder:
We posted notes all over the place. It was the only way! I put them on the bathroom wall for when [the PSWs] came in. There was one for the morning, one for the daytime, one for the evening, and it was simply, “This is what [the client] requires.” It was listed. They didn’t have to search through charts...I had so many thank-yous from PSWs that were coming in. [Participant 13, hired caregiver (home care nurse)]
These notes, which were participants 13’s highly effective method for ensuring that other caregivers could see information at the time and place that it was needed, obviated the need for calling or texting and captured the attention of the caregivers when they were providing specific care tasks. However, beyond physical documentation, the other process involved in updating the participant’s caregiver teams was verbal communication during client handoffs. The participants updated others in the caregiver team on new information to ensure their awareness about changes in their home care situation since the incoming caregiver’s last visit. A hired caregiver participant mentioned the details about which they needed to update other caregivers:
Whenever there’s someone’s turn to take over my shift, I would just say that “[They have] been okay. [They have] been very calm, but there are times that [they were] a bit manic.” Usually, I tell them that [they] already ate, that [they] already took [their] meds at this time, and I usually tell [them] that the only thing that’s missing is [their] meds for this hour. [Participant 2, hired caregiver (PSW)]
Information shared verbally supplemented the written record by providing a holistic picture of the situation and supported emphasizing time-sensitive details. Some family caregiver participants felt burdened by having to continually communicate with other caregivers about critical safety information that could have severe consequences if not applied correctly. A family caregiver mentioned their concerns with having to update new caregivers in their home on details about keeping their parent safe:
It’s reminding them stuff like [thickening their drinking water], which is a really, really big risk because my [parent] is prone to something called aspiration, which means if [they] eat any food that can go in [their] lungs, which has happened before, then that can develop into pneumonia...We’ve had to take [them] to the hospital multiple times for that, and that can be really scary because someone like [my parent], who is more vulnerable and prone to getting disease and infection. Especially, taking [them] to the hospital like now [during the COVID-19 pandemic] is pretty scary. [Participant 6, family caregiver]
There is a potential fear of future adverse events occurring because family caregivers understand the specific risks associated with their home environment. However, when in-person communication was not possible, but essential information needed to be shared with the caregiver team, the participants used telecommunication devices to provide updates via a telephone call or an SMS text message. A family caregiver participant mentioned that they would call their agency if an adverse event occurred in their home:
If it’s really important, then I’ll call the agency and tell them that [their] workers need to know that such and such is happening...like if there’s been a fall, for instance. [Participant 7, family caregiver]
There may be an expectation that information communicated to caregiver agencies over the telephone is subsequently shared with other caregivers involved with the client to ensure widespread awareness when visiting the home.
Telecommunication devices may also afford hired caregiver participants the means to have direct communication with caregivers. A hired caregiver participant highlighted the efficiency of this method of sharing information:
Especially with younger people, with younger family members, they will often text me on my work phone. That’s the most efficient way I find, I text. I call, but I find it even easier to text a lot with the visiting nurses who I talked to recently. [Participant 5, hired caregiver (home care nurse)]
However, the demographics of the caregivers, the urgency of the information that needs to be shared, time constraints, and the ease of use may be contributing factors to whether telephone calls or SMS text messages can be used as a reliable communication channel for complex home care.
This theme captured how caregivers acted on information from various sources to provide care. Family and hired caregivers in this study continually learned about their patient’s conditions and the nuances of the home care situation to improve the quality of the care they provided and support their decision-making.
The degree to which family caregivers felt the need to learn new information and develop caregiving expertise resulted from their loved one’s conditions or symptoms, as a family caregiver participant explained:
[My spouse] had delirium frequently, and [I was] trying to navigate through the delirium where you can’t deny what somebody is experiencing in a delirious state...I could never quite understand it. [Participant 10, family caregiver]
Although they did not have a medical background, there was a desire among family caregiver participants to better understand what their loved one was experiencing, despite the challenges of overcoming this knowledge gap. Navigating information often felt similar to doing their own research through reading about the condition or symptoms, learning about medical treatments, and gathering information from health care professionals:
I’ve learned that the more you can engage [individuals with Parkinson disease] intellectually and emotionally with contact, with people, and with things that they like and love, the better they are, even with their mobility. I read up on things. I learned about [my sibling’s] medications, and I know the effects of all of them, and I know the effects of that horrible [medication they were] taking that caused psychosis. I’ve got an informational sheet from some of the people who worked with us who have gone on to become RPNs [registered practical nurses] and so on. [They] gave me a whole handout on how to deal with delusional behavior, and I’ve read about it too. [Participant 8, family caregiver]
While some information that family caregivers were learning from health care professionals supported their loved ones through improved care, learning more about providing care in the home also supported their well-being, specifically for performing physical tasks. The family caregiver participant further described how they learned to help their sibling’s mobility while also supporting their own health:
I was doing things wrong for a while too. [My sibling has] mobility issues, and [they] would have difficulty getting up out of a chair. We devised a way of counting and using momentum to pull [them] up. Then I realized I’m hurting my back this way. I learned from some of the various physiotherapists and occupational therapists, and they gave us instructions. [Participant 8, family caregiver]
It is important to note that the family caregiver participants in this study were not medically trained professionals. Unlike hired caregivers, the family caregiver participants did not have a standardized knowledge base to support medical decision-making or information gathering.
The health care workers in this study highlighted the importance of their training and background in providing care; for example, a participant noted the importance of their education in recognizing a severe medical issue that could have quickly developed into sepsis, a situation in which a family caregiver might not have responded as promptly:
Well, I was doing it with the knowledge base—the preidentified wounds on [their] leg, ulcers. I knew right away, but someone that didn’t have that background wouldn’t have pushed the issue. [Participant 13, hired caregiver (home care nurse)]
A knowledge base helped participant 13 with their perception-action response to the medical issue. However, while family caregiver participants provide a significant amount of care, there may be barriers to developing perception-action responses for those without a medical background.
The health care workers in this study tailored their caregiving expertise through information acquired within the home care environment as well as information provided by family caregivers or clients. Sometimes, members of the at-home caregiver team verbally communicated this information, supporting hired caregivers who were new to the environment, to ensure that the client’s unique preferences were met, as explained by a hired caregiver participant:
I ask the ones who are already in [client 1]’s team, “What does [client 1] want to do? Whenever [client 1’s sibling] is here, I usually ask [them] what things would let [client 1] ease up [their] feelings of uneasiness or what will be their preference? [Or] you ask [the client], “You want me to do it this way or that way?” We have to be keen and diligent when it comes to [their] liking. [Participant 2, hired caregiver (PSW)]
Family caregiver participants’ importance in maintaining detailed health records was an approach to supporting all caregivers with a baseline knowledge base and enhancing their capacity to recognize potential medical issues and optimize their caregiving. Learning from physical documentation was necessary to support decision-making for hired caregiver participants who visited multiple clients daily. A hired caregiver explained how they relied on physical notes—documents that included information from the family caregiver and other hired caregivers—to learn about the most recent events that had occurred in the home and make decisions about the safest time for their client to take their medications:
I also look up their records of what happened all throughout the weekend. It’s usually placed on the table here in [my client’s] home. It’s just the first thing that you go over when you come here...You try to summarize what happened and what time [their] previous extra dose was given so that you can say, “OK, we can give [them] an extra dose at this time,” it’s safe to give [them] an extra dose. [Participant 2, hired caregiver (PSW)]
However, there remains a cognitive challenge in tailoring caregiving expertise to each home care environment to inform decisions: hired caregivers need to transform information into short summaries to support other in-home caregivers. The time required to transform the information from paper-based records may constrain busy work schedules in complex home care.
This theme captured the struggles and breakdowns in communication and coordination among caregivers, which often impacted care continuity and increased their frustration and lack of trust in each other. These conflicts stemmed from unclear roles and responsibilities as well as communication and coordination issues.
Communication challenges existed between family caregiver participants and the hired caregivers as well as between hired caregivers, their clients, and other health care professionals. Conflicts were especially evident when there was a barrier to using technologies meant to ensure that 2-way communication was occurring. This was important in situations where caregivers were required to maintain the older adult’s safety in the home. The technologies used to support communication often only provided a 1-way channel, with no feedback or confirmation of the receiving caregivers’ understanding. A hired caregiver stated as follows:
Most of the time, my frustration was with communicating with the home care and caregivers...There was no connection with me. I got to call a number and leave a voice message. I may or may not have heard back. [Participant 13, hired caregiver (home care nurse)]
Limitations in communication technologies may result in uncertainties about receiving and promptly understanding care messages. Reliable communication is critical to reduce tensions, given the number of individuals whom caregivers provide care. The challenges identified in communication among caregivers were also evident with hired and family caregivers, where conflicts emerged due to the hierarchies in caregiver teams. Perceived hierarchy issues raised frustrations for a hired caregiver, who was concerned with the effectiveness of the communication (nonstandardized information-sharing methods created stress for the caregiver team and hindered the coordination of information sharing about home care):
I was frustrated in the fact that if I identified a problem, then there needed to be only 1 person calling the doctor’s office, only 1 person calling the [agency]. They didn’t need multiple phone calls from multiple members or care providers because it was not effective. [The family caregiver] had verbally given all of these people consent for me to handle everything [but] then [they] would start calling. [Participant 13, hired caregiver (home care nurse)]
The impact of the COVID-19 pandemic meant that hired caregivers were visiting clients less frequently or performing more virtual visits, depending on the severity of health needs:
The visiting frequency really depends on their acuity now and I can see that because of COVID-19...the nursing agencies have pulled that back. Even they went to more virtual visits, which was a huge headspace change for visiting nursing agencies. [Participant 5, hired caregiver (home care nurse)]
Shifting to virtual visits would mean that physical binder-based health documents and other caregiving notes would not be readily accessible to hired caregivers. Family caregiver participants discussed the challenge of ensuring that every individual caregiver understood the nuances and preferences within their home care situation at the beginning of the COVID-19 pandemic and their responsibility to find ways to continue ensuring effective communication of their family’s needs regarding home care services:
And we’ve had some trouble with navigating that sort of thing where finding PSWs, especially at a time like now [during the COVID-19 pandemic], is pretty limited. It’s just been a little bit difficult to get them to understand our perspective and what the client needs. What my [parent] needs. [Participant 6, family caregiver]
The risk of losing a hired caregiver at the beginning of the COVID-19 pandemic, despite the communication challenges involved in having a hired caregiver care for their loved one, created more stress for family caregivers.
As a result of conflicts over ensuring that specific care needs were being met, some family caregivers felt additional responsibility to monitor the care tasks in their homes, potentially due to a lack of trust. There was an observed need to provide feedback in real time that was specific to their home, which was not always appreciated by the hired caregiver; for example, family caregivers may have lacked trust in the ability of hired caregivers to provide safe care because they did not have expert knowledge about fall risks in their specific home environment:
If I see something not right when I’m with [them] for the last half hour [of their shift], then I will say, “This is not right. You have to stand here, or [my spouse will] fall over.” That kind of thing. Some of them like it, and some of them don’t like it. [Participant 7, family caregiver]
The conflict in this context of information sharing may stem from a lack of trust in hired caregivers performing care in their home where they are not familiar with the nuances of the physical space, but the unclear power dynamic regarding who holds primary health information or acts as the lead caregiver may also play a role.
The family caregiver participant also expressed uncertainty about whether the care needs that they had communicated were being met in their absence:
I’m there for half of the shift because [my spouse] does the last half as an exercise plan, and that’s done downstairs. I see it. If there’s a problem, they’ll tell me. But the thing is, I don’t know whether they’re [watching for fall risks] when I’m not around. That’s my biggest worry. I can’t be all there all the time. It’s just not possible. [Participant 7, family caregiver]
Ultimately, the uncertainty around hired caregivers’ vigilance with regard to specific safety risks in their homes created anxieties for family caregivers, reducing respite care’s benefits due to a potential lack of trust in others in the caregiver team.
This study captured the health documentation and communication experiences of family and hired caregivers in complex home care settings. Most of the participants (13/15, 87%) in this study were women, who often experience higher caregiving burdens and stress [ 49 ], aligning with the Canadian literature and 2022 Statistics Canada data that found women to be more likely to be care providers in the home than men [ 2 , 50 ]. The results also identify the overlap in caregiving experiences among the participants regarding how they were updating the caregiver team with new information about the person receiving care and learning to improve care and decision-making through information obtained from caregivers and by other means. In addition, the results identify disparate experiences with respect to conflicts within caregiver teams when communicating health information and coordinating care responsibilities. The insights gained from this study can inform design requirements for technologies that can meet family and hired caregiver needs with respect to supporting team-based caregiving, considering the sociotechnical complexities of this work domain. Understanding caregivers’ experiences within this complex domain is essential to launch such technology development effectively [ 51 ].
Although the caregiving situations discussed in this study were complex, the participants described overlapping experiences within the first and second overarching themes and disparate experiences in the third. Technologies designed to keep caregiver teams updated and support learning and decision-making, while alleviating potential communication conflicts, could help both family and hired caregivers. A growing body of research describes the importance of including family caregivers as collaborators for home care and bridging their contributions to home care with hired caregivers [ 13 , 25 , 52 ]. Much of the current literature on home care technologies focuses on either family caregivers [ 18 - 26 ] or home care workers [ 15 - 17 ] when examining design and development. Our study builds on this work by highlighting the potential overlap in design needs and user requirements between these caregiver roles.
First, hired caregivers are often required to manually document their care delivery for the agencies that employ them. As we found in our study, some hired caregivers have access to electronic documentation systems that are not accessible to family caregivers, or they use paper-based systems to communicate information to other caregivers. Family caregivers may develop their own paper-based recordkeeping systems that they ask their caregivers to fill out, which can create a documentation burden for others in the caregiver team. Despite the need to involve family caregivers in digital technology design and the growing literature on family caregivers’ technology needs and experiences [ 18 , 19 , 22 , 23 , 25 ], caregiving documentation research focuses on hired caregivers [ 17 , 53 - 55 ], likely due to organizational and institutional requirements. Our study identifies that health information generated by family caregivers is important for safety in a home care environment, and future technologies should find accessible ways to include all caregivers to effectively communicate and share documented health information.
Second, given the communication challenges that caregivers described in this study, where family caregivers were concerned with ensuring that hired caregivers understood the nuances of how to safely care for their loved one in the context of their home, both desired to learn from caregivers and other health information. There is a need to combine the findings from the existing body of literature to build technologies that can address these systems-level needs and support coordinated care; for example, to support handoffs, potential technologies may provide value by efficiently gathering health information from users and intelligently transforming it into situational summaries through the use of large language models [ 56 ]. As it is vital to recognize family caregivers as important individuals in documenting the care of their loved one [ 57 ] and alleviate the high burdens that family and hired caregivers often face [ 58 , 59 ], automating this aspect of health information and communication could provide significant benefits to all caregivers.
Third, by examining the perspectives of family and hired caregivers and how their work intersects, our study identifies some of the ways in which established literature highlighting only a single caregiving perspective can be enhanced to support caregiver teams; for example, within our third theme regarding communication conflicts, we found examples of the lack of fundamental 2-way communication between caregivers, resulting in uncertainty about whether other caregivers received and understood the information shared, along with challenges related to understanding caregivers’ communication roles and responsibilities. Other research on family caregivers recommends that digital systems include secure messaging, customization, shared calendars, checklists, medication lists, and knowledge about the patient’s condition [ 25 ]. Our study highlights the importance of considering the work experience perspectives of family and hired caregivers working together. This suggests that technology design should include features that allow caregivers to confirm whether others in the caregiver team have understood shared health information across functionalities to reduce uncertainties in their caregiving tasks; in addition, the ability to share nuanced home environment details could foster trust within the caregiver team.
Other family caregiver–centered research recommends that IT should put the family caregiver in control [ 24 ]. While this is critical for situations led by a family caregiver, when multiple types of caregivers are involved, these technologies should consider all caregiving users’ needs [ 18 ], such as the needs of hired caregivers. Hired caregivers have a need for control over health documentation processes—likely due to their training, experiences, and their home care agency’s needs—and for setting appropriate communication boundaries with family caregivers because they often provide care for multiple people. Technology design could play an important role in hired caregivers’ relationships with family caregivers and perceived levels of control. Going forward, a design recommendation may include integrating caregiver profiles to support formalizing roles and care coordination responsibilities in the home.
As also indicated in prior work [ 17 , 18 , 23 ], there is agreement on the need to digitalize health information management and communication processes to support family and hired caregivers; yet, there are no standardized systems that support all caregivers. One of the challenges of building technologies for older adults’ home care environments identified across this study may be the reliance on paper-based records by home health care systems [ 24 ], where issues with the ease of use and ease of integration may prevent adoption over the status quo [ 21 ]. It is important to highlight that the participants in this study described how paper-based records supported health information documentation and provided an acceptable and effective method for sharing information with other caregivers. Unfortunately, paper-based records inherently lack functionality for real-time 2-way communication; may not support caregivers adapting to change in a fast-paced, dynamic home environment; and may be limited in supporting cognitive work demands across homes due to nonstandard designs [ 60 - 62 ].
As complex home care continues to evolve and family caregivers take on increasingly critical roles and responsibilities that require quick access to information and clearer communication, paper-based communication tools may not be a sufficient information management strategy [ 63 ] or a resilient technology during a pandemic. Existing research shows that digital personal health records for home care are perceived as useful in replacing a paper-based system because they keep relevant information in a single location, save physical space [ 24 , 25 , 64 ], and support information access on ubiquitous technologies such as smartphones and PCs [ 21 ]. The successful implementation of new technologies for caregivers of older adults, which would enable them to share information with others in the caregiver team without a physical documentation burden, review health information documented by others in the caregiver team to stay updated on the status of care, and reduce conflicts resulting from poor communication tools, hinges on maximizing the ease of use and satisfaction [ 21 , 53 , 65 , 66 ] and minimizing implementation burdens. More research is needed to identify technology designs and implementation strategies for complex home care that address these overarching needs to support the efficacy of care tasks, caregiver engagement, and system-level adoption among all caregivers.
To the best of our knowledge, this is one of the first studies that combines the perspectives of family and hired caregivers and their experiences regarding health information management and communication in the context of complex home care during the ongoing COVID-19 pandemic. The interview data captured rich details about the participants’ experiences and how they work with others in the caregiver team, providing insight that can guide the future development of digital technologies that support caregiving of older adults. Our findings support the need for future research to combine these work experience perspectives when developing design requirements based on user needs for complex home care.
The limitations of our study include the concentrated sample of participants from Ontario; the results may not apply to other Canadian provinces and territories or other countries. In addition, the majority of the participants (13/15, 87%) were women, and the sample size for the hired caregivers was limited. We also did not explicitly ask participants about their client’s or loved one’s specific conditions, diseases, or syndromes; however, some participants shared this information, which we have included in the Results section. One participant’s interview transcript data were unavailable for coding or presentation as anonymous quotes because they did not grant permission for their interview to be audio recorded; hence, the data were captured in detailed written notes for the analysis. While we reached code saturation in our analysis, future studies could expand on this work by recruiting caregiver team focus groups, which could contribute further insights into care coordination and communication in this complex care domain.
This study highlights the overlapping experiences of family and hired caregivers and the challenges they face when communicating health information and coordinating care responsibilities in complex home care settings. The results suggest the need for digitalized solutions that better support caregiver coordination and ease information sharing to consider how design requirements and user needs from 1 caregiving role overlap with those of other caregivers while addressing disparate communication challenges. Going forward, future research should involve the experiences of family and hired caregivers working together in the design and development of such technologies. By addressing these challenges and leveraging the insights from this study, we can improve the quality of care provided to those who need it most and support caregivers in their vital roles.
The authors are grateful for the participants’ willingness to share their experiences for this study. Partial financial support was received from Telus Health and a Natural Sciences and Engineering Research Council of Canada Collaborative Research and Development grant (CRDPJ-503484-2016). RT was also supported by the Ontario Graduate Scholarship and the University of Waterloo Alumni@Microsoft Graduate Scholarship.
The deidentified data sets generated and analyzed during this study are available from the corresponding author on reasonable request.
None declared.
personal support worker |
Edited by A Mavragani; submitted 02.10.23; peer-reviewed by A Sestino, S Oh, J Alpert; comments to author 09.03.24; revised version received 20.03.24; accepted 14.05.24; published 04.07.24.
©Ryan Tennant, Sana Allana, Kate Mercer, Catherine M Burns. Originally published in JMIR Formative Research (https://formative.jmir.org), 04.07.2024.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Formative Research, is properly cited. The complete bibliographic information, a link to the original publication on https://formative.jmir.org, as well as this copyright and license information must be included.
In today’s digital age, the opportunity to earn money from home has become increasingly accessible. With the right strategies and tools, anyone can create a steady income without leaving their home. Here are seven simple ways to make money from home in 2024, all of which are legal and legitimate.
What is cloud mining.
Cloud mining is a process where you can mine cryptocurrencies without owning or maintaining any hardware. Instead, you rent mining power from a company that operates mining farms with specialized hardware. This allows you to participate in cryptocurrency mining without the technical know-how or the upfront costs of purchasing mining equipment.
By investing in a cloud mining contract, you essentially buy a portion of the mining power provided by the mining farm. The mining profits generated from this power are then shared with you. The returns depend on factors like the cryptocurrency mined, market prices, and the efficiency of the mining operation.
GDMining is one of the world’s leading cloud mining platforms. Known for its reliability and user-friendly interface, GDMining offers a variety of mining plans to cater to different investment levels. One of the platform’s biggest advantages is offering free cloud mining contracts. Upon successful registration, each user receives a $50 bonus , which can be used to participate in free cloud mining and earn daily profits.
Freelancing is an excellent way to monetize your skills and expertise. Platforms like Upwork, Fiverr, and Freelancer connect freelancers with clients worldwide. Whether you are a writer, designer, developer, or marketer, there’s a market for your skills. The flexibility of freelancing allows you to set your rates and work hours, making it a popular choice for many.
If you have expertise in a particular subject, online tutoring can be a rewarding way to earn money. Websites like VIPKid, Chegg Tutors, and Tutor.com offer platforms where you can teach students of all ages. This can be particularly lucrative for subjects like math, science, and languages.
Platforms like Etsy provide a marketplace for selling handmade goods. Whether you create jewelry, crafts, clothing, or art, you can reach a global audience. The key to success on platforms like Etsy is to offer unique, high-quality products and excellent customer service.
Dropshipping is an e-commerce model that allows you to sell products without holding any inventory. You set up an online store, list products from suppliers, and when an order is placed, the supplier ships the product directly to the customer. This method minimizes risk and investment, making it a popular choice for entrepreneurs. Shopify and WooCommerce are excellent platforms to start your dropshipping business.
Creating content for platforms like YouTube, TikTok, and Instagram can be highly profitable. By building a substantial following, you can earn money through ad revenue, sponsorships, and merchandise sales. Consistency and creativity are key to growing your audience and monetizing your content.
Participating in online surveys and market research can be an easy way to make some extra cash. Websites like Swagbucks, Survey Junkie, and Vindale Research pay users for their opinions on various products and services. While this won’t make you rich, it’s a simple way to earn money in your spare time.
Earning money from home has never been easier with the array of opportunities available today. Whether through cloud mining with GDMining , freelancing, online tutoring, or any of the other methods listed, you can find a way to generate income that suits your skills and lifestyle. The key is to start with a reliable and legitimate platform, be consistent, and keep exploring new opportunities.
Disclaimer: The views and opinions presented in this article do not necessarily reflect the views of CoinCheckup. The content of this article should not be considered as investment advice. Always do your own research before deciding to buy, sell or transfer any crypto assets. Past returns do not always guarantee future profits.
Next post meme mania: mbappé’s euros performance sparks a surge in mpeppe (mpepe), related posts.
Trading and investing in digital assets is highly speculative and comes with many risks. The analysis / stats / articles on CoinCheckup.com are for informational purposes and should not be considered investment advice. Statements and financial information on CoinCheckup.com should not be construed as an endorsement or recommendation to buy, sell or hold. Please do your own research on all of your investments carefully. Scores are based on common sense Formulas that we personally use to analyse crypto coins & tokens. We’ll open source these formulas soon. Past performance is not necessarily indicative of future results. Read the full disclaimer here . Over here you’ll find our privacy policy and cookies policy .
Published on 4.7.2024 in Vol 26 (2024)
Authors of this article:
1 School of Nursing, Johns Hopkins University, Baltimore, MD, United States
2 College of Nursing, Suwon Women's University, Suwon, Republic of Korea
3 College of Nursing, Mo-Im Kim Nursing Research Institute, Yonsei University, Seoul, Republic of Korea
4 School of Nursing, Yale University, Orange, CT, United States
5 Department of Surgery, College of Medicine, Yonsei University, Seoul, Republic of Korea
6 College of Nursing, Mo-Im Kim Nursing Research Institute, Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Republic of Korea
JiYeon Choi, PhD
College of Nursing, Mo-Im Kim Nursing Research Institute, Institute for Innovation in Digital Healthcare, Yonsei University
50-1 Yonsei-ro, Seodaemun-gu
Seoul, 03722
Republic of Korea
Phone: 82 2 2228 3301
Fax:82 2 2227 8303
Email: [email protected]
Background: Liver transplantation has become increasingly common as a last-resort treatment for end-stage liver diseases and liver cancer, with continually improving success rates and long-term survival rates. Nevertheless, liver transplant recipients face lifelong challenges in self-management, including immunosuppressant therapy, lifestyle adjustments, and navigating complex health care systems. eHealth technologies hold the potential to aid and optimize self-management outcomes, but their adoption has been slow in this population due to the complexity of post–liver transplant management.
Objective: This study aims to examine the use of eHealth technologies in supporting self-management for liver transplant recipients and identify their benefits and challenges to suggest areas for further research.
Methods: Following the Arksey and O’Malley methodology for scoping reviews, we conducted a systematic search of 5 electronic databases: PubMed, CINAHL, Embase, PsycINFO, and Web of Science. We included studies that (1) examined or implemented eHealth-based self-management, (2) included liver transplant recipients aged ≥18 years, and (3) were published in a peer-reviewed journal. We excluded studies that (1) were case reports, conference abstracts, editorials, or letters; (2) did not focus on the posttransplantation phase; (3) did not focus on self-management; and (4) did not incorporate the concept of eHealth or used technology solely for data collection. The quality of the selected eHealth interventions was evaluated using (1) the Template for Intervention Description and Replication guidelines and checklist and (2) the 5 core self-management skills identified by Lorig and Holman.
Results: Of 1461 articles, 15 (1.03%) studies were included in the final analysis. Our findings indicate that eHealth-based self-management strategies for adult liver transplant recipients primarily address lifestyle management, medication adherence, and remote monitoring, highlighting a notable gap in alcohol relapse interventions. The studies used diverse technologies, including mobile apps, videoconferencing, and telehealth platforms, but showed limited integration of decision-making or resource use skills essential for comprehensive self-management. The reviewed studies highlighted the potential of eHealth in enhancing individualized health care, but only a few included collaborative features such as 2-way communication or tailored goal setting. While adherence and feasibility were generally high in many interventions, their effectiveness varied due to diverse methodologies and outcome measures.
Conclusions: This scoping review maps the current literature on eHealth-based self-management support for liver transplant recipients, assessing its potential and challenges. Future studies should focus on developing predictive models and personalized eHealth interventions rooted in patient-generated data, incorporating digital human-to-human interactions to effectively address the complex needs of liver transplant recipients. This review emphasizes the need for future eHealth self-management research to address the digital divide, especially with the aging liver transplant recipient population, and ensure more inclusive studies across diverse ethnicities and regions.
As the last treatment resort for individuals with end-stage liver diseases or liver cancer [ 1 ], liver transplantation (LT) has become one of the fastest-growing solid organ transplant procedures worldwide. Since its first case in 1963, LT has evolved into a more viable treatment option for those living with end-stage liver conditions. In the United States, >9000 individuals receive LTs annually [ 2 ]. In South Korea, the number of LT cases increased from 1066 in 2010 to 1515 in 2021 [ 3 ]. Over the past decades, there has been notable progress in the success of LT surgery and long-term survival rates [ 4 ]. In the United States, the 1-year survival rate reached 89%, and the 5-year survival rate is >74%, although variations exist depending on donor types, underlying diagnoses, recipient age, and region [ 5 ].
Despite the improving trend of posttransplant survival, optimizing the benefits of LT remains a complex and challenging issue for LT recipients. Research on post-LT outcomes to date has primarily focused on graft function and overall survival, corresponding to rapidly advancing surgical techniques and drug development [ 6 ]. Relatively little attention has been paid to promoting posttransplant self-management and its impact on long-term quality of life (QOL) [ 7 ]. After transplant, LT recipients must manage risks of complications, such as intestinal adhesion, bleeding, and bile leakages, and maintain a balance between graft failure risks and the side effects of immunosuppressant therapy, which often necessitate frequent dosage changes [ 8 , 9 ]. Additional lifelong challenges include management of common side effects of immunosuppressant therapy, such as hyperlipidemia, high blood pressure, chronic kidney failure, obesity, diabetes, and infection [ 10 , 11 ].
To address these challenges and maximize the benefits of LT, vigilant posttransplant self-management is crucial. Self-management has been defined in the literature as a comprehensive process that encompasses focusing on one’s illness needs (eg, acquiring knowledge and skills, monitoring symptoms, problem-solving, and decision-making), using available resources, building partnerships with health care providers (HCPs), and integrating illness management into daily life [ 12 - 14 ]. For LT recipients, major self-management issues include symptom monitoring, medication management, and engaging in healthy lifestyles after transplant [ 15 - 17 ]. Furthermore, LT recipients must navigate complex health care systems, face changes in social roles, and cope with uncertainty and mental distress associated with the ever-present risk of graft rejection [ 18 ]. During the COVID-19 pandemic, with reduced human contact support and the strained health care systems reallocating resources, self-management became more challenging for immunocompromised individuals such as LT recipients [ 19 ]. However, the increased accessibility to the internet and digital devices, coupled with the challenges posed by the pandemic, has rapidly escalated interest in interventions using the internet to promote or manage health (eHealth). These technologies hold the potential to overcome challenges related to resource allocation, geographical accessibility, and health care cost.
eHealth, defined as the use of the internet and communication technologies to deliver and improve health care services [ 20 ], has been rapidly expanding to promote self-management in acute and chronic conditions [ 21 - 23 ]. However, the application of eHealth for LT recipients has been relatively slow due to the complexity of LT management, the need for close physical examinations, and the importance of building rapport with HCPs for lifelong posttransplant care [ 24 ]. Although there have been studies investigating the application of eHealth among solid organ transplant recipients [ 25 , 26 ], to date, no review has specifically focused on eHealth for self-management support in LT recipients. Therefore, this study aimed to map the current state of the literature on self-management using eHealth technologies for LT recipients and assess their benefits and challenges to suggest areas needing further investigation in the field.
This review aimed to examine the current literature on eHealth-based self-management among adult LT recipients and its associated factors by addressing the following questions: (1) what are the characteristics and associated factors of eHealth strategies in the adult LT recipient population? (2) how effective and feasible are eHealth-based self-management interventions after LT? and (3) what are the future potential and challenges of eHealth in facilitating self-management among this population? By mapping the existing literature through this scoping review, we aimed to identify gaps and propose future directions for the development and application of eHealth-based self-management interventions for adult LT recipients.
We conducted a scoping review based on the 6-stage scoping review framework by Arksey and O’Malley [ 27 ]. This methodology was chosen to examine the breadth and depth of knowledge in an emerging field of research. We used the population, concept, and context criteria to devise the research question for this review: adult LT recipients (population), eHealth (concept), and facilitating self-management (context) [ 28 ]. Given that previous studies on self-management among LT recipients have primarily concentrated on medication adherence, alcohol recidivism, and healthy lifestyle maintenance [ 15 ], our review specifically focused on these areas of self-management.
The search and screening procedure of this scoping review adhered to the guidelines provided by the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) checklist. We systematically searched 5 electronic databases: PubMed, CINAHL, Embase, PsycINFO, and Web of Science. The search terms comprised a combination of the following: adult LTR , e-Health , and self-management . Our concept of eHealth encompasses a range of technology, including telehealth and internet-, computer-, or mobile-based health, and strategies using video, audio, SMS text messaging, wearables, and virtual reality. To conduct the search on self-management, we included and modified terms such as alcohol , nutrition , exercise , physical activity , medication , medication adherence , self-care , self-management , and health behavior . Our search spanned inception to June 19, 2023, without any restrictions on specific study design. We validated our search strategies through consultation with a university librarian and present the detailed search strategies in Multimedia Appendix 1 .
Articles were included if they were studies that (1) examined or implemented eHealth-based self-management, (2) included LT recipients aged ≥18 years, and (3) were published in a peer-reviewed journal. We excluded studies that (1) were case reports, conference abstracts, editorials, or letters; (2) did not focus on the posttransplantation phase; (3) did not focus on self-management; and (4) did not incorporate the concept of eHealth or solely used technology for the purpose of data collection. We also considered studies that targeted various solid organ transplant recipients provided they included adult LT recipients. Our review specifically targeted adult patients in the post-LT phase as LT in children often involves dissimilar underlying conditions for transplant, such as biliary atresia [ 29 ], and post-LT self-management in pediatric patients may present additional challenges related to life stage development.
A total of 1460 articles were identified. After removing duplicates (51/1460, 3.49%), 1409 articles were imported to Microsoft Excel (Microsoft Corp) for screening using the inclusion and exclusion criteria. First, 2 authors (SHK and HK) independently screened the titles and excluded 95.95% (1352/1409) of the articles, which did not include LT recipients or were not about eHealth or self-management (eg, drug trials and surgery). This yielded 57 articles. In the second stage, 2 authors independently reviewed the abstracts of the 57 articles. Finally, a full-text review was conducted on 42% (24/57) of the articles. The references of the selected articles were manually examined to search for additional articles that could be eligible for this review. Consequently, 1 article was added through the manual search. A total of 15 articles were included in the final sample. The whole process was supervised by the corresponding author, and disagreements between authors were discussed in research team meetings until a consensus was reached. Figure 1 illustrates the PRISMA flow diagram.
Due to the heterogeneity of the interventions and measured outcomes, a meta-analysis or meta-synthesis of the results was not feasible. Instead, we presented the organized data in tables, which include the summaries of the descriptive and intervention studies and a detailed summarization of the interventions.
The following information was extracted using data-charting forms: first author’s last name, publication year, country, study design, sample characteristics (sample size, average age, percentage of male individuals, and time since transplant), type of technology, variables with measures, and outcomes. For intervention studies, we analyzed the details of the intervention and control groups and extracted the following characteristics of the interventions: duration, providers, adherence, adverse events, and reasons for attrition.
We also evaluated the quality of the interventions reported in these studies using the Template for Intervention Description and Replication (TIDieR) checklist and guide [ 30 ]. The TIDieR checklist and guide address the items of interventions that need to be thoroughly described to enhance the replicability of trials and facilitate the appraisal of intervention reporting. To gauge the comprehensiveness of intervention content, we analyzed whether the interventions addressed the 5 core self-management skills identified by Lorig and Holman [ 14 ]. These core skills, which include problem-solving, decision-making, using resources, partnering with HCPs, and taking action, have been considered as fundamental elements of self-management in the literature that examines the definitions, components, and processes of self-management [ 12 , 13 , 31 , 32 ].
No ethics approval was required for this scoping review as published articles rather than primary data were used in the analysis.
The general characteristics of the 5 descriptive studies and 10 intervention studies are summarized in Tables 1 - 4 . Of the 5 descriptive studies, 2 (40%) were qualitative and 3 (60%) were quantitative studies. Of the 10 intervention studies, 4 (40%) were randomized controlled trials (RCTs), 4 (40%) were prospective observational studies with cohorts, 1 (10%) was a study with a historical control group, and 1 (10%) was a single-group qualitative evaluation of a feasibility study. A total of 67% (10/15) of the studies were published in 2020 or later, with all studies (15/15, 100%) being published after 2016. Most studies were conducted in North America (7/15, 47% in the United States and 1/15, 7% in Canada) and Europe (1/15, 7% in Austria; 2/15, 13% in Belgium; and 1/15, 7% in Spain). The sample sizes of the selected studies varied, ranging from 19 to 710 participants, with the average age of the participants ranging from 46 to 63 years.
Study | Year | Country | Study design | Sample size | Age (y) | Sex (male; %) | Time since transplant |
Lieber et al [ ] | 2021 | United States | Qualitative study | 20 | Median 61 | 65 | Not reported |
Maroney et al [ ] | 2021 | United States | Quantitative survey | 178 KTRs and 110 LTRs | Mean 52.6 | 54.5 | 46.88% between 1 and 2 years after transplant |
Mathur et al [ ] | 2021 | Canada | Qualitative study | 5 LTRs out of 21 SOTs | Mean 47 | 48 | 2 years to 8 years |
Vanhoof et al [ ] | 2018 | Belgium | Cross-sectional descriptive study | 30 LTRs out of 122 SOTs | Mean 55.9 | 57.4 | Median 6 years |
Wedd et al [ ] | 2019 | United States | Cross-sectional descriptive study | 455 KTRs and 255 LTRs | Median 49 (KTRs) and 53 (LTRs) | 55.2 (KTRs) and 59.6 (LTRs) | 6 months before transplant to 2 years after transplant (study period) |
a KTR: kidney transplant recipient.
b LTR: liver transplant recipient.
c SOT: solid organ transplant.
Study | Type of technology | Variable (measure) | Outcome |
Lieber et al [ ] | App | recipients and HCPs , gain educational information and support medication taking, and log biometric data. | |
Maroney et al [ ] | Patient portal (internet or smartphone) | | >LTRs ( =.04) <.001) =.04) <.001). |
Mathur et al [ ] | Digital health tools | | population. |
Vanhoof et al [ ] | IHT | | |
Wedd et al [ ] | Patient portal (internet) | =.003); college education or higher>high school education or lower ( <.001) |
a LT: liver transplant.
b HCP: health care provider.
c eHEALS: eHealth Literacy Scale.
d KTR: kidney transplant recipient.
e LTR: liver transplant recipient.
f PA: physical activity.
g SOT: solid organ transplant.
h IHT: interactive health technology.
i ICT: information and communications technology.
Study | Year | Country | Study design | Sample size, n | Age (y) | Sex (male; %) | Time since transplant |
Barnett et al [ ] | 2021 | Australia | Qualitative evaluation of a feasibility study | 19 | Mean 52 | 63 | Median 4.4 years |
Hickman et al [ ] | 2021 | Australia | RCT with delayed intervention control | IG : 23; CG : 12 | IG: mean 51; CG: mean 50 | IG: 65; CG: 83 | Median 4 years (IG) and 3 years (CG) |
Ertel et al [ ] | 2016 | United States | Prospective observational study | IG: 20; CG: 20 | Mean 56 | 80 | Not reported |
Koc et al [ ] | 2022 | Belgium | Prospective cohort study | Autonomous IG: 39; nonautonomous IG: 48; CG: 28 | Median 59.1 (autonomous IG); 67.2 (nonautonomous IG); 66.0 (CG) | 61.5 (autonomous IG); 60.4 (nonautonomous IG); 50 (CG) | Median 6.4 years (autonomous IG); 7.4 (nonautonomous IG); 7.0 (CG) |
Lee et al [ ] | 2019 | United States | RCT | IG: 50; CG: 50 | IG: median 60; CG: median 58.5 | IG: 52; CG: 60 | Not reported |
Tian et al [ ] | 2021 | China | RCT | IG: 52; CG: 50 | Mean 46.65 | 70.6 | Not reported |
Andrä et al [ ] | 2022 | Austria | Prospective cohort study | 124 (IG: 42) | Mean 63.2 (IG: mean 55.4) | 74.1 | Mean 6.5 years |
Melilli et al [ ] | 2021 | Spain | Prospective observational trial | 84 KTRs and 6 LTRs | Mean 46 | 73 | Mean 69 months |
Serper et al [ ] | 2020 | United States | RCT | 61 KTRs and 66 LTRs | Mean 52 | 64 | Median 9.5 months |
Zanetti-Yabur et al [ ] | 2017 | United States | Prospective cohort study | 67 KTRs and 7 LTRs (IG: 21; CG: 53) | IG: mean 52.6; CG: mean 54.1 | 60.8 | Not reported |
a RCT: randomized controlled trial.
b IG: intervention group.
c CG: control group.
Study | Intervention | Control | Measurement timeline | Variable (measure) | Outcome |
Barnett et al [ ] | Telehealth-delivered diet and exercise program | — | After the intervention (at 12 weeks) | ||
Hickman et al [ ] | Telehealth-delivered lifestyle intervention | Delayed intervention control (12-24 weeks) | and 24 weeks in CG ) | : SF-12 | =.004) : IG>CG ( =.03); increase in IG after the intervention ( =.03) =.01) |
Ertel et al [ ] | Educational video program and telehealth monitoring of vital statistics using Bluetooth peripheral | Standard care (historic control) | |||
Koc et al [ ] | Telemedicine-based remote monitoring program | Standard follow-up | , and satisfactory score | <.001) <.001 and =.003 for the autonomous and nonautonomous IG, respectively) =.04 and =.002 for the autonomous and nonautonomous IG, respectively). | |
Lee et al [ ] | THMP | Standard care | | =.004) =.02); general health increase in IG ( =.05) | |
Tian et al [ ] | Telemedicine-based follow-up management | Usual care | =.03 and =.049, respectively). =.02) =.65) | ||
Andrä et al [ ] | Medication tracking and healthy lifestyle management app | — | |||
Melilli et al [ ] | App to monitor immunosuppressant adherence, classified into regular users, random users, and nonusers | — | . of >30%. | ||
Serper et al [ ] | Home-based exercise program using wearable devices, health engagement questions, and loss-framed financial incentives | CG arm 1: standard instructions regarding healthy diet and physical activity; CG arm 2: accelerometer without financial incentives | <.001). =.001). | ||
Zanetti-Yabur et al [ ] | Mobile app with medication-taking alarm system | Non–app users | | =.006). =.19). |
a Not applicable.
d MEDAS: Mediterranean Diet Adherence Screener.
e QOL: quality of life.
f SF-12: 12-item Short Form Health Survey.
g MetSSS: Metabolic Syndrome Severity Score.
h MCS-12: Mental Component Summary–12 (vitality, social functioning, role limitations due to emotional health, and mental health).
i CDSS: clinical decision support system.
j THMP: telemedicine-based home management program.
k SF-36: 36-item Short Form Health Survey.
l LTR: liver transplant recipient.
m CV: intrapatient variability.
n BMQ: Beliefs About Medicines Questionnaire.
o MMAS-8: Morisky Medication Adherence Scale-8.
p IAT: immunosuppression assessment test.
Tables 5 and 6 summarize the details of the interventions reported in the selected studies. The most frequently addressed aspect of self-management was lifestyle education (6/10, 60%). Other topics of the interventions, allowing for overlap, included telemedicine-based remote monitoring (4/10, 40%) and medication management (3/10, 30%). The technological methods to deliver the interventions varied, including mobile apps (4/10, 40%; one of which included a wearable app), a 2-way videoconference portal (3/10, 30%), a web-based platform (1/10, 10%), Bluetooth peripherals (2/10, 20%), and a robot (1/10, 10%). The duration of the interventions ranged from short term (2 weeks after transplantation) to long term (up to 2 years after transplantation), with most (6/10, 60%) lasting 12 weeks.
Among the 6 studies that involved lifestyle interventions, 3 (50%) used synchronous video streaming to deliver exercise or diet educational sessions [ 38 , 39 , 43 ]. A total of 33% (2/6) of the studies offered mobile apps, with 17% (1/6) of the studies encompassing both lifestyle education and medication management [ 44 ]. The latter study provided information on self-management issues and allowed patients to self-document in a patient diary [ 44 ]. Another study provided a wearable accelerometer app, which was paired with financial incentives and questions regarding health engagement available on a patient portal [ 46 ]. A total of 40% (4/10) of the studies used telehealth to remotely monitor recipients’ vital signs and blood glucose levels [ 40 , 42 , 43 ] and conduct postoperative management regarding medication, gastrointestinal function, wound care, and laboratory test results [ 41 - 43 ]. For remote monitoring via telehealth, daily vital signs were collected using Bluetooth devices [ 40 , 42 ] or a robot [ 43 ].
In terms of medication management, 30% (3/10) of the studies used mobile app interventions that emphasized scheduled immunosuppressant intake [ 44 , 45 , 47 ]. These interventions used methods such as QR codes, reminder systems, and access to various resources (eg, medication and dose converter, medication lists) to facilitate medication adherence. In addition, 10% (1/10) of the studies, which delivered a telemedicine-based remote program, also monitored laboratory test results using an alarm system of predefined thresholds [ 41 ].
Type of technology and study | Focus of self-management | Collaboration | Personalization | Adherence | |||||
Barnett et al [ ] | Lifestyle management (diet and exercise education) | 2-way videoconference portal | Exercise sessions were tailored to individual needs, capabilities, and preference for supervision. | ||||||
Hickman et al [ ] | Lifestyle management (diet and exercise education) | 2-way videoconference portal | Participants received up to 3 SMS text messages between sessions based on preference. At the end of the exercise sessions, participants received advice with personal prescriptions | ||||||
Ertel et al [ ] | Lifestyle education (posttransplant management) and remote monitoring (vital signs) | Not described | Not described | ||||||
Koc et al [ ] | Remote monitoring (laboratory test result management) | Not described | Not described | entered 1526 (90.9%) of the 1679 required data items. and switched to the nonautonomous group but still communicated with the nurse. | |||||
Lee et al [ ] | Remote monitoring (vital sign management, posttransplantation education, and communication) | Video communication and phone calls were available. | Not described | ||||||
Tian et al [ ] | Remote monitoring (vital sign and posttransplantation management and communication) and lifestyle management (exercise) | Synchronous and asynchronous communication was available via robot, which was controlled by specialists via computer, phone, or iPad. | Not described | ||||||
Andrä et al [ ] | Lifestyle management and medication management | No direct connection with physicians | Not described | ||||||
Melilli et al [ ] | Medication management | Not described | Not described | ||||||
Serper et al [ ] | Lifestyle management (exercise) | Questions and answers related to health engagement were exchanged through bidirectional SMS text messaging. | Biweekly walking goals were tailored to their baseline based on the mean steps. | ||||||
Zanetti-Yabur et al [ ] | Medication management | Not described | Not described |
a IG: intervention group.
b CDSS: clinical decision support system.
Type of technology and study | Adverse events | Reasons for attrition | Duration | Provider | TIDieR checklist score (1-12) | |
Barnett et al [ ] | Not reported | — | 12 weeks | Dietitians and exercise physiologists | 10 | |
Hickman et al [ ] | None | 12 weeks | Dietitian and exercise physiologist | 10 | ||
Ertel et al [ ] | Not reported | — | Perioperative period education until 90 days after discharge and telemonitoring after discharge | Unspecified health care providers | 8 | |
Koc et al [ ] | Not reported | — | Median follow-up 2.0 years in the autonomous IG , 2.1 years in the nonautonomous IG, and 2.4 years in the CG | Physicians and specialized nurses | 9 | |
Lee et al [ ] | Not reported | 3 months (daily monitoring) | Nurse care coordinators and providers | 10 | ||
Tian et al [ ] | Not reported | 2 weeks | Transplant specialists | 9 | ||
Andrä et al [ ] | Not reported | — | 2 months | Unspecified health care providers | 7 | |
Melilli et al [ ] | Not reported | 12 months | Physicians | 9 | ||
Serper et al [ ] | None | 2-week run-in period and 16 weeks of intervention | Unspecified health care providers | 9 | ||
Zanetti-Yabur et al [ ] | Not reported | — | 3 months | Unspecified health care providers | 6 |
a TIDieR: Template for Intervention Description and Replication.
b Not applicable.
c IG: intervention group.
d CG: control group.
On the basis of the TIDieR guide, the included intervention studies’ scores ranged from 6 to 10 ( Tables 5 and 6 ). Detailed scores for each criterion can be found in Multimedia Appendix 2 [ 38 - 47 ]. All studies described the content and procedure of interventions, the type of technology used, and the locations where they were implemented. Of the 10 studies, 7 (70%) reported the duration and doses of the interventions, and 6 (60%) included the providers of the interventions. Personalized interventions were delivered to participants in 30% (3/10) of the studies. A total of 30% (3/10) of the studies included strategies or assessments to improve intervention fidelity, whereas 70% (7/10) of the studies monitored the adherence and fidelity of the delivered interventions. No intervention study reported any unforeseen changes in the interventions during the study process.
Table 7 shows how the selected interventions addressed the 5 core self-management skills identified by Lorig and Holman [ 14 ]. Of the 10 interventions, 4 (40%) included training in all 5 self-management skills. The number of core skills included in other studies ranged from 1 to 3. Taking action was a component in all interventions (10/10, 100%). Partnering with health care providers was featured in 80% (8/10) of the interventions, whereas Problem-solving was included in 70% (7/10) of the interventions. Decision-making was part of 60% (6/10) of the interventions, and Using resources was the least included, addressed in 50% (5/10) of the interventions.
Study | Problem-solving | Decision-making | Using resources | Partnering with health care providers | Taking action |
Barnett et al [ ] | ● | ● | ● | ● | ● |
Hickman et al [ ] | ● | ● | ● | ● | ● |
Ertel et al [ ] | ● | ● | ● | ● | ● |
Koc et al [ ] | ○ | ○ | ○ | ● | ● |
Lee et al [ ] | ● | ● | ○ | ● | ● |
Tian et al [ ] | ● | ● | ○ | ● | ● |
Andrä et al [ ] | ◐ | ◐ | ● | ◐ | ● |
Melilli et al [ ] | ● | ○ | ○ | ● | ● |
Serper et al [ ] | ● | ● | ● | ● | ● |
Zanetti-Yabur et al [ ] | ○ | ○ | ○ | ○ | ● |
a Reported.
b Not reported.
The use of and preferences regarding eHealth technologies were the most commonly examined outcomes in the descriptive studies. Study results concerning the use of technologies and its correlation with educational level and age varied. In the qualitative study by Lieber et al [ 33 ], 90% of the 20-person LT recipient sample reported using smartphones. In contrast, in the study by Vanhoof et al [ 36 ], only 27.9% of 122 solid organ transplant recipients owned a smartphone despite >70% having access to a computer with internet connection.
Concerning educational characteristics, 40% (2/5) of the studies found that individuals with college-level education or higher demonstrated greater eHealth literacy and more frequent use of the web patient portal than those with a high school education or lower [ 34 , 37 ]. Conversely, the study by Vanhoof et al [ 36 ] indicated that the group with a college education and higher had lower technology acceptance than those with a high school education or lower. Regarding age, younger patients had higher eHealth literacy in one study [ 34 ]. Another study found that those with previous experience using health apps, as well as those who tried the new app, had a younger average age than that of the entire cohort [ 44 ]. However, age was not a substantial factor in the willingness to use health technologies or patient portals in another 40% (2/5) of the studies [ 36 , 37 ]. Previous or routine use of health technologies was associated with higher eHealth literacy [ 34 ] and greater technology acceptance [ 36 ].
Moreover, 40% (2/5) of the studies highlighted that patients currently used smartphones or patient portals for reminders to take medications or to view laboratory test results. However, their preferences for future eHealth technologies extended beyond these uses. They expressed interest in connecting through web-based platforms with peer recipients and HCPs and gaining access to additional supportive features that included educational resources, medication management tools, and reward systems that consider affordability [ 33 , 35 ].
The most frequently measured outcomes in the intervention studies were adherence to the intervention and feasibility. A total of 80% (8/10) of the studies reported intervention adherence using various methods, including session attendance, device use frequency, response rate, and monitoring rate [ 38 - 42 , 44 - 46 ]. In 62% (5/8) of these studies, the overall adherence rate was >70% despite variability in measures [ 32 , 40 - 42 , 46 ]. Feasibility was measured using various methods, including qualitative interviews; recruitment rates; attendance rates; initiation and continuation rates; and reported levels of adequacy, confidence, effectiveness, or satisfaction [ 38 - 41 ]. Although rates of recruitment, attendance, initiation, and continuation varied between studies, the interventions were generally well received. Participant-reported satisfactory scores were >80% in 20% (2/10) of the studies [ 40 , 41 ], and participant-reported adequacy, confidence, and effectiveness levels were >90% in 30% (3/10) of the studies [ 39 - 41 ]. In a qualitative study, participants expressed that perceived burdens of face-to-face care were reduced regarding travel, time, or pressure and that confidence level in exercise increased due to tailored and self-directed telehealth education sessions [ 38 ].
A total of 4 studies involving telemedicine-based remote monitoring included 30- or 90-day readmission rates (n=3, 75%) and QOL (n=2, 50%) as outcomes. Regarding readmission rates, all studies reported a decrease in readmission rates after the interventions, 20% (2/10) of which were RCTs that reported a significant reduction in readmission rates [ 40 , 42 , 43 ]. A total of 20% (2/10) of the studies reported improvement in varying components of QOL, such as mental and physical function and general health [ 39 , 42 ].
Due to the heterogeneity of the interventions, various clinical outcomes were measured, such as dietary or medication adherence, weight change, level of metabolic syndrome, and tacrolimus drug level. Among the studies that incorporated mobile app interventions for medication management, the study by Melilli et al [ 45 ] reported that correct dose intakes on schedule occurred 69% to 76% of the time among the regular users of the delivered mobile app, whereas the study by Zanetti-Yabur et al [ 47 ] reported no difference in medication adherence on a validated scale between the intervention and control groups. Positive results on dietary adherence and metabolic syndrome were reported on a telehealth-delivered diet and exercise education program [ 38 , 39 ], but there was no significant change in weight after a home-based exercise program using a wearable accelerometer [ 46 ]. In a study incorporating remote monitoring focused on laboratory test results, tacrolimus level determinations were higher and blood level concentrations remained lower in the intervention group [ 41 ]. Regarding the reporting of adverse events, most studies (8/10, 80%) did not provide specific descriptions. However, 20% (2/10) of the studies reported no adverse events during the intervention period [ 39 , 46 ].
In this scoping review, we investigated the breadth of application and associated factors of eHealth-based self-management strategies in adult LT recipients. While previous literature on self-management among LT recipients has primarily focused on medication adherence, alcohol abstinence, and health maintenance (eg, smoking cessation, vaccination, and health screening) [ 15 ], the eHealth-based self-management studies in our review predominantly covered lifestyle management, medication adherence, and remote monitoring. Given the heterogeneity of the interventions and study measures, we assessed outcomes by describing trends, consistencies, or discrepancies among studies reporting similar outcomes. Although significant effects on reducing readmission rates or improving QOL were observed, synthesizing quantitative outcomes was not feasible due to a small number of RCTs. However, based on outcomes measured in various ways and participants’ qualitative reports, the interventions were well received, with generally high levels of feasibility, adherence, and satisfaction. The lifestyle management interventions used various modes of delivery, such as videoconferencing, web-based prerecorded videos, mobile apps, and patient portals. Remote monitoring was facilitated through a range of telehealth platforms, whereas interventions for medication adherence mainly used mobile apps. Notably, our review found that none of the eHealth-based self-management studies addressed the topic of prevention and management of alcohol relapse, a well-known concern among LT recipients [ 48 ].
Compared to intervention studies focusing on lifestyle management, the intervention studies focusing on medication adherence included relatively basic features, such as alarm reminders and logs for tracking medication intake. While these features target the action of medication taking, they fall short in promoting other essential skills such as decision-making or effective resource use to improve adherence to immunosuppressants. Given the complexity and variety of self-management behaviors required for LT recipients, eHealth technologies should be designed to support them in navigating multiple concurrent problematic situations to integrate disease management into their daily lives [ 15 ]. This objective extends beyond ensuring compliance with self-management behaviors and requires strategies to improve the self-efficacy of LT recipients and foster self-tailoring strategies [ 14 ]. This involves integrating their values, preferences, and readiness to increase motivation and confidence while also considering the various challenging scenarios that these LT recipients face, such as managing multiple medications due to comorbidities, coping with side effects, and handling varying schedules [ 9 ]. In interventions focused on lifestyle management and remote monitoring, features such as prerecorded or synchronous education sessions and platforms for asking questions and receiving answers were available. Such components could be beneficial in improving immunosuppressant adherence. In addition, incorporating elements such as role-play and quizzes that reflect challenging medication-taking scenarios along with web-based chatbots developed using frequently asked question algorithms and supplemented with emergency hotlines could enhance the decision-making and resource engagement skills of LT recipients.
While most of the reviewed studies (12/15, 80%) referred to the potential of eHealth in enhancing collaborative and individualized health care, only 33% (5/15) of them featured 2-way communication, and just 20% (3/15) incorporated personalized prescriptions or tailored goal setting. Videoconferencing emerged as the most common method for 2-way communication and building personalized strategies. Regular web-based meetings with HCPs or coaches and facilitators during these sessions can be effective, offering benefits such as reinforcing socially desirable behaviors; increasing accountability through clear, reciprocal goals and expectations; and enhancing interpersonal connectedness through support and feedback [ 49 ]. In addition, collaborative goal-setting strategies tailored to individual needs have been reported as effective in posttransplant recovery by acknowledging the variability in posttransplant health level, strength, and capacity among LT recipients [ 50 ]. The interest of LT recipients in connecting with peer recipients web-based also indicates a need for incorporating peer support groups to foster higher motivation and interpersonal connectedness [ 33 ].
In contrast, the studies that scored the lowest on the core self-management skills included minimal human collaborative elements such as communication or education sessions with HCPs [ 41 , 45 , 47 ]. These interventions primarily leveraged eHealth for its advantages in reducing labor-intensive tasks, enabling immediate evaluations, and improving accessibility while reducing exposure to infection sources [ 24 , 51 , 52 ] but overlooked the value of human support. Previous findings have suggested that digital person-to-person components can significantly improve effectiveness and adherence in eHealth interventions [ 49 , 53 ]. The selected interventions with lower levels of guidance and support included phone calls or SMS text messaging. However, assessing the relationship between the level of human support and postintervention outcomes was not feasible due to the heterogeneity of intervention strategies and the lack of clear causality between specific strategies and outcomes. Although it has been demonstrated that eHealth interventions with feedback channels are generally more effective than those without [ 49 ], further research is warranted to understand how the directiveness, interactivity, and immediacy of feedback impact the effectiveness of these interventions for sustainable behavior change in LT recipients with complex self-management needs.
In exploring untapped benefits of eHealth among the reviewed studies, we suggest that future research focus on developing predictive models and tailored interventions based on patient-generated data. The potential for creating algorithms to identify behavior patterns could be promising for personalized management or decision support systems. For instance, algorithms analyzing medication-taking logs could proactively identify individuals at risk, enabling more intensive monitoring to prevent medication errors or nonadherence [ 9 ]. The capacity of eHealth to collect extensive patient information remotely and conveniently should be maximized to create personalized management plans. By leveraging advanced data analysis and machine learning techniques, coupled with the incorporation of the preferences, needs, and circumstances of LT recipients, there is potential for a more sophisticated, patient-centered design of self-management interventions.
Another critical consideration when developing and implementing eHealth interventions is the age of the LT recipient population. Notably, in 87% (13/15) of the reviewed studies, the average age among the LT recipients was >50 years. Older age has been identified as contributing to the digital divide [ 54 , 55 ], potentially affecting the ability and access of LT recipients to self-management support using eHealth technologies [ 56 , 57 ]. While the proportion of LT recipients aged ≥65 years has increased in the past decade [ 58 ], research on older LT recipients has primarily revolved around graft function and long-term survival [ 59 , 60 ]. This indicates a need for further research addressing self-management and QOL in this demographic group [ 59 , 61 ]. The digital literacy of older adults should be assessed as a potential influential factor in eHealth self-management intervention studies [ 62 ]. The study by Andrä et al [ 44 ] examined the variability in mobile device use and usability with age as a key factor in the discrepancy between patients interested in the mobile app and those who actually used it. The study recommended a longer trial period and repeated training for the older individuals [ 44 ]. Moreover, intervention designs should accommodate older users or those with limited digital literacy. This could involve simplifying interfaces, using intuitive features, and providing clear instructions or support to aid their understanding and use of technology.
Furthermore, there is a pressing need for more studies on eHealth use and self-management outcomes among diverse ethnic groups and regions worldwide. The LT recipients in our review were primarily from North America and Europe, which does not proportionately represent the increasing number of LTs in many Asian countries. While the reviewed descriptive studies did not cover a wide array of eHealth-related characteristics, future studies examining the relationship between the digital divide and social determinants—such as ethnicity, educational level, economic status, health care access, and community resources among LT recipients—should consider the variability across different countries and regions. Such research would more accurately reflect the current global situation of LT recipients and validate the effects of eHealth in this population.
This review has several limitations. First, as we searched for articles explicitly including terms related to self-management based on previous literature on self-management among LT recipients, it is possible that articles including nuanced aspects of self-management were excluded. Second, it should be considered that the samples of the studies in this review comprised relatively old individuals as our review specifically focused on adult LT recipients. Thus, caution should be exercised when interpreting findings as age may influence adherence and self-management outcomes. As adherence and self-management needs significantly differ across developmental stages, future reviews focusing on younger populations are warranted. Third, this review included only studies published in English. Therefore, we may have missed relevant studies published in non-English languages, which should be considered with our finding related to the disproportional geographical distribution of the studies. Finally, it was inherently challenging to stratify and compare results for a detailed synthesis because this scoping review involved a small number of studies with heterogeneous designs, aims, and contents. Consistent with the purpose of the scoping review approach [ 63 ], our focus was on providing an overall mapping of the identified literature in this topic area rather than conducting an in-depth comparison of quantitative findings. Because the topic of eHealth interventions for self-management after LT is in its infancy but rapidly evolving, analyzing the replicability of the interventions to date using the TIDieR checklist may provide better insights for researchers and clinicians interested in further advancing this topic area. We suggest that future reviews prioritize analyzing the effectiveness of eHealth-based self-management interventions on various health outcomes and examine the interactions of social determinant factors as more evidence becomes available.
This scoping review has highlighted the significant potential and emerging challenges of eHealth-based self-management strategies for LT recipients. The reviewed studies predominantly focused on lifestyle management, medication adherence, and remote monitoring. However, there is a noticeable gap in eHealth research concerning alcohol recidivism and the psychosocial and cognitive dimensions of progressing and evaluating self-management (eg, self-efficacy and self-regulation). Future research should aim to develop tailored eHealth interventions that encompass multifaceted elements of self-management skills. These interventions should not only leverage the benefits of technology but also incorporate digital human-to-human interactions to adequately address the complex needs of LT recipients. In addition, ensuring inclusive and equitable self-management support requires addressing the challenges of digital literacy, catering to the unique needs of older LT recipients, and considering the sociocultural contexts of LT recipients from diverse geographic regions.
This research was supported by the National Research Foundation of Korea funded by the Ministry of Education (2022R1I1A2053635; JC); the Institute for Innovation in Digital Healthcare, Yonsei University (JC); the Mo-Im Kim Nursing Research Institute (SHC and JC); and the Multidisciplinary Research Fund (6-2021-0199; SHC and JC) and Faculty Research Fund (6-2021-0177; SHC and JC) from Yonsei University College of Nursing. The authors used ChatGPT (OpenAI) [ 64 ] for grammar and language correction.
JC and SHC conceptualized and supervised the study. JC, SHK, and SHC developed the methodology. SHK and HK screened the studies and performed the formal analysis. SHK and KK performed the validation. JC, SHK, KK, SHC, DJJ, and JGL wrote, reviewed, and edited the manuscript. All authors have read and agreed to the published version of the manuscript.
None declared.
Summary of database search strategies.
Detailed scores according to the Template for Intervention Description and Replication checklist for the selected intervention studies.
health care provider |
liver transplantation |
Preferred Reporting Items for Systematic Reviews and Meta-Analyses |
quality of life |
randomized controlled trial |
Template for Intervention Description and Replication |
Edited by G Eysenbach, S Ma; submitted 23.01.24; peer-reviewed by K Bul; comments to author 20.02.24; revised version received 24.03.24; accepted 03.06.24; published 04.07.24.
©Soo Hyun Kim, Kyoung-A Kim, Sang Hui Chu, Hyunji Kim, Dong Jin Joo, Jae Geun Lee, JiYeon Choi. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 04.07.2024.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in the Journal of Medical Internet Research (ISSN 1438-8871), is properly cited. The complete bibliographic information, a link to the original publication on https://www.jmir.org/, as well as this copyright and license information must be included.
BMC Nursing volume 23 , Article number: 452 ( 2024 ) Cite this article
49 Accesses
Metrics details
The central component in impactful healthcare decisions is evidence. Understanding how nurse leaders use evidence in their own managerial decision making is still limited. This mixed methods systematic review aimed to examine how evidence is used to solve leadership problems and to describe the measured and perceived effects of evidence-based leadership on nurse leaders and their performance, organizational, and clinical outcomes.
We included articles using any type of research design. We referred nurses, nurse managers or other nursing staff working in a healthcare context when they attempt to influence the behavior of individuals or a group in an organization using an evidence-based approach. Seven databases were searched until 11 November 2021. JBI Critical Appraisal Checklist for Quasi-experimental studies, JBI Critical Appraisal Checklist for Case Series, Mixed Methods Appraisal Tool were used to evaluate the Risk of bias in quasi-experimental studies, case series, mixed methods studies, respectively. The JBI approach to mixed methods systematic reviews was followed, and a parallel-results convergent approach to synthesis and integration was adopted.
Thirty-one publications were eligible for the analysis: case series ( n = 27), mixed methods studies ( n = 3) and quasi-experimental studies ( n = 1). All studies were included regardless of methodological quality. Leadership problems were related to the implementation of knowledge into practice, the quality of nursing care and the resource availability. Organizational data was used in 27 studies to understand leadership problems, scientific evidence from literature was sought in 26 studies, and stakeholders’ views were explored in 24 studies. Perceived and measured effects of evidence-based leadership focused on nurses’ performance, organizational outcomes, and clinical outcomes. Economic data were not available.
This is the first systematic review to examine how evidence is used to solve leadership problems and to describe its measured and perceived effects from different sites. Although a variety of perceptions and effects were identified on nurses’ performance as well as on organizational and clinical outcomes, available knowledge concerning evidence-based leadership is currently insufficient. Therefore, more high-quality research and clinical trial designs are still needed.
The study was registered (PROSPERO CRD42021259624).
Peer Review reports
Global health demands have set new roles for nurse leaders [ 1 ].Nurse leaders are referred to as nurses, nurse managers, or other nursing staff working in a healthcare context who attempt to influence the behavior of individuals or a group based on goals that are congruent with organizational goals [ 2 ]. They are seen as professionals “armed with data and evidence, and a commitment to mentorship and education”, and as a group in which “leaders innovate, transform, and achieve quality outcomes for patients, health care professionals, organizations, and communities” [ 3 ]. Effective leadership occurs when team members critically follow leaders and are motivated by a leader’s decisions based on the organization’s requests and targets [ 4 ]. On the other hand, problems caused by poor leadership may also occur, regarding staff relations, stress, sickness, or retention [ 5 ]. Therefore, leadership requires an understanding of different problems to be solved using synthesizing evidence from research, clinical expertise, and stakeholders’ preferences [ 6 , 7 ]. If based on evidence, leadership decisions, also referred as leadership decision making [ 8 ], could ensure adequate staffing [ 7 , 9 ] and to produce sufficient and cost-effective care [ 10 ]. However, nurse leaders still rely on their decision making on their personal [ 11 ] and professional experience [ 10 ] over research evidence, which can lead to deficiencies in the quality and safety of care delivery [ 12 , 13 , 14 ]. As all nurses should demonstrate leadership in their profession, their leadership competencies should be strengthened [ 15 ].
Evidence-informed decision-making, referred to as evidence appraisal and application, and evaluation of decisions [ 16 ], has been recognized as one of the core competencies for leaders [ 17 , 18 ]. The role of evidence in nurse leaders’ managerial decision making has been promoted by public authorities [ 19 , 20 , 21 ]. Evidence-based management, another concept related to evidence-based leadership, has been used as the potential to improve healthcare services [ 22 ]. It can guide nursing leaders, in developing working conditions, staff retention, implementation practices, strategic planning, patient care, and success of leadership [ 13 ]. Collins and Holton [ 23 ] in their systematic review and meta-analysis examined 83 studies regarding leadership development interventions. They found that leadership training can result in significant improvement in participants’ skills, especially in knowledge level, although the training effects varied across studies. Cummings et al. [ 24 ] reviewed 100 papers (93 studies) and concluded that participation in leadership interventions had a positive impact on the development of a variety of leadership styles. Clavijo-Chamorro et al. [ 25 ] in their review of 11 studies focused on leadership-related factors that facilitate evidence implementation: teamwork, organizational structures, and transformational leadership. The role of nurse managers was to facilitate evidence-based practices by transforming contexts to motivate the staff and move toward a shared vision of change.
As far as we are aware, however, only a few systematic reviews have focused on evidence-based leadership or related concepts in the healthcare context aiming to analyse how nurse leaders themselves uses evidence in the decision-making process. Young [ 26 ] targeted definitions and acceptance of evidence-based management (EBMgt) in healthcare while Hasanpoor et al. [ 22 ] identified facilitators and barriers, sources of evidence used, and the role of evidence in the process of decision making. Both these reviews concluded that EBMgt was of great importance but used limitedly in healthcare settings due to a lack of time, a lack of research management activities, and policy constraints. A review by Williams [ 27 ] showed that the usage of evidence to support management in decision making is marginal due to a shortage of relevant evidence. Fraser [ 28 ] in their review further indicated that the potential evidence-based knowledge is not used in decision making by leaders as effectively as it could be. Non-use of evidence occurs and leaders base their decisions mainly on single studies, real-world evidence, and experts’ opinions [ 29 ]. Systematic reviews and meta-analyses rarely provide evidence of management-related interventions [ 30 ]. Tate et al. [ 31 ] concluded based on their systematic review and meta-analysis that the ability of nurse leaders to use and critically appraise research evidence may influence the way policy is enacted and how resources and staff are used to meet certain objectives set by policy. This can further influence staff and workforce outcomes. It is therefore important that nurse leaders have the capacity and motivation to use the strongest evidence available to effect change and guide their decision making [ 27 ].
Despite of a growing body of evidence, we found only one review focusing on the impact of evidence-based knowledge. Geert et al. [ 32 ] reviewed literature from 2007 to 2016 to understand the elements of design, delivery, and evaluation of leadership development interventions that are the most reliably linked to outcomes at the level of the individual and the organization, and that are of most benefit to patients. The authors concluded that it is possible to improve individual-level outcomes among leaders, such as knowledge, motivation, skills, and behavior change using evidence-based approaches. Some of the most effective interventions included, for example, interactive workshops, coaching, action learning, and mentoring. However, these authors found limited research evidence describing how nurse leaders themselves use evidence to support their managerial decisions in nursing and what the outcomes are.
To fill the knowledge gap and compliment to existing knowledgebase, in this mixed methods review we aimed to (1) examine what leadership problems nurse leaders solve using an evidence-based approach and (2) how they use evidence to solve these problems. We also explored (3) the measured and (4) perceived effects of the evidence-based leadership approach in healthcare settings. Both qualitative and quantitative components of the effects of evidence-based leadership were examined to provide greater insights into the available literature [ 33 ]. Together with the evidence-based leadership approach, and its impact on nursing [ 34 , 35 ], this knowledge gained in this review can be used to inform clinical policy or organizational decisions [ 33 ]. The study is registered (PROSPERO CRD42021259624). The methods used in this review were specified in advance and documented in a priori in a published protocol [ 36 ]. Key terms of the review and the search terms are defined in Table 1 (population, intervention, comparison, outcomes, context, other).
In this review, we used a mixed methods approach [ 37 ]. A mixed methods systematic review was selected as this approach has the potential to produce direct relevance to policy makers and practitioners [ 38 ]. Johnson and Onwuegbuzie [ 39 ] have defined mixed methods research as “the class of research in which the researcher mixes or combines quantitative and qualitative research techniques, methods, approaches, concepts or language into a single study.” Therefore, we combined quantitative and narrative analysis to appraise and synthesize empirical evidence, and we held them as equally important in informing clinical policy or organizational decisions [ 34 ]. In this review, a comprehensive synthesis of quantitative and qualitative data was performed first and then discussed in discussion part (parallel-results convergent design) [ 40 ]. We hoped that different type of analysis approaches could complement each other and deeper picture of the topic in line with our research questions could be gained [ 34 ].
Inclusion and exclusion criteria of the study are described in Table 1 .
A three-step search strategy was utilized. First, an initial limited search with #MEDLINE was undertaken, followed by analysis of the words used in the title, abstract, and the article’s key index terms. Second, the search strategy, including identified keywords and index terms, was adapted for each included data base and a second search was undertaken on 11 November 2021. The full search strategy for each database is described in Additional file 1 . Third, the reference list of all studies included in the review were screened for additional studies. No year limits or language restrictions were used.
The database search included the following: CINAHL (EBSCO), Cochrane Library (academic database for medicine and health science and nursing), Embase (Elsevier), PsycINFO (EBSCO), PubMed (MEDLINE), Scopus (Elsevier) and Web of Science (academic database across all scientific and technical disciplines, ranging from medicine and social sciences to arts and humanities). These databases were selected as they represent typical databases in health care context. Subject headings from each of the databases were included in the search strategies. Boolean operators ‘AND’ and ‘OR’ were used to combine the search terms. An information specialist from the University of Turku Library was consulted in the formation of the search strategies.
All identified citations were collated and uploaded into Covidence software (Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia www.covidence.org ), and duplicates were removed by the software. Titles and abstracts were screened and assessed against the inclusion criteria independently by two reviewers out of four, and any discrepancies were resolved by the third reviewer (MV, KH, TL, WC). Studies meeting the inclusion criteria were retrieved in full and archived in Covidence. Access to one full-text article was lacking: the authors for one study were contacted about the missing full text, but no full text was received. All remaining hits of the included studies were retrieved and assessed independently against the inclusion criteria by two independent reviewers of four (MV, KH, TL, WC). Studies that did not meet the inclusion criteria were excluded, and the reasons for exclusion were recorded in Covidence. Any disagreements that arose between the reviewers were resolved through discussions with XL.
Eligible studies were critically appraised by two independent reviewers (YT, SH). Standardized critical appraisal instruments based on the study design were used. First, quasi-experimental studies were assessed using the JBI Critical Appraisal Checklist for Quasi-experimental studies [ 44 ]. Second, case series were assessed using the JBI Critical Appraisal Checklist for Case Series [ 45 ]. Third, mixed methods studies were appraised using the Mixed Methods Appraisal Tool [ 46 ].
To increase inter-reviewer reliability, the review agreement was calculated (SH) [ 47 ]. A kappa greater than 0.8 was considered to represent a high level of agreement (0–0.1). In our data, the agreement was 0.75. Discrepancies raised between two reviewers were resolved through discussion and modifications and confirmed by XL. As an outcome, studies that met the inclusion criteria were proceeded to critical appraisal and assessed as suitable for inclusion in the review. The scores for each item and overall critical appraisal scores were presented.
For data extraction, specific tables were created. First, study characteristics (author(s), year, country, design, number of participants, setting) were extracted by two authors independently (JC, MV) and reviewed by TL. Second, descriptions of the interventions were extracted by two reviewers (JV, JC) using the structure of the TIDIeR (Template for Intervention Description and Replication) checklist (brief name, the goal of the intervention, material and procedure, models of delivery and location, dose, modification, adherence and fidelity) [ 48 ]. The extractions were confirmed (MV).
Third, due to a lack of effectiveness data and a wide heterogeneity between study designs and presentation of outcomes, no attempt was made to pool the quantitative data statistically; the findings of the quantitative data were presented in narrative form only [ 44 ]. The separate data extraction tables for each research question were designed specifically for this study. For both qualitative (and a qualitative component of mixed-method studies) and quantitative studies, the data were extracted and tabulated into text format according to preplanned research questions [ 36 ]. To test the quality of the tables and the data extraction process, three authors independently extracted the data from the first five studies (in alphabetical order). After that, the authors came together to share and determine whether their approaches of the data extraction were consistent with each other’s output and whether the content of each table was in line with research question. No reason was found to modify the data extraction tables or planned process. After a consensus of the data extraction process was reached, the data were extracted in pairs by independent reviewers (WC, TY, SH, GL). Any disagreements that arose between the reviewers were resolved through discussion and with a third reviewer (MV).
We were not able to conduct a meta-analysis due to a lack of effectiveness data based on clinical trials. Instead, we used inductive thematic analysis with constant comparison to answer the research question [ 46 , 49 ] using tabulated primary data from qualitative and quantitative studies as reported by the original authors in narrative form only [ 47 ]. In addition, the qualitizing process was used to transform quantitative data to qualitative data; this helped us to convert the whole data into themes and categories. After that we used the thematic analysis for the narrative data as follows. First, the text was carefully read, line by line, to reveal topics answering each specific review question (MV). Second, the data coding was conducted, and the themes in the data were formed by data categorization. The process of deriving the themes was inductive based on constant comparison [ 49 ]. The results of thematic analysis and data categorization was first described in narrative format and then the total number of studies was calculated where the specific category was identified (%).
The method of reporting stakeholders’ involvement follows the key components by [ 50 ]: (1) people involved, (2) geographical location, (3) how people were recruited, (4) format of involvement, (5) amount of involvement, (6) ethical approval, (7) financial compensation, and (8) methods for reporting involvement.
In our review, stakeholder involvement targeted nurses and nurse leader in China. Nurse Directors of two hospitals recommended potential participants who received a personal invitation letter from researchers to participate in a discussion meeting. Stakeholders’ participation was based on their own free will. Due to COVID-19, one online meeting (1 h) was organized (25 May 2022). Eleven participants joined the meeting. Ethical approval was not applied and no financial compensation was offered. At the end of the meeting, experiences of stakeholders’ involvement were explored.
The meeting started with an introductory presentation with power points. The rationale, methods, and preliminary review results were shared with the participants [ 51 ].The meeting continued with general questions for the participants: (1) Are you aware of the concepts of evidence-based practice or evidence-based leadership?; (2) How important is it to use evidence to support decisions among nurse leaders?; (3) How is the evidence-based approach used in hospital settings?; and (4) What type of evidence is currently used to support nurse leaders’ decision making (e.g. scientific literature, organizational data, stakeholder views)?
Two people took notes on the course and content of the conversation. The notes were later transcripted in verbatim, and the key points of the discussions were summarised. Although answers offered by the stakeholders were very short, the information was useful to validate the preliminary content of the results, add the rigorousness of the review, and obtain additional perspectives. A recommendation of the stakeholders was combined in the Discussion part of this review increasing the applicability of the review in the real world [ 50 ]. At the end of the discussion, the value of stakeholders’ involvement was asked. Participants shared that the experience of participating was unique and the topic of discussion was challenging. Two authors of the review group further represented stakeholders by working together with the research team throughout the review study.
From seven different electronic databases, 6053 citations were identified as being potentially relevant to the review. Then, 3133 duplicates were removed by an automation tool (Covidence: www.covidence.org ), and one was removed manually. The titles and abstracts of 3040 of citations were reviewed, and a total of 110 full texts were included (one extra citation was found on the reference list but later excluded). Based on the eligibility criteria, 31 studies (32 hits) were critically appraised and deemed suitable for inclusion in the review. The search results and selection process are presented in the PRISMA [ 52 ] flow diagram Fig. 1 . The full list of references for included studies can be find in Additional file 2 . To avoid confusion between articles of the reference list and studies included in the analysis, the studies included in the review are referred inside the article using the reference number of each study (e.g. ref 1, ref 2).
Search results and study selection and inclusion process [ 52 ]
The studies had multiple purposes, aiming to develop practice, implement a new approach, improve quality, or to develop a model. The 31 studies (across 32 hits) were case series studies ( n = 27), mixed methods studies ( n = 3) and a quasi-experimental study ( n = 1). All studies were published between the years 2004 and 2021. The highest number of papers was published in year 2020.
Table 2 describes the characteristics of included studies and Additional file 3 offers a narrative description of the studies.
Quasi-experimental studies.
We had one quasi-experimental study (ref 31). All questions in the critical appraisal tool were applicable. The total score of the study was 8 (out of a possible 9). Only one response of the tool was ‘no’ because no control group was used in the study (see Additional file 4 for the critical appraisal of included studies).
Case series studies . A case series study is typically defined as a collection of subjects with common characteristics. The studies do not include a comparison group and are often based on prevalent cases and on a sample of convenience [ 53 ]. Munn et al. [ 45 ] further claim that case series are best described as observational studies, lacking experimental and randomized characteristics, being descriptive studies, without a control or comparator group. Out of 27 case series studies included in our review, the critical appraisal scores varied from 1 to 9. Five references were conference abstracts with empirical study results, which were scored from 1 to 3. Full reports of these studies were searched in electronic databases but not found. Critical appraisal scores for the remaining 22 studies ranged from 1 to 9 out of a possible score of 10. One question (Q3) was not applicable to 13 studies: “Were valid methods used for identification of the condition for all participants included in the case series?” Only two studies had clearly reported the demographic of the participants in the study (Q6). Twenty studies met Criteria 8 (“Were the outcomes or follow-up results of cases clearly reported?”) and 18 studies met Criteria 7 (“Q7: Was there clear reporting of clinical information of the participants?”) (see Additional file 4 for the critical appraisal of included studies).
Mixed-methods studies involve a combination of qualitative and quantitative methods. This is a common design and includes convergent design, sequential explanatory design, and sequential exploratory design [ 46 ]. There were three mixed-methods studies. The critical appraisal scores for the three studies ranged from 60 to 100% out of a possible 100%. Two studies met all the criteria, while one study fulfilled 60% of the scored criteria due to a lack of information to understand the relevance of the sampling strategy well enough to address the research question (Q4.1) or to determine whether the risk of nonresponse bias was low (Q4.4) (see Additional file 4 for the critical appraisal of included studies).
The intervention of program components were categorized and described using the TiDier checklist: name and goal, theory or background, material, procedure, provider, models of delivery, location, dose, modification, and adherence and fidelity [ 48 ]. A description of intervention in each study is described in Additional file 5 and a narrative description in Additional file 6 .
In line with the inclusion criteria, data for the leadership problems were categorized in all 31 included studies (see Additional file 7 for leadership problems). Three types of leadership problems were identified: implementation of knowledge into practice, the quality of clinical care, and resources in nursing care. A narrative summary of the results is reported below.
Eleven studies (35%) aimed to solve leadership problems related to implementation of knowledge into practice. Studies showed how to support nurses in evidence-based implementation (EBP) (ref 3, ref 5), how to engage nurses in using evidence in practice (ref 4), how to convey the importance of EBP (ref 22) or how to change practice (ref 4). Other problems were how to facilitate nurses to use guideline recommendations (ref 7) and how nurses can make evidence-informed decisions (ref 8). General concerns also included the linkage between theory and practice (ref 1) as well as how to implement the EBP model in practice (ref 6). In addition, studies were motivated by the need for revisions or updates of protocols to improve clinical practice (ref 10) as well as the need to standardize nursing activities (ref 11, ref 14).
Thirteen (42%) focused on solving problems related to the quality of clinical care. In these studies, a high number of catheter infections led a lack of achievement of organizational goals (ref 2, ref 9). A need to reduce patient symptoms in stem cell transplant patients undergoing high-dose chemotherapy (ref 24) was also one of the problems to be solved. In addition, the projects focused on how to prevent pressure ulcers (ref 26, ref 29), how to enhance the quality of cancer treatment (ref 25) and how to reduce the need for invasive constipation treatment (ref 30). Concerns about patient safety (ref 15), high fall rates (ref 16, ref 19), dissatisfaction of patients (ref 16, ref 18) and nurses (ref 16, ref 30) were also problems that had initiated the projects. Studies addressed concerns about how to promote good contingency care in residential aged care homes (ref 20) and about how to increase recognition of human trafficking problems in healthcare (ref 21).
Nurse leaders identified problems in their resources, especially in staffing problems. These problems were identified in seven studies (23%), which involved concerns about how to prevent nurses from leaving the job (ref 31), how to ensure appropriate recruitment, staffing and retaining of nurses (ref 13) and how to decrease nurses’ burden and time spent on nursing activities (ref 12). Leadership turnover was also reported as a source of dissatisfaction (ref 17); studies addressed a lack of structured transition and training programs, which led to turnover (ref 23), as well as how to improve intershift handoff among nurses (ref 28). Optimal design for new hospitals was also examined (ref 27).
Out of 31 studies, 17 (55%) included all four domains of an evidence-based leadership approach, and four studies (13%) included evidence of critical appraisal of the results (see Additional file 8 for the main features of evidence-based Leadership) (ref 11, ref 14, ref 23, ref 27).
Twenty-seven studies (87%) reported how organizational evidence was collected and used to solve leadership problems (ref 2). Retrospective chart reviews (ref 5), a review of the extent of specific incidents (ref 19), and chart auditing (ref 7, ref 25) were conducted. A gap between guideline recommendations and actual care was identified using organizational data (ref 7) while the percentage of nurses’ working time spent on patient care was analyzed using an electronic charting system (ref 12). Internal data (ref 22), institutional data, and programming metrics were also analyzed to understand the development of the nurse workforce (ref 13).
Surveys (ref 3, ref 25), interviews (ref 3, ref 25) and group reviews (ref 18) were used to better understand the leadership problem to be solved. Employee opinion surveys on leadership (ref 17), a nurse satisfaction survey (ref 30) and a variety of reporting templates were used for the data collection (ref 28) reported. Sometimes, leadership problems were identified by evidence facilitators or a PI’s team who worked with staff members (ref 15, ref 17). Problems in clinical practice were also identified by the Nursing Professional Council (ref 14), managers (ref 26) or nurses themselves (ref 24). Current practices were reviewed (ref 29) and a gap analysis was conducted (ref 4, ref 16, ref 23) together with SWOT analysis (ref 16). In addition, hospital mission and vision statements, research culture established and the proportion of nursing alumni with formal EBP training were analyzed (ref 5). On the other hand, it was stated that no systematic hospital-specific sources of data regarding job satisfaction or organizational commitment were used (ref 31). In addition, statements of organizational analysis were used on a general level only (ref 1).
Twenty-six studies (84%) reported the use of scientific evidence in their evidence-based leadership processes. A literature search was conducted (ref 21) and questions, PICO, and keywords were identified (ref 4) in collaboration with a librarian. Electronic databases, including PubMed (ref 14, ref 31), Cochrane, and EMBASE (ref 31) were searched. Galiano (ref 6) used Wiley Online Library, Elsevier, CINAHL, Health Source: Nursing/Academic Edition, PubMed, and the Cochrane Library while Hoke (ref 11) conducted an electronic search using CINAHL and PubMed to retrieve articles.
Identified journals were reviewed manually (ref 31). The findings were summarized using ‘elevator speech’ (ref 4). In a study by Gifford et al. (ref 9) evidence facilitators worked with participants to access, appraise, and adapt the research evidence to the organizational context. Ostaszkiewicz (ref 20) conducted a scoping review of literature and identified and reviewed frameworks and policy documents about the topic and the quality standards. Further, a team of nursing administrators, directors, staff nurses, and a patient representative reviewed the literature and made recommendations for practice changes.
Clinical practice guidelines were also used to offer scientific evidence (ref 7, ref 19). Evidence was further retrieved from a combination of nursing policies, guidelines, journal articles, and textbooks (ref 12) as well as from published guidelines and literature (ref 13). Internal evidence, professional practice knowledge, relevant theories and models were synthesized (ref 24) while other study (ref 25) reviewed individual studies, synthesized with systematic reviews or clinical practice guidelines. The team reviewed the research evidence (ref 3, ref 15) or conducted a literature review (ref 22, ref 28, ref 29), a literature search (ref 27), a systematic review (ref 23), a review of the literature (ref 30) or ‘the scholarly literature was reviewed’ (ref 18). In addition, ‘an extensive literature review of evidence-based best practices was carried out’ (ref 10). However, detailed description how the review was conducted was lacking.
A total of 24 studies (77%) reported methods for how the views of stakeholders, i.e., professionals or experts, were considered. Support to run this study was received from nursing leadership and multidisciplinary teams (ref 29). Experts and stakeholders joined the study team in some cases (ref 25, ref 30), and in other studies, their opinions were sought to facilitate project success (ref 3). Sometimes a steering committee was formed by a Chief Nursing Officer and Clinical Practice Specialists (ref 2). More specifically, stakeholders’ views were considered using interviews, workshops and follow-up teleconferences (ref 7). The literature review was discussed with colleagues (ref 11), and feedback and support from physicians as well as the consensus of staff were sought (ref 16).
A summary of the project findings and suggestions for the studies were discussed at 90-minute weekly meetings by 11 charge nurses. Nurse executive directors were consulted over a 10-week period (ref 31). An implementation team (nurse, dietician, physiotherapist, occupational therapist) was formed to support the implementation of evidence-based prevention measures (ref 26). Stakeholders volunteered to join in the pilot implementation (ref 28) or a stakeholder team met to determine the best strategy for change management, shortcomings in evidence-based criteria were discussed, and strategies to address those areas were planned (ref 5). Nursing leaders, staff members (ref 22), ‘process owners (ref 18) and program team members (ref 18, ref 19, ref 24) met regularly to discuss the problems. Critical input was sought from clinical educators, physicians, nutritionists, pharmacists, and nurse managers (ref 24). The unit director and senior nursing staff reviewed the contents of the product, and the final version of clinical pathways were reviewed and approved by the Quality Control Commission of the Nursing Department (ref 12). In addition, two co-design workshops with 18 residential aged care stakeholders were organized to explore their perspectives about factors to include in a model prototype (ref 20). Further, an agreement of stakeholders in implementing continuous quality services within an open relationship was conducted (ref 1).
In five studies (16%), a critical appraisal targeting the literature search was carried out. The appraisals were conducted by interns and teams who critiqued the evidence (ref 4). In Hoke’s study, four areas that had emerged in the literature were critically reviewed (ref 11). Other methods were to ‘critically appraise the search results’ (ref 14). Journal club team meetings (ref 23) were organized to grade the level and quality of evidence and the team ‘critically appraised relevant evidence’ (ref 27). On the other hand, the studies lacked details of how the appraisals were done in each study.
Perceived effects of evidence-based leadership on nurses’ performance.
Eleven studies (35%) described perceived effects of evidence-based leadership on nurses’ performance (see Additional file 9 for perceived effects of evidence-based leadership), which were categorized in four groups: awareness and knowledge, competence, ability to understand patients’ needs, and engagement. First, regarding ‘awareness and knowledge’, different projects provided nurses with new learning opportunities (ref 3). Staff’s knowledge (ref 20, ref 28), skills, and education levels improved (ref 20), as did nurses’ knowledge comprehension (ref 21). Second, interventions and approaches focusing on management and leadership positively influenced participants’ competence level to improve the quality of services. Their confidence level (ref 1) and motivation to change practice increased, self-esteem improved, and they were more positive and enthusiastic in their work (ref 22). Third, some nurses were relieved that they had learned to better handle patients’ needs (ref 25). For example, a systematic work approach increased nurses’ awareness of the patients who were at risk of developing health problems (ref 26). And last, nurse leaders were more engaged with staff, encouraging them to adopt the new practices and recognizing their efforts to change (ref 8).
Nine studies (29%) described the perceived effects of evidence-based leadership on organizational outcomes (see Additional file 9 for perceived effects of evidence-based leadership). These were categorized into three groups: use of resources, staff commitment, and team effort. First, more appropriate use of resources was reported (ref 15, ref 20), and working time was more efficiently used (ref 16). In generally, a structured approach made implementing change more manageable (ref 1). On the other hand, in the beginning of the change process, the feedback from nurses was unfavorable, and they experienced discomfort in the new work style (ref 29). New approaches were also perceived as time consuming (ref 3). Second, nurse leaders believed that fewer nursing staff than expected left the organization over the course of the study (ref 31). Third, the project helped staff in their efforts to make changes, and it validated the importance of working as a team (ref 7). Collaboration and support between the nurses increased (ref 26). On the other hand, new work style caused challenges in teamwork (ref 3).
Five studies (16%) reported the perceived effects of evidence-based leadership on clinical outcomes (see Additional file 9 for perceived effects of evidence-based leadership), which were categorized in two groups: general patient outcomes and specific clinical outcomes. First, in general, the project assisted in connecting the guideline recommendations and patient outcomes (ref 7). The project was good for the patients in general, and especially to improve patient safety (ref 16). On the other hand, some nurses thought that the new working style did not work at all for patients (ref 28). Second, the new approach used assisted in optimizing patients’ clinical problems and person-centered care (ref 20). Bowel management, for example, received very good feedback (ref 30).
The measured effects on nurses’ performance.
Data were obtained from 20 studies (65%) (see Additional file 10 for measured effects of evidence-based leadership) and categorized nurse performance outcomes for three groups: awareness and knowledge, engagement, and satisfaction. First, six studies (19%) measured the awareness and knowledge levels of participants. Internship for staff nurses was beneficial to help participants to understand the process for using evidence-based practice and to grow professionally, to stimulate for innovative thinking, to give knowledge needed to use evidence-based practice to answer clinical questions, and to make possible to complete an evidence-based practice project (ref 3). Regarding implementation program of evidence-based practice, those with formal EBP training showed an improvement in knowledge, attitude, confidence, awareness and application after intervention (ref 3, ref 11, ref 20, ref 23, ref 25). On the contrary, in other study, attitude towards EBP remained stable ( p = 0.543). and those who applied EBP decreased although no significant differences over the years ( p = 0.879) (ref 6).
Second, 10 studies (35%) described nurses’ engagement to new practices (ref 5, ref 6, ref 7, ref 10, ref 16, ref 17, ref 18, ref 21, ref 25, ref 27). 9 studies (29%) studies reported that there was an improvement of compliance level of participants (ref 6, ref 7, ref 10, ref 16, ref 17, ref 18, ref 21, ref 25, ref 27). On the contrary, in DeLeskey’s (ref 5) study, although improvement was found in post-operative nausea and vomiting’s (PONV) risk factors documented’ (2.5–63%), and ’risk factors communicated among anaesthesia and surgical staff’ (0–62%), the improvement did not achieve the goal. The reason was a limited improvement was analysed. It was noted that only those patients who had been seen by the pre-admission testing nurse had risk assessments completed. Appropriate treatment/prophylaxis increased from 69 to 77%, and from 30 to 49%; routine assessment for PONV/rescue treatment 97% and 100% was both at 100% following the project. The results were discussed with staff but further reasons for a lack of engagement in nursing care was not reported.
And third, six studies (19%) reported nurses’ satisfaction with project outcomes. The study results showed that using evidence in managerial decisions improved nurses’ satisfaction and attitudes toward their organization ( P < 0.05) (ref 31). Nurses’ overall job satisfaction improved as well (ref 17). Nurses’ satisfaction with usability of the electronic charting system significantly improved after introduction of the intervention (ref 12). In handoff project in seven hospitals, improvement was reported in all satisfaction indicators used in the study although improvement level varied in different units (ref 28). In addition, positive changes were reported in nurses’ ability to autonomously perform their job (“How satisfied are you with the tools and resources available for you treat and prevent patient constipation?” (54%, n = 17 vs. 92%, n = 35, p < 0.001) (ref 30).
Thirteen studies (42%) described the effects of a project on organizational outcomes (see Additional file 10 for measured effects of evidence-based leadership), which were categorized in two groups: staff compliance, and changes in practices. First, studies reported improved organizational outcomes due to staff better compliance in care (ref 4, ref 13, ref 17, ref 23, ref 27, ref 31). Second, changes in organization practices were also described (ref 11) like changes in patient documentation (ref 12, ref 21). Van Orne (ref 30) found a statistically significant reduction in the average rate of invasive medication administration between pre-intervention and post-intervention ( p = 0.01). Salvador (ref 24) also reported an improvement in a proactive approach to mucositis prevention with an evidence-based oral care guide. On the contrary, concerns were also raised such as not enough time for new bedside report (ref 16) or a lack of improvement of assessment of diabetic ulcer (ref 8).
A variety of improvements in clinical outcomes were reported (see Additional file 10 for measured effects of evidence-based leadership): improvement in patient clinical status and satisfaction level. First, a variety of improvement in patient clinical status was reported. improvement in Incidence of CAUTI decreased 27.8% between 2015 and 2019 (ref 2) while a patient-centered quality improvement project reduced CAUTI rates to 0 (ref 10). A significant decrease in transmission rate of MRSA transmission was also reported (ref 27) and in other study incidences of CLABSIs dropped following of CHG bathing (ref 14). Further, it was possible to decrease patient nausea from 18 to 5% and vomiting to 0% (ref 5) while the percentage of patients who left the hospital without being seen was below 2% after the project (ref 17). In addition, a significant reduction in the prevalence of pressure ulcers was found (ref 26, ref 29) and a significant reduction of mucositis severity/distress was achieved (ref 24). Patient falls rate decreased (ref 15, ref 16, ref 19, ref 27).
Second, patient satisfaction level after project implementation improved (ref 28). The scale assessing healthcare providers by consumers showed improvement, but the changes were not statistically significant. Improvement in an emergency department leadership model and in methods of communication with patients improved patient satisfaction scores by 600% (ref 17). In addition, new evidence-based unit improved patient experiences about the unit although not all items improved significantly (ref 18).
To ensure stakeholders’ involvement in the review, the real-world relevance of our research [ 53 ], achieve a higher level of meaning in our review results, and gain new perspectives on our preliminary findings [ 50 ], a meeting with 11 stakeholders was organized. First, we asked if participants were aware of the concepts of evidence-based practice or evidence-based leadership. Responses revealed that participants were familiar with the concept of evidence-based practice, but the topic of evidence-based leadership was totally new. Examples of nurses and nurse leaders’ responses are as follows: “I have heard a concept of evidence-based practice but never a concept of evidence-based leadership.” Another participant described: “I have heard it [evidence-based leadership] but I do not understand what it means.”
Second, as stakeholder involvement is beneficial to the relevance and impact of health research [ 54 ], we asked how important evidence is to them in supporting decisions in health care services. One participant described as follows: “Using evidence in decisions is crucial to the wards and also to the entire hospital.” Third, we asked how the evidence-based approach is used in hospital settings. Participants expressed that literature is commonly used to solve clinical problems in patient care but not to solve leadership problems. “In [patient] medication and care, clinical guidelines are regularly used. However, I am aware only a few cases where evidence has been sought to solve leadership problems.”
And last, we asked what type of evidence is currently used to support nurse leaders’ decision making (e.g. scientific literature, organizational data, stakeholder views)? The participants were aware that different types of information were collected in their organization on a daily basis (e.g. patient satisfaction surveys). However, the information was seldom used to support decision making because nurse leaders did not know how to access this information. Even so, the participants agreed that the use of evidence from different sources was important in approaching any leadership or managerial problems in the organization. Participants also suggested that all nurse leaders should receive systematic training related to the topic; this could support the daily use of the evidence-based approach.
To our knowledge, this article represents the first mixed-methods systematic review to examine leadership problems, how evidence is used to solve these problems and what the perceived and measured effects of evidence-based leadership are on nurse leaders and their performance, organizational, and clinical outcomes. This review has two key findings. First, the available research data suggests that evidence-based leadership has potential in the healthcare context, not only to improve knowledge and skills among nurses, but also to improve organizational outcomes and the quality of patient care. Second, remarkably little published research was found to explore the effects of evidence-based leadership with an efficient trial design. We validated the preliminary results with nurse stakeholders, and confirmed that nursing staff, especially nurse leaders, were not familiar with the concept of evidence-based leadership, nor were they used to implementing evidence into their leadership decisions. Our data was based on many databases, and we screened a large number of studies. We also checked existing registers and databases and found no registered or ongoing similar reviews being conducted. Therefore, our results may not change in the near future.
We found that after identifying the leadership problems, 26 (84%) studies out of 31 used organizational data, 25 (81%) studies used scientific evidence from the literature, and 21 (68%) studies considered the views of stakeholders in attempting to understand specific leadership problems more deeply. However, only four studies critically appraised any of these findings. Considering previous critical statements of nurse leaders’ use of evidence in their decision making [ 14 , 30 , 31 , 34 , 55 ], our results are still quite promising.
Our results support a previous systematic review by Geert et al. [ 32 ], which concluded that it is possible to improve leaders’ individual-level outcomes, such as knowledge, motivation, skills, and behavior change using evidence-based approaches. Collins and Holton [ 23 ] particularly found that leadership training resulted in significant knowledge and skill improvements, although the effects varied widely across studies. In our study, evidence-based leadership was seen to enable changes in clinical practice, especially in patient care. On the other hand, we understand that not all efforts to changes were successful [ 56 , 57 , 58 ]. An evidence-based approach causes negative attitudes and feelings. Negative emotions in participants have also been reported due to changes, such as discomfort with a new working style [ 59 ]. Another study reported inconvenience in using a new intervention and its potential risks for patient confidentiality. Sometimes making changes is more time consuming than continuing with current practice [ 60 ]. These findings may partially explain why new interventions or program do not always fully achieve their goals. On the other hand, Dubose et al. [ 61 ] state that, if prepared with knowledge of resistance, nurse leaders could minimize the potential negative consequences and capitalize on a powerful impact of change adaptation.
We found that only six studies used a specific model or theory to understand the mechanism of change that could guide leadership practices. Participants’ reactions to new approaches may be an important factor in predicting how a new intervention will be implemented into clinical practice. Therefore, stronger effort should be put to better understanding the use of evidence, how participants’ reactions and emotions or practice changes could be predicted or supported using appropriate models or theories, and how using these models are linked with leadership outcomes. In this task, nurse leaders have an important role. At the same time, more responsibilities in developing health services have been put on the shoulders of nurse leaders who may already be suffering under pressure and increased burden at work. Working in a leadership position may also lead to role conflict. A study by Lalleman et al. [ 62 ] found that nurses were used to helping other people, often in ad hoc situations. The helping attitude of nurses combined with structured managerial role may cause dilemmas, which may lead to stress. Many nurse leaders opt to leave their positions less than 5 years [ 63 ].To better fulfill the requirements of health services in the future, the role of nurse leaders in evidence-based leadership needs to be developed further to avoid ethical and practical dilemmas in their leadership practices.
It is worth noting that the perceived and measured effects did not offer strong support to each other but rather opened a new venue to understand the evidence-based leadership. Specifically, the perceived effects did not support to measured effects (competence, ability to understand patients’ needs, use of resources, team effort, and specific clinical outcomes) while the measured effects could not support to perceived effects (nurse’s performance satisfaction, changes in practices, and clinical outcomes satisfaction). These findings may indicate that different outcomes appear if the effects of evidence-based leadership are looked at using different methodological approach. Future study is encouraged using well-designed study method including mixed-method study to examine the consistency between perceived and measured effects of evidence-based leadership in health care.
There is a potential in nursing to support change by demonstrating conceptual and operational commitment to research-based practices [ 64 ]. Nurse leaders are well positioned to influence and lead professional governance, quality improvement, service transformation, change and shared governance [ 65 ]. In this task, evidence-based leadership could be a key in solving deficiencies in the quality, safety of care [ 14 ] and inefficiencies in healthcare delivery [ 12 , 13 ]. As WHO has revealed, there are about 28 million nurses worldwide, and the demand of nurses will put nurse resources into the specific spotlight [ 1 ]. Indeed, evidence could be used to find solutions for how to solve economic deficits or other problems using leadership skills. This is important as, when nurses are able to show leadership and control in their own work, they are less likely to leave their jobs [ 66 ]. On the other hand, based on our discussions with stakeholders, nurse leaders are not used to using evidence in their own work. Further, evidence-based leadership is not possible if nurse leaders do not have access to a relevant, robust body of evidence, adequate funding, resources, and organizational support, and evidence-informed decision making may only offer short-term solutions [ 55 ]. We still believe that implementing evidence-based strategies into the work of nurse leaders may create opportunities to protect this critical workforce from burnout or leaving the field [ 67 ]. However, the role of the evidence-based approach for nurse leaders in solving these problems is still a key question.
This study aimed to use a broad search strategy to ensure a comprehensive review but, nevertheless, limitations exist: we may have missed studies not included in the major international databases. To keep search results manageable, we did not use specific databases to systematically search grey literature although it is a rich source of evidence used in systematic reviews and meta-analysis [ 68 ]. We still included published conference abstract/proceedings, which appeared in our scientific databases. It has been stated that conference abstracts and proceedings with empirical study results make up a great part of studies cited in systematic reviews [ 69 ]. At the same time, a limited space reserved for published conference publications can lead to methodological issues reducing the validity of the review results [ 68 ]. We also found that the great number of studies were carried out in western countries, restricting the generalizability of the results outside of English language countries. The study interventions and outcomes were too different across studies to be meaningfully pooled using statistical methods. Thus, our narrative synthesis could hypothetically be biased. To increase transparency of the data and all decisions made, the data, its categorization and conclusions are based on original studies and presented in separate tables and can be found in Additional files. Regarding a methodological approach [ 34 ], we used a mixed methods systematic review, with the core intention of combining quantitative and qualitative data from primary studies. The aim was to create a breadth and depth of understanding that could confirm to or dispute evidence and ultimately answer the review question posed [ 34 , 70 ]. Although the method is gaining traction due to its usefulness and practicality, guidance in combining quantitative and qualitative data in mixed methods systematic reviews is still limited at the theoretical stage [ 40 ]. As an outcome, it could be argued that other methodologies, for example, an integrative review, could have been used in our review to combine diverse methodologies [ 71 ]. We still believe that the results of this mixed method review may have an added value when compared with previous systematic reviews concerning leadership and an evidence-based approach.
Our mixed methods review fills the gap regarding how nurse leaders themselves use evidence to guide their leadership role and what the measured and perceived impact of evidence-based leadership is in nursing. Although the scarcity of controlled studies on this topic is concerning, the available research data suggest that evidence-based leadership intervention can improve nurse performance, organizational outcomes, and patient outcomes. Leadership problems are also well recognized in healthcare settings. More knowledge and a deeper understanding of the role of nurse leaders, and how they can use evidence in their own managerial leadership decisions, is still needed. Despite the limited number of studies, we assume that this narrative synthesis can provide a good foundation for how to develop evidence-based leadership in the future.
Based on our review results, several implications can be recommended. First, the future of nursing success depends on knowledgeable, capable, and strong leaders. Therefore, nurse leaders worldwide need to be educated about the best ways to manage challenging situations in healthcare contexts using an evidence-based approach in their decisions. This recommendation was also proposed by nurses and nurse leaders during our discussion meeting with stakeholders.
Second, curriculums in educational organizations and on-the-job training for nurse leaders should be updated to support general understanding how to use evidence in leadership decisions. And third, patients and family members should be more involved in the evidence-based approach. It is therefore important that nurse leaders learn how patients’ and family members’ views as stakeholders are better considered as part of the evidence-based leadership approach.
Future studies should be prioritized as follows: establishment of clear parameters for what constitutes and measures evidence-based leadership; use of theories or models in research to inform mechanisms how to effectively change the practice; conducting robust effectiveness studies using trial designs to evaluate the impact of evidence-based leadership; studying the role of patient and family members in improving the quality of clinical care; and investigating the financial impact of the use of evidence-based leadership approach within respective healthcare systems.
The authors obtained all data for this review from published manuscripts.
World Health Organization. State of the world’s nursing 2020: investing in education, jobs and leadership. 2020. https://www.who.int/publications/i/item/9789240003279 . Accessed 29 June 2024.
Hersey P, Campbell R. Leadership: a behavioral science approach. The Center for; 2004.
Cline D, Crenshaw JT, Woods S. Nurse leader: a definition for the 21st century. Nurse Lead. 2022;20(4):381–4. https://doi.org/10.1016/j.mnl.2021.12.017 .
Article Google Scholar
Chen SS. Leadership styles and organization structural configurations. J Hum Resource Adult Learn. 2006;2(2):39–46.
Google Scholar
McKibben L. Conflict management: importance and implications. Br J Nurs. 2017;26(2):100–3.
Article PubMed Google Scholar
Haghgoshayie E, Hasanpoor E. Evidence-based nursing management: basing Organizational practices on the best available evidence. Creat Nurs. 2021;27(2):94–7. https://doi.org/10.1891/CRNR-D-19-00080 .
Majers JS, Warshawsky N. Evidence-based decision-making for nurse leaders. Nurse Lead. 2020;18(5):471–5.
Tichy NM, Bennis WG. Making judgment calls. Harvard Business Rev. 2007;85(10):94.
Sousa MJ, Pesqueira AM, Lemos C, Sousa M, Rocha Á. Decision-making based on big data analytics for people management in healthcare organizations. J Med Syst. 2019;43(9):1–10.
Guo R, Berkshire SD, Fulton LV, Hermanson PM. %J L in HS. Use of evidence-based management in healthcare administration decision-making. 2017;30(3): 330–42.
Liang Z, Howard P, Rasa J. Evidence-informed managerial decision-making: what evidence counts?(part one). Asia Pac J Health Manage. 2011;6(1):23–9.
Hasanpoor E, Janati A, Arab-Zozani M, Haghgoshayie E. Using the evidence-based medicine and evidence-based management to minimise overuse and maximise quality in healthcare: a hybrid perspective. BMJ evidence-based Med. 2020;25(1):3–5.
Shingler NA, Gonzalez JZ. Ebm: a pathway to evidence-based nursing management. Nurs 2022. 2017;47(2):43–6.
Farokhzadian J, Nayeri ND, Borhani F, Zare MR. Nurse leaders’ attitudes, self-efficacy and training needs for implementing evidence-based practice: is it time for a change toward safe care? Br J Med Med Res. 2015;7(8):662.
Article PubMed PubMed Central Google Scholar
American Nurses Association. ANA leadership competency model. Silver Spring, MD; 2018.
Royal College of Nursing. Leadership skills. 2022. https://www.rcn.org.uk/professional-development/your-career/nurse/leadership-skills . Accessed 29 June 2024.
Kakemam E, Liang Z, Janati A, Arab-Zozani M, Mohaghegh B, Gholizadeh M. Leadership and management competencies for hospital managers: a systematic review and best-fit framework synthesis. J Healthc Leadersh. 2020;12:59.
Liang Z, Howard PF, Leggat S, Bartram T. Development and validation of health service management competencies. J Health Organ Manag. 2018;32(2):157–75.
World Health Organization. Global Strategic Directions for Nursing and Midwifery. 2021. https://apps.who.int/iris/bitstream/handle/10665/344562/9789240033863-eng.pdf . Accessed 29 June 2024.
NHS Leadership Academy. The nine leadership dimensions. 2022. https://www.leadershipacademy.nhs.uk/resources/healthcare-leadership-model/nine-leadership-dimensions/ . Accessed 29 June 2024.
Canadian Nurses Association. Evidence-informed decision-making and nursing practice: Position statement. 2018. https://hl-prod-ca-oc-download.s3-ca-central-1.amazonaws.com/CNA/2f975e7e-4a40-45ca-863c-5ebf0a138d5e/UploadedImages/documents/Evidence_informed_Decision_making_and_Nursing_Practice_position_statement_Dec_2018.pdf . Accessed 29 June 2024.
Hasanpoor E, Hajebrahimi S, Janati A, Abedini Z, Haghgoshayie E. Barriers, facilitators, process and sources of evidence for evidence-based management among health care managers: a qualitative systematic review. Ethiop J Health Sci. 2018;28(5):665–80.
PubMed PubMed Central Google Scholar
Collins DB, Holton EF III. The effectiveness of managerial leadership development programs: a meta-analysis of studies from 1982 to 2001. Hum Res Dev Q. 2004;15(2):217–48.
Cummings GG, Lee S, Tate K, Penconek T, Micaroni SP, Paananen T, et al. The essentials of nursing leadership: a systematic review of factors and educational interventions influencing nursing leadership. Int J Nurs Stud. 2021;115:103842.
Clavijo-Chamorro MZ, Romero-Zarallo G, Gómez-Luque A, López-Espuela F, Sanz-Martos S, López-Medina IM. Leadership as a facilitator of evidence implementation by nurse managers: a metasynthesis. West J Nurs Res. 2022;44(6):567–81.
Young SK. Evidence-based management: a literature review. J Nurs Adm Manag. 2002;10(3):145–51.
Williams LL. What goes around comes around: evidence-based management. Nurs Adm Q. 2006;30(3):243–51.
Fraser I. Organizational research with impact: working backwards. Worldviews Evidence-Based Nurs. 2004;1:S52–9.
Roshanghalb A, Lettieri E, Aloini D, Cannavacciuolo L, Gitto S, Visintin F. What evidence on evidence-based management in healthcare? Manag Decis. 2018;56(10):2069–84.
Jaana M, Vartak S, Ward MM. Evidence-based health care management: what is the research evidence available for health care managers? Eval Health Prof. 2014;37(3):314–34.
Tate K, Hewko S, McLane P, Baxter P, Perry K, Armijo-Olivo S, et al. Learning to lead: a review and synthesis of literature examining health care managers’ use of knowledge. J Health Serv Res Policy. 2019;24(1):57–70.
Geerts JM, Goodall AH, Agius S, %J SS. Medicine. Evidence-based leadership development for physicians: a systematic literature review. 2020;246: 112709.
Barends E, Rousseau DM, Briner RB. Evidence-based management: The basic principles. Amsterdam; 2014. https://research.vu.nl/ws/portalfiles/portal/42141986/complete+dissertation.pdf#page=203 . Accessed 29 June 2024.
Stern C, Lizarondo L, Carrier J, Godfrey C, Rieger K, Salmond S, et al. Methodological guidance for the conduct of mixed methods systematic reviews. JBI Evid Synthesis. 2020;18(10):2108–18. https://doi.org/10.11124/JBISRIR-D-19-00169 .
Lancet T. 2020: unleashing the full potential of nursing. Lancet (London, England). 2019. p. 1879.
Välimäki MA, Lantta T, Hipp K, Varpula J, Liu G, Tang Y, et al. Measured and perceived impacts of evidence-based leadership in nursing: a mixed-methods systematic review protocol. BMJ Open. 2021;11(10):e055356. https://doi.org/10.1136/bmjopen-2021-055356 .
The Joanna Briggs Institute. Joanna Briggs Institute reviewers’ manual: 2014 edition. Joanna Briggs Inst. 2014; 88–91.
Pearson A, White H, Bath-Hextall F, Salmond S, Apostolo J, Kirkpatrick P. A mixed-methods approach to systematic reviews. JBI Evid Implement. 2015;13(3):121–31.
Johnson RB, Onwuegbuzie AJ. Mixed methods research: a research paradigm whose time has come. Educational Researcher. 2004;33(7):14–26.
Hong, Pluye P, Bujold M, Wassef M. Convergent and sequential synthesis designs: implications for conducting and reporting systematic reviews of qualitative and quantitative evidence. Syst Reviews. 2017;6(1):61. https://doi.org/10.1186/s13643-017-0454-2 .
Ramis MA, Chang A, Conway A, Lim D, Munday J, Nissen L. Theory-based strategies for teaching evidence-based practice to undergraduate health students: a systematic review. BMC Med Educ. 2019;19(1):1–13.
Sackett DL, Rosenberg WM, Gray JM, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. Bmj. British Medical Journal Publishing Group; 1996. pp. 71–2.
Goodman JS, Gary MS, Wood RE. Bibliographic search training for evidence-based management education: a review of relevant literatures. Acad Manage Learn Educ. 2014;13(3):322–53.
Aromataris E, Munn Z. Chapter 3: Systematic reviews of effectiveness. JBI Manual for Evidence Synthesis. 2020; https://synthesismanual.jbi.global .
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. 2020;18(10): 2127–33.
Hong Q, Pluye P, Fàbregues S, Bartlett G, Boardman F, Cargo M, et al. Mixed methods Appraisal Tool (MMAT) Version 2018: user guide. Montreal: McGill University; 2018.
McKenna J, Jeske D. Ethical leadership and decision authority effects on nurses’ engagement, exhaustion, and turnover intention. J Adv Nurs. 2021;77(1):198–206.
Maxwell M, Hibberd C, Aitchison P, Calveley E, Pratt R, Dougall N, et al. The TIDieR (template for intervention description and replication) checklist. The patient Centred Assessment Method for improving nurse-led biopsychosocial assessment of patients with long-term conditions: a feasibility RCT. NIHR Journals Library; 2018.
Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Res Psychol. 2006;3(2):77–101.
Pollock A, Campbell P, Struthers C, Synnot A, Nunn J, Hill S, et al. Stakeholder involvement in systematic reviews: a scoping review. Syst Reviews. 2018;7:1–26.
Braye S, Preston-Shoot M. Emerging from out of the shadows? Service user and carer involvement in systematic reviews. Evid Policy. 2005;1(2):173–93.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1):1–11.
Porta M. Pilot investigation, study. A dictionary of epidemiology. Oxford University Press Oxford; 2014. p. 215.
Kreis J, Puhan MA, Schünemann HJ, Dickersin K. Consumer involvement in systematic reviews of comparative effectiveness research. Health Expect. 2013;16(4):323–37.
Joseph ML, Nelson-Brantley HV, Caramanica L, Lyman B, Frank B, Hand MW, et al. Building the science to guide nursing administration and leadership decision making. JONA: J Nurs Adm. 2022;52(1):19–26.
Gifford W, Davies BL, Graham ID, Tourangeau A, Woodend AK, Lefebre N. Developing Leadership Capacity for Guideline Use: a pilot cluster Randomized Control Trial: Leadership Pilot Study. Worldviews Evidence-Based Nurs. 2013;10(1):51–65. https://doi.org/10.1111/j.1741-6787.2012.00254.x .
Hsieh HY, Henker R, Ren D, Chien WY, Chang JP, Chen L, et al. Improving effectiveness and satisfaction of an electronic charting system in Taiwan. Clin Nurse Specialist. 2016;30(6):E1–6. https://doi.org/10.1097/NUR.0000000000000250 .
McAllen E, Stephens K, Swanson-Biearman B, Kerr K, Whiteman K. Moving Shift Report to the Bedside: an evidence-based Quality Improvement Project. OJIN: Online J Issues Nurs. 2018;23(2). https://doi.org/10.3912/OJIN.Vol23No02PPT22 .
Thomas M, Autencio K, Cesario K. Positive outcomes of an evidence-based pressure injury prevention program. J Wound Ostomy Cont Nurs. 2020;47:S24.
Cullen L, Titler MG. Promoting evidence-based practice: an internship for Staff nurses. Worldviews Evidence-Based Nurs. 2004;1(4):215–23. https://doi.org/10.1111/j.1524-475X.2004.04027.x .
DuBose BM, Mayo AM. Resistance to change: a concept analysis. Nursing forum. Wiley Online Library; 2020. pp. 631–6.
Lalleman PCB, Smid GAC, Lagerwey MD, Shortridge-Baggett LM, Schuurmans MJ. Curbing the urge to care: a bourdieusian analysis of the effect of the caring disposition on nurse middle managers’ clinical leadership in patient safety practices. Int J Nurs Stud. 2016;63:179–88.
Article CAS PubMed Google Scholar
Martin E, Warshawsky N. Guiding principles for creating value and meaning for the next generation of nurse leaders. JONA: J Nurs Adm. 2017;47(9):418–20.
Griffiths P, Recio-Saucedo A, Dall’Ora C, Briggs J, Maruotti A, Meredith P, et al. The association between nurse staffing and omissions in nursing care: a systematic review. J Adv Nurs. 2018;74(7):1474–87. https://doi.org/10.1111/jan.13564 .
Lúanaigh PÓ, Hughes F. The nurse executive role in quality and high performing health services. J Nurs Adm Manag. 2016;24(1):132–6.
de Kok E, Weggelaar-Jansen AM, Schoonhoven L, Lalleman P. A scoping review of rebel nurse leadership: descriptions, competences and stimulating/hindering factors. J Clin Nurs. 2021;30(17–18):2563–83.
Warshawsky NE. Building nurse manager well-being by reducing healthcare system demands. JONA: J Nurs Adm. 2022;52(4):189–91.
Paez A. Gray literature: an important resource in systematic reviews. J Evidence-Based Med. 2017;10(3):233–40.
McAuley L, Tugwell P, Moher D. Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet. 2000;356(9237):1228–31.
Sarah S. Introduction to mixed methods systematic reviews. https://jbi-global-wiki.refined.site/space/MANUAL/4689215/8.1+Introduction+to+mixed+methods+systematic+reviews . Accessed 29 June 2024.
Whittemore R, Knafl K. The integrative review: updated methodology. J Adv Nurs. 2005;52(5):546–53.
Download references
We want to thank the funding bodies, the Finnish National Agency of Education, Asia Programme, the Department of Nursing Science at the University of Turku, and Xiangya School of Nursing at the Central South University. We also would like to thank the nurses and nurse leaders for their valuable opinions on the topic.
The work was supported by the Finnish National Agency of Education, Asia Programme (grant number 26/270/2020) and the University of Turku (internal fund 26003424). The funders had no role in the study design and will not have any role during its execution, analysis, interpretation of the data, decision to publish, or preparation of the manuscript.
Authors and affiliations.
Department of Nursing Science, University of Turku, Turku, FI-20014, Finland
Maritta Välimäki, Tella Lantta, Kirsi Hipp & Jaakko Varpula
School of Public Health, University of Helsinki, Helsinki, FI-00014, Finland
Maritta Välimäki
Xiangya Nursing, School of Central South University, Changsha, 410013, China
Shuang Hu, Jiarui Chen, Yao Tang, Wenjun Chen & Xianhong Li
School of Health and Social Services, Häme University of Applied Sciences, Hämeenlinna, Finland
Hunan Cancer Hospital, Changsha, 410008, China
Gaoming Liu
You can also search for this author in PubMed Google Scholar
Study design: MV, XL. Literature search and study selection: MV, KH, TL, WC, XL. Quality assessment: YT, SH, XL. Data extraction: JC, MV, JV, WC, YT, SH, GL. Analysis and interpretation: MV, SH. Manuscript writing: MV. Critical revisions for important intellectual content: MV, XL. All authors read and approved the final manuscript.
Correspondence to Xianhong Li .
Ethics approval and consent to participate.
No ethical approval was required for this study.
Not applicable.
The authors declare no competing interests.
We modified criteria for the included studies: we included published conference abstracts/proceedings, which form a relatively broad knowledge base in scientific knowledge. We originally planned to conduct a survey with open-ended questions followed by a face-to-face meeting to discuss the preliminary results of the review. However, to avoid extra burden in nurses due to COVID-19, we decided to limit the validation process to the online discussion only.
Publisher’s note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Supplementary material 2, supplementary material 3, supplementary material 4, supplementary material 5, supplementary material 6, supplementary material 7, supplementary material 8, supplementary material 9, supplementary material 10, rights and permissions.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
Cite this article.
Välimäki, M., Hu, S., Lantta, T. et al. The impact of evidence-based nursing leadership in healthcare settings: a mixed methods systematic review. BMC Nurs 23 , 452 (2024). https://doi.org/10.1186/s12912-024-02096-4
Download citation
Received : 28 April 2023
Accepted : 13 June 2024
Published : 03 July 2024
DOI : https://doi.org/10.1186/s12912-024-02096-4
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1472-6955
Journal of Translational Medicine volume 22 , Article number: 601 ( 2024 ) Cite this article
210 Accesses
Metrics details
CCN4 (cellular communication network factor 4), a highly conserved, secreted cysteine-rich matricellular protein is emerging as a key player in the development and progression of numerous disease pathologies, including cancer, fibrosis, metabolic and inflammatory disorders. Over the past two decades, extensive research on CCN4 and its family members uncovered their diverse cellular mechanisms and biological functions, including but not limited to cell proliferation, migration, invasion, angiogenesis, wound healing, repair, and apoptosis. Recent studies have demonstrated that aberrant CCN4 expression and/or associated downstream signaling is key to a vast array of pathophysiological etiology, suggesting that CCN4 could be utilized not only as a non-invasive diagnostic or prognostic marker, but also as a promising therapeutic target. The cognate receptor of CCN4 remains elusive till date, which limits understanding of the mechanistic insights on CCN4 driven disease pathologies. However, as therapeutic agents directed against CCN4 begin to make their way into the clinic, that may start to change. Also, the pathophysiological significance of CCN4 remains underexplored, hence further research is needed to shed more light on its disease and/or tissue specific functions to better understand its clinical translational benefit. This review highlights the compelling evidence of overlapping and/or diverse functional and mechanisms regulated by CCN4, in addition to addressing the challenges, study limitations and knowledge gaps on CCN4 biology and its therapeutic potential.
Extracellular matrix (ECM) proteins, including but not limited to collagens, fibronectins, and elastin, provide structural stability and physical framework for cellular organization across all mammalian tissues and organs. In addition to physical scaffolding, ECM proteins play a crucial role in regulating cellular processes by interacting with cell surface receptors, cytokines, growth factors and other extracellular proteins. These regulatory functions are primarily driven by a subgroup of ECM proteins known as matricellular proteins which are non-structural in nature. Matricellular proteins, such as secreted protein acidic and rich in cysteine (SPARC)-protein family, thrombospondin, periostin, osteopontin and fibulins amongst others are multidomain proteins that are secreted in the ECM and are critical for day-to-day physiological processes, including cell proliferation, migration, and adhesion [ 1 ].
In addition to other known matricellular proteins, CCN family members are highly conserved, secreted multi-modular cysteine rich proteins, composed of six homologous proteins. The first three family members namely, (i) cysteine-rich protein 61 (Cyr61), (ii) connective tissue growth factor (CTGF) and (iii) nephroblastoma overexpressed (NOV) were discovered in early 1990’s which led to the acronym CCN based on their order of discovery. CCN is also abbreviated for “Cellular Communication Network” [ 2 ]. The other three members were discovered in the late 1990’s and were associated with Wnt-1 induced signaling pathway and hence were named, (iv) Wnt-1 induced secreted protein-1 (WISP1), (v) WISP2 and (vi) WISP3. Over the past two decades, extensive research on CCN family members uncovered their diverse cellular and biological functions, designating them with alternative names listed in Table 1 . The International CCN Society proposed a unifying nomenclature for the CCN family members to avoid confusion due to numerous synonymic names interchangeably used in scientific literature [ 3 ]. In 2018, the HUGO (Human Genome Organization) Gene Nomenclature Committee officially approved and adapted the new names CCN1-6 for the family members [ 2 , 3 ]. For this review, these proteins are named CCN1-CCN6, in accordance with the official nomenclature recommendations.
Based on PubMed (R) database, there are over 3000 publications on CCN protein family, out of which surprisingly more than 2900 studies primarily focus on CCN2 and only about 300 publications focus on CCN4, highlighting the dearth of literature and disparity towards other CCN members. Despite the overwhelming attention given to CCN protein family, relatively little is known about the role of CCN4 both in human health and diseases. Notably, the role of CCN4 has been previously studied and reviewed by researchers in a disease specific context [ 4 , 5 ]. However, here, we aim to comprehensively review the growing body of literature on the diverse functions of CCN4 and its role in a vast array of pathophysiological conditions, including cancer, fibrosis, inflammatory conditions (i.e., arthritis) and metabolic disorders, including obesity and diabetes.
CCN4 is the fourth member of the CCN family, commonly known as WISP1. The earliest study published on CCN4 dates back to the late 1990s where Pennica and colleagues first identified CCN4 in mouse mammary epithelial cells and its role in tumorigenesis [ 6 ]. WISP1 gene on chromosome 8q24.22 in humans encodes the 367 amino acid CCN4 protein with a predicted molecular mass of approximately 40 kDa. The murine and human CCN4 cDNA length is 1766 and 2830 bases, respectively, comprising of four introns and five exons [ 6 , 7 ]. Structurally, all CCN family members are characterized by four conserved cysteine rich domains, except CCN5 which lacks domain 4. The N-terminus of CCN proteins consists of a signal peptide sequence, essential for secretory proteins, which is followed by four structural domains named based on the sequence homology to (i) insulin-like growth factor binding protein like domain (IGFBP; domain 1), (ii) the von Willebrand factor C repeat (VWC; domain 2), (iii) thrombospondin-homology type 1 repeat (TSP1; domain 3) and (iv) the C-terminal Cysteine knot containing domain (CT; domain 4) as shown in Fig. 1 . The protein sequence contains 38 conserved cysteine residues, distributed across domain 1 (12 cysteine residues), domain 2 (10 cysteine residues), domain 3 (6 cysteine residues), and domain 4 (10 cysteine residues). CCN4 shares approximately 39%, 37% and 42% amino acid sequence homology to CCN2, CCN5 and CCN6, respectively [ 8 , 9 ].
Multi-modular structure of CCN family. All the CCN matricellular proteins consist of a signal peptide (SP), insulin-like growth factor binding protein like domain (IGFBP; domain 1), von Willebrand factor C repeat (VWC; domain 2), thrombospondin-homology type 1 repeat (TSP1; domain 3) and C-terminal Cysteine knot containing domain (CT; domain 4) encoded by exon 1 to exon 5 respectively. Domain 2 and domain 4 are connected by a variable hinge region which is highly susceptible to cleavage by proteolytic enzymes such as, Kallikrein-related peptidases 12 (KLK12), a disintegrin and metalloproteinase domain-containing protein 28 (ADAM28) and matrix metalloproteases (MMPs). Domain specific total cysteine residues and binding partners are also listed in the table. The image was created with BioRender.com. IGFBP: insulin-like growth factor binding protein; VWC: von Willebrand factor C repeat; TSP1: thrombospondin-homology type 1 repeat; CT: C-terminal Cysteine knot containing domain; IGF: insulin-like growth factors; BMP4: bone morphogenic protein 4; LRP1: Low density lipoprotein receptor-related protein 1; HSPGs: heparin sulphate proteoglycans; TGF-β: transforming growth factor beta
CCN family proteins have been shown to physically bind and interact with a plethora of multi-ligand receptors and proteins, ranging from ECM proteins (such as fibronectin [ 10 , 11 ], vitronectin [ 12 ], perlecan [ 13 ], integrins [ 14 , 15 , 16 ], growth factors (such as fibroblast growth factors (FGFs) [ 17 , 18 , 19 ], vascular endothelial growth factor (VEGF) [ 20 ], bone morphogenetic protein (BMP) [ 21 ] and transforming growth factor (TGF-β) [ 21 ], proteoglycans (such as heparan sulfate proteoglycans (HSPG) [ 22 , 23 , 24 ], aggrecan, decorin and biglycan [ 25 ] and low-density lipoprotein receptor-related proteins (LRP) [ 26 , 27 ], cation-independent mannose-6-phosphate [ 28 ], Neurogenic locus notch homolog protein (Notch) [ 29 ], and receptor activator of nuclear factor kappa B (NF-κB) (RANK) [ 9 , 30 , 31 ]. Despite abundance of binding partners available for CCN family of proteins, CCN4 has only been shown to interact with integrins [ 32 , 33 ] and small leucine rich proteoglycans, such as decorin and biglycan [ 25 ], and domain specific binding sites that facilitate these interactions remain unknown, owing to the bias towards other CCN members, particularly CCN1 and CCN2.
Post-translational modifications (PTMs) play a crucial role in structural and functional characteristics of a protein. With respect to the CCN family, four potential N-glycosylation sites have been identified in CCN4 [ 6 ]. Similar glycosylation patterns have also been observed in CCN2, particularly at asparagine 28 and 225 leading to either 36 kDa or 38 kDa molecular weight that appears as a double band upon immunoblotting [ 34 , 35 ]. Furthermore, researchers have also demonstrated that the glycosylated versus non-glycosylated ratio of CCN3 profoundly influences the cell proliferative, migrative and invasive properties of chondrosarcoma cell line Jeg3 [ 36 ]. Differences in the glycosylation patterns between normal and cancerous cells have also been reported, highlighting its functional significance in disease pathologies [ 37 ]. Besides glycosylation, O-fucosylation (O-linked fucose modification) has been recently identified in the TSP domain 3 of CCN2 protein [ 38 ]. Overall, these PTMs could be exploited to modulate CCN4 function; yet the PTM analysis in CCN family remains in its infancy, and more research is needed to shed more light on its clinical significance.
As previously mentioned, CCN genes contain four introns and five exons. Each of the exon codes for each domain in the structure. The N-terminus signal peptide is encoded by exon 1, whereas domain 1–4 are encoded by exon 2–5, respectively. From the evolutionary perspective, the order of CCN domains remains highly conserved and are connected through a linker. The linker connecting domain 1–2 (3aa) and domain 3–4 (9aa) in CCN4 structure are relatively short compared to domain 2–3 hinge (27aa) which makes it susceptible to proteolytic cleavage by protease enzymes, such as matrix metalloproteases (MMPs) generating truncated versions of the protein. The central variable linker has been shown to be targeted by MMP1, MMP3, MMP 7, MMP9, MMP13, MMP14 along with other peptidases, such as disintegrin and metalloproteinase domain-containing protein 28 (ADAM28), Kallikrein-related peptidases 12 (KLK12), plasmin and elastase [ 39 , 40 , 41 , 42 ]. Experimentally, the protease mediated degradome pattern has been extensively elucidated for CCN1, CCN2, CCN3 and CCN5 [ 39 , 43 , 44 , 45 ]. While the cleavage sites for CCN4 remain undiscovered, researchers have identified three truncated versions in biological samples as shown in Fig. 2 . In addition, the CCN4 mRNA is also subjected to alternative splicing, which can result in truncated variants of proteins, lacking one or more domains [ 46 ]. In 2001, Tanaka and colleagues reported a novel truncated CCN4 variant (Mol. Wt. 30 kDa), commonly known as WISP1v lacking domain 2 or VWR module as a product of alternative splicing in human scirrhous gastric carcinoma tissue [ 47 ]. Stable transfection of this variant increased gastric carcinoma cell migration up to five-fold as compared to full length CCN4 in a co-culture Boyden Chamber. Later in 2003, they also detected CCN4 truncated variant, WISP1v in human invasive cholangiocarcinoma tissues [ 48 ]. Further, in 2008, Inksonand colleagues at the National Institutes of Health (NIH) detected a similar CCN4 spliced variant lacking exon 3 in human bone marrow stromal cells (hBMSC) using RT-PCR, which they referred to as WISP1va [ 49 ]. In 2004, another truncated variant of CCN4, lacking domain 2, 3 and 4, also known as WISP1Δex3-4 was reported in 4 different human hepatocellular carcinoma cell lines (HuH-6, HuH-7, VGH and HepG2) in conjugation with full length and WISP1v. WISP1Δex3-4 variant only contains IGFBP/ domain 1 due to the alternative splicing of mRNA. The transcript contains exon 1, 2 and 5, however the conjugation of exon 2 and 5 causes a frame shift at residue 117, resulting in a premature stop of the reading frame and hence only translating to domain 1 [ 50 ]. Similarly, WISP1Δex3-4 truncated variant was also detected in chondrocytes derived from human chondrosarcoma cell line (HCS-2/8) and rabbit growth cartilage [ 51 ]. Although the functional significance of full length CCN4 has been extensively demonstrated, the domain specific activity remains unknown till date despite the detection of CCN4 truncated versions in human tissues.
Functional effects of CCN4 Truncated variants. The image was created with BioRender.com
Meanwhile, emerging evidence in the literature suggests that CCN4 can in turn modulate MMP expression. CCN4 treatment for 24 h in human chondrosarcoma cell line, JJ012 increased MMP2 expression in cell lysate and supernatant, detected at both protein and transcript level utilizing western blot and qPCR [ 33 ]. Further, CCN4 has also been shown to promote cell motility by upregulating MMP2 and MMP9 expression in human osteosarcoma cell line, U2OS as pretreatment with selective MMP2 and MMP9 inhibitors abrogated CCN4 induced wound healing and migration [ 32 ]. In addition, stimulation of murine macrophages (RAW 264.7), primary human chondrocytes and synovial cells with CCN4 (1.0 µg/ml) for 24 h upregulates MMP3 and MMP9 expression [ 52 ]. Also, CCN4 drives MMP2 and MMP9 expression in murine primary renal tubular epithelial cells as shRNA mediated CCN4 knockdown decreased MMP2 and MMP9 [ 53 ]. Finally, CCN4 has also been shown to upregulate the expression of MMP1, MMP2, MMP3, MMP9 and MMP14 in vein smooth muscle cells via β-catenin mediated pathways. CCN4 mediated MMP9 induction is partly due to activator protein-1 (AP-1) [ 54 ].
The control exercised by CCN4 on the MMPs can drive cell motility via two distinct, though parallel mechanisms. The observations derived from literature unveil that CCNs can indirectly influence cell motility by upregulating MMPs, which drives ECM degradation, facilitating cell migration and invasion [ 55 ]. Another direct mechanism by which CCN4 can influence cellular processes could be through MMP-dependent self-regulation, where CCN4-induced MMP can in turn act on CCN4 itself to generate different truncated versions of the protein. Depending on the tissue expression profile of MMP subtypes and their corresponding CCN4 cleavage sites, these truncated variants can possess similar and/or unique functional signature as compared to the full length CCN4 protein. Further, alterations in CCN4 expression profile have been observed in a plethora of diseases, ranging from cancer [ 56 ], liver fibrosis [ 57 ], idiopathic pulmonary fibrosis (IPF) [ 58 , 59 , 60 ], obesity and type 2 diabetes mellitus [ 61 , 62 ], amongst others. The CCN-MMP interplay can continue to regulate one another, leading to a vicious positive-feedback cycle which can potentially aggravate the underlying condition by generating truncated CCN4 which could be responsible for diverse cellular functions. Taken together, CCN4 mediated regulation of MMPs is a highly complex, expression dependent, cell type and tissue-specific mechanism which yet remains underexamined and warrants further investigation.
In humans, CCN4 expression has been confirmed in various organs, such as lung, heart, kidney, pancreas, placenta, brain, small intestine, ovaries, and skeletal muscle, amongst others [ 6 ]. Within the organs, the expression is cell type specific. For example, CCN4 is mainly expressed in fibroblasts (lung [ 63 ], liver [ 57 ], heart [ 64 ]), epithelial cells (lung) [ 60 ], cardiomyocytes (heart) [ 65 ], neurons [ 66 ], microglia (brains) [ 67 ], chondrocytes [ 33 ], osteoblast (bone) [ 32 ] and many more. The diverse expression profile endows CCN4 protein with pleotropic functions in a tissue and cell specific manner. CCN4 plays a crucial role in cell proliferation, migration, adhesion, wound healing and repair in embryogenesis, fibrosis, tumorigenesis, osteoarthritis, etc. [ 68 ]. In addition, differential expression of CCN4 has been attributed to numerous diseases, which can be utilized as a prognostic biomarker.
Cancer represents a global health issue with increasing cases every year [ 69 ]. According to the national cancer society, cancer is the second leading cause of death, with approximately 1 in 3 people suffering in the US. Recent technological advances in cellular and molecular biology have opened endless avenues for the development of targeted anti-cancer treatment, ranging from stem-cell therapy, gene therapy to targeted precision therapy [ 70 ]. Differential gene expression and novel biomarker discovery efforts help identify promising druggable targets with potential therapeutic benefits in the clinic. CCN4 is one such recently identified protein which plays a crucial role in inflammation and tumorigenesis [ 71 ].
Over two decades, numerous studies have investigated the role of CCN4 in tumor microenvironment, however the ambiguous expression profile and paradoxical functional outcomes of CCN4 in various cancers makes it a challenging yet controversial target. Generally, CCN4 dysregulation and atypical expression profile have been linked in a range of pathophysiological conditions, such as fibrosis, diabetes, obesity etc. [ 57 , 72 ]. Similar aberrant expression profile has been observed in various cancer types as well. For instance, CCN4 is upregulated in a vast array of cancer tissue specimens compared to healthy controls, such as lung cancer [ 73 ], ovarian cancer [ 74 ], colon cancer [ 75 ], gastric cancer [ 76 ], breast cancer [ 77 ] and esophageal squamous cell carcinoma [ 78 ], among others. CCN4 is also characterized as an oncogene, that promotes tumor progression by positively regulating pro-oncogenic cellular functions, like cell proliferation, migration, and invasion. In addition, higher CCN4 protein levels were associated with low survival rate in cancer patients [ 79 , 80 , 81 ]. In contrast, others have reported tumor suppressive nature of CCN4, promoting cellular apoptosis whilst inhibiting cell growth, migration, invasion, and metastasis. Many researchers have also reported CCN4 downregulation in breast cancer [ 82 , 83 ], liver cancer [ 84 ] and skin cancer [ 85 ]. The discrepancies could also be attributed to other confounding variables, such as patient family-history, age, gender, co-morbidities, treatment regimen, cancer-type, cancer-stage, tumor size etc., however in-depth analysis is required before establishing any correlation. Rather than simply distinguishing all diseased patients as either high or low expressers, some studies also segregate the diseased cohort into two groups, CCN4 low and high expressing patients based on the expression profile [ 79 , 80 , 81 ]. The spatial and temporal tumor heterogeneity leads to a complex dynamic cellular state which can also govern the distinct CCN4 expression patterns. A summary of the functional and mechanistic effects of CCN4 on diverse tumor types, along with the expression patterns is provided in Table 2 .
Tumor microenvironment is composed of cancer cells, stromal cells, such as immune cells, fibroblasts, endothelial cells in conjunction with ECM, all of which are constantly communicating and influencing each other via cytokines, chemokines and inflammatory signaling molecules [ 86 ]. Although numerous cell-based and animal experimental models have been utilized to study the effect of CCN4 in cancer, majority of the studies are conducted in an isolated single cancer cell line model, which fails to capture the intricate crosstalk amongst different cell types within the tumor microenvironment. Given that CCN4 is a secreted protein, better understanding of both autocrine and paracrine effects is crucial to decipher the functional disparity and clinical significance of CCN4 to develop novel pharmacological interventions targeting CCN4 in cancer [ 87 ]. Furthermore, mechanistic data is derived from either loss-of function approach, including shRNA, siRNA or CRISPR mediated transcriptional repression or protein overexpression approach using viral vector. Every experimental approach has its own caveats, here both approaches may fail to capture the true function of endogenous CCN4 due to the off-target effects and lack of specificity leading to partial loss-of function or by attaining supraphysiological protein levels [ 88 , 89 ]. Some studies also utilize recombinant CCN4 protein to understand its biology, which has its own drawbacks. Besides the time-consuming and costly process, the multi-modular structure of CCN4 is susceptible to proteolytic cleavage generating functionally active or in-active truncated variants. Additionally, species to species variations in post-translational modification patterns could also influence the biological activity of the protein [ 90 ]. Hence, caution must be exercised while interpreting the functional consequences of full-length CCN4 protein.
Molecular pathways governing CCN4 mediated cellular oncogenic responses remains undiscovered, due to the lack of one CCN-specific cognate receptor. However, within the limited available literature, integrins have been identified as the major contributors in driving CCN4-dependent biological responses. Researchers have shown that CCN4 binds and interacts with integrins, such as, αVβ1, αVβ3, αVβ5, α4β1, α5β1 and α6β1 in myriad cancerous conditions to drive cell proliferation, migration, invasion etc. making them one of the most extensively documented functionally significant receptors for CCN4 till date [ 32 , 33 , 37 , 74 , 87 , 91 , 92 , 93 , 94 , 95 ]. In addition, CCN4 polymorphism directly influences the risk of developing tumor [ 96 , 97 ], disease progression [ 98 ], response to chemotherapy toxicity [ 99 ] and CCN4 expression via epigenetic modulation such as DNA methylation [ 100 ].
Fibroblasts are highly plastic cells with mesenchymal origin found throughout the body to provide structural integrity and basic framework for cells and tissues. Fibroblasts are elongated stellate shaped cells that are most commonly present in the stroma. They are responsible for maintaining, synthesizing, and organizing ECM proteins, such as collagen, fibronectin (FN1), laminins etc. and therefore, play a key role in wound healing and tissue repair [ 128 ]. Mechanical or chemical stimuli from the site of injury can activate the otherwise quiescent tissue resident fibroblasts and initiate their transformation into myofibroblasts. Under physiological homeostasis, once the wound healing and repair has been completed, myofibroblasts undergo apoptosis to prevent excessive ECM deposition. However, chronic persistent injury and insult, can dysregulate and disrupt the body’s natural restorative process, leading to excessive ECM deposition, tissue scarring and architectural remodeling, loss of tissue elasticity and function, resulting in fibrosis [ 129 ]. Fibrosis is the most common pathological outcome in chronic inflammatory conditions related to lungs (Idiopathic pulmonary fibrosis; IPF), skin (scleroderma), kidney diseases, liver, and heart (cardiac fibrosis) [ 130 ].
Fibrosis is a chronic, highly progressive, and irreversible condition that is the leading cause of organ dysfunction and death. Although, two FDA (Food and Drug Administration) approved drugs, Nintedanib and Pirfenidone provide symptomatic relief in IPF, there are currently no drugs that address the underlying cause to cure fibrosis [ 131 ]. Emerging evidence indicates that CCN4 protein is pro-fibrotic in nature and modulates fibroblast proliferation. CCN4 is highly upregulated in both pre-clinical bleomycin model of pulmonary fibrosis, paraquat induced model [ 132 , 133 ] and in clinical IPF patients compared to non-diseased control. Furthermore, Klee and colleagues demonstrated that CCN4 is downstream of TGF-β and TNF-α, which are the master regulators of fibrosis and inflammation. CCN4 promotes the proliferation of human lung fibroblast in an IL-6 dependent manner as siRNA mediated knockdown or antibody-mediated neutralization of CCN4 abrogates the effect [ 63 ]. The CCN4 upregulation could be partly due to the downstream effects of TGF-β in conjunction with the downregulation of microRNAs (miRNAs), particularly miR-92a, which has been shown to modulate CCN4 expression. miR-92a expression is inversely corelated with CCN4 expression in IPF patient lung specimens [ 134 ]. In addition, miR-101 and miR-181a-5p regulate CCN4 expression in cystic fibrosis [ 135 ]. Airway epithelial cells not only act as the first line of defense against environmental threats but also serve as a dynamic junction to relay the extracellular signal to other immune cells that underlay smooth muscle cells, fibroblasts and myofibroblasts. Chronic epithelial insult and dysfunction have been attributed to the pathogenesis of asthma and IPF [ 136 , 137 , 138 ]. Heise and colleagues demonstrated that mechanical stress and stretch can induce CCN4 expression in primary mouse type II alveolar epithelial cells (AT-II cells) and drive epithelial to mesenchymal transition (EMT). Further, CCN4 neutralizing antibody significantly abrogated stretch induced EMT, emphasizing the critical role of CCN4 in EMT [ 139 ]. Similar findings were validated by another group, where treatment with recombinant CCN4 (1 µg/ml) promoted cell proliferation and EMT in primary mouse AT-II cells. In addition, stimulation with CCN4 (1 µg/ml) for 6 to 12 h upregulates fibrotic genes, such as Col1A1, Col1A2 and FN1 in mouse and human fibroblasts and the effects were attenuated in the presence of a CCN4 neutralizing antibody in the bleomycin model [ 60 ]. CCN4 mediated cell adhesion in airway epithelial cells (A549) is partly mediated by integrins, as αVβ5, αVβ3 or αVβ1 neutralizing antibodies partially blocked the effect [ 140 ]. Irradiation has been shown to upregulate CCN4 expression in human lung fibroblasts with implications in radiation-induced lung injury in cancer patients [ 141 ]. Nintedanib, a small molecule receptor tyrosine kinase inhibitor, approved for IPF has also been shown to regulate Wnt/β-catenin pathway and prevent myofibroblast activation by inhibiting CCN4 in mouse lung myofibroblast cell line, Mlg [ 142 ]. Furthermore, secreted CCN4 was significantly decreased upon treatment with Nintedanib (1 µM) in ex-vivo 3D-human lung tissue. While CCN4 levels remained unaffected upon treatment with Pirfenidone (500 µM) detected by ELISA (Enzyme-linked immunosorbent assay) [ 143 ]. However, in another study, both Nintedanib (0.3 µM) and Pirfenidone (1 mM) reduced in precision cut rat-lung slices [ 144 ]. CCN4 can also facilitate inflammatory response in fibrosis. In addition to IL6 and CCL2 production [ 63 , 145 ]. CCN4 also mediates the release of the proinflammatory cytokine TNF-α from macrophages (RAW264.7) in an integrin αVβ3 dependent manner and regulates TLR4 signaling in an acute lung injury pre-clinical model [ 146 ].
Apart from pulmonary fibrosis, CCN4 has also been involved in liver fibrosis and inhibition of CCN4 can reverse liver fibrosis [ 147 , 148 , 149 ]. Stimulation with pro-fibrotic/ pleotropic cytokines, such as TGF-β and TNF-α increased CCN4 induction in-vitro in hepatic stellate cell lines (LX-2 and HSC-T6/ HSC). In addition, recombinant CCN4 drives LX-2 cell proliferation in a dose-dependent manner. CCN4 protein expression was also significantly upregulated in-vivo in carbon tetrachloride (CCl 4 )-induced liver fibrosis model [ 148 ] and CCN4 antibody significantly decreased pro-fibrotic protein expression (collagen, α-smooth muscle actin (αSMA), TGF-β1), reduced liver necrosis, NF-κB activation and pro-inflammatory cytokine production, such as IL-6, CCL-2 and TNF-α [ 149 ]. Huang and colleagues utilized RNA sequencing analysis to identify a set of differentially expressed genes in ex-vivo precision-cut lung tissue slice to design a robust biomarker panel to assess antifibrotic effects of various interventions. CCN4 was amongst other genes and secretory proteins in the panel and was used as a reliable end point parameter to evaluate the efficacy and anti-fibrotic activity of the compounds [ 144 ]. Interestingly, as the molecular mechanisms driving the initiation and progression of fibrosis remain poorly understood, recent study identified a novel pathway dissecting the role of CCN4 in the progression of liver fibrosis and not initiation of the disease as CCN4 knockout animals were protected against liver-fibrosis progression in pre-clinical CCl 4 -liver fibrosis and choline-deficient, L-amino-acid-defined, along with the high-fat diet (CDA-HFD)-induced NASH models. Furthermore, functional analysis confirmed that CCN4 mediated fibrogenesis and myofibroblast motility is partly driven by integrin (αV, α11) dependent myocardin-related transcription factor (MRTF) activation, that drives MRTF-downstream cytoskeletal gene targets, such as αSMA, myosin light chain 9, filamin A, etc., in primary HSCs. Although the precise mechanism of fibrosis remains elusive, evidence from current literature indicate that CCN4 could serve as a potential therapeutic target for the treatment of liver fibrosis and small or large molecule therapeutic modalities that inhibit CCN4 can elicit protective effects in liver injury and fibrosis.
CCN4 has a crucial role in skin biology, wound healing, and repair. CCN4 protein expression was upregulated 4–7 days post cutaneous wounding and facilitated wound healing as the extent of wound closure was significantly delayed in CCN4-knockout mice due to the downregulation of ECM proteins, such as Col1A1 and FN1 [ 150 ]. Immunohistochemistry analysis of the incision reveals that CCN4 is also abundantly expressed in inflammatory cells, such as neutrophils. CCN4 is crucial for wound healing as it drives proliferation and migration of both human and mouse dermal fibroblasts through integrin α5β1 as selective siRNA mediated CCN4-knockdown resulted in the loss of function. Furthermore, stimulation with 100 ng/ml CCN4 induced activation and phosphorylation of ERK and c-Jun N-terminal kinase (JNK), crucial for cell proliferation, an effect which was blocked in the presence of selective small molecule MAPK inhibitor, PD98059 and αVβ1-antibody [ 150 ]. CCN4 not only binds with integrins but can also interact with cell surface small-leucine rich proteoglycans such as, decorin and biglycan on human dermal fibroblasts [ 25 ], although the downstream mechanistic pathway engagement from the latter remains unknown.
Besides the role of CCN4 in lung, liver, and skin fibrosis, CCN4 has also been shown to be implicated in cardiac remodeling and fibrosis associated with cardiomyopathies. Similar to what others have shown in diverse pathological conditions, CCN4 is substantially upregulated post-myocardial infarction (MI) and ischemic injury [ 64 , 65 , 151 , 152 ]. CCN4 modulates cardiac remodeling by positively influencing cardiomyocyte hypertrophy in an Akt-dependent manner and stimulation with recombinant CCN4 induces cardiac fibroblast proliferation and enhances ECM protein deposition, particularly collagen [ 65 ]. As previously mentioned, pro-inflammatory cytokines and chemokines are closely intertwined with CCN4 biology, and both have been shown to positively regulate each other. Along the same lines, stimulation with either TNF-α and/or IL-1β significantly induced CCN4 protein expression both in left-ventricular myocardium post-MI in-vivo and in rat cardiac myocytes in-vitro [ 65 ]. These findings were further strengthened in another study, where TNF- α induced CCN4 upregulation was shown to be dependent on ERK1/2 mediated CREB phosphorylation at Ser133 as pretreatment with small molecule inhibitors such as PD98059 (ERK1/2) and U0126 (MEK) failed to induce CREB-phosphorylation [ 64 ]. As TNF-α is known to activate a vast array of downstream signaling molecules, the authors also ruled out the involvement of JNK- and NF-κB activation for CCN4 upregulation and concluded that TNF-α mediated responses were strictly dependent on MEK1-ERK1/2-CREB signaling in cardiac fibroblasts [ 64 ]. In addition to CCN4, biglycan, the potential binding partner of CCN4 is also upregulated in cardiac fibroblasts up to threefold post-MI in-vivo suggesting intracellular CCN4 signal amplification [ 65 ].
Renal fibrosis is one of the most common pathological hallmarks in chronic kidney diseases (CKD). A recent study found that CCN4 levels were highly upregulated in preclinical unilateral ureteral obstruction (UUO) renal fibrosis model in animals and clinically in serum and kidney tissue biopsy samples from CKD patients [ 153 , 154 , 155 ]. Mechanistically, antibody mediated neutralization or siRNA mediation knockdown of CCN4 provides protection against renal fibrosis by attenuating fibrotic markers, such as Collagen, FN1 and αSMA deposition both in tubular epithelial cells (NRK52E cell line) and in-vivo in mouse models. Interestingly, the role of autophagy in fibrosis remains controversial as there are opposing results on whether it promotes or inhibits fibrogenesis. However, previous investigations have reported enhanced autophagic markers in proximal tubular cells, pharmacological inhibition of which reversed renal fibrosis. Similarly, CCN4 inhibition significantly reduced autophagy in UUO renal fibrosis model, suggesting that CCN4 also exercise control over pathways governing programmed cell death, modulating the development of renal fibrosis [ 156 ]. Serum CCN4 levels were also found to be elevated in vast array of CKDs (chronic kidney disease), such as diabetic nephropathy, IgA nephropathy and primary focal segmental glomerular sclerosis [ 153 , 157 ]. CCN4 has also been implicated to drive migration, invasion and EMT in primary renal tubular epithelial cells in uremia associated with end-stage renal failure [ 53 ]. In addition, the growing body of literature on non-coding RNAs, particularly miRNA and circular RNA (circRNA) and its prominent role in the pathophysiology of a wide array of disease highlights them as potent gene regulators. Regarding CCN4 gene regulators, miR-92a, miR-101 and miR-181a-5p have been identified to inversely modulate CCN4 expression in lungs. A recent study discovered two novel non-coding RNAs that target CCN4 to modulate renal fibrosis. The results demonstrate that circRNA-33702 is overexpressed in UUU-renal fibrosis models and possess profibrotic role by aggravating collagen and FN1 expression [ 158 ]. Conversely, miR-29b-3p negatively modulates CCN4 expression, in conjunction with other ECM proteins in mouse proximal tubule cell line (BUMPT cells). Since circRNA-33702 and miR-29b-3p have opposing effects on CCN4 expression and colocalization, luciferase analysis revealed that circRNA-33702 directly binds miR-29b-3p to upregulate CCN4 expression and consequently promote renal fibrosis [ 158 ]. The anti-fibrotic effects of miR-29b-3p on cardiac and liver fibrosis have also been demonstrated by others [ 159 , 160 , 161 , 162 ]. Apart from miR-29b, long non-coding RNA, Gm12840 and miR-677-5p also target CCN4/Akt signaling pathway to modulate fibroblast activation in ischemia–reperfusion induced renal fibrosis [ 163 ]. Overall, non-coding RNAs possess exciting potential as novel therapeutic targets for the treatment of fibrosis, however more investigation in this area is required to comprehensively understand the crosstalk amongst non-coding RNAs in a tissue-specific context to target CCN4.
In addition, all the CCN family members are functionally interconnected with a high degree of crosstalk by compensatory or opposing mechanisms. Emerging evidence points towards the anti-fibrotic effects of CCN3 protein and one of the possible anti-fibrotic mechanisms involves downregulation of profibrotic CCN4 protein. Overexpression of CCN3 in the skin fibroblast cell line NIH3T3 significantly downregulated CCN4 expression and hence conferred protection against fibrosis, although the exact mechanisms by which CCN3 modulates CCN4 remains unknown. It is speculated that due to its presence in the nucleus, CCN3 may behave as a transcription factor and can directly inhibit CCN4 gene transcription. Another mechanistic explanation could be due to direct sequestration of CCN4 by protein–protein interaction, preventing the initiation of CCN4 mediated pro-fibrotic pathway [ 164 ]. Similar findings were also reported by others where CCN3 was identified as an endogenous inhibitor of pro-fibrotic CCN family members. A deeper understanding of the interactome of CCN family members is required for utilizing the antagonistic approach to develop anti-fibrotic therapeutics [ 165 , 166 ]. Taken together, these results show that CCN4 is highly upregulated in fibrotic tissues, such as lungs, heart, liver and skin and can directly influence fibrogenesis, partly by integrin dependent mechanisms to promote fibroblast proliferation and migration, suggesting that CCN4 can not only serve as a diagnostic biomarker but also be exploited as a novel therapeutic target for the treatment of fibrosis. In addition, targeting CCN4 may eliminate the need for multiple tissue specific therapies in multi-organ fibrosis, given its role in the fibrogenesis of major organs, such as lung, liver, heart, kidney, and skin which encompasses a majority of all the fibrosis cases.
Obesity is defined as excessive accumulation of fat in the adipose tissue throughout the body due to imbalance in the energy intake and expenditure, leading to various cardiovascular and metabolic disorders. Numerous environmental, genetic and lifestyle related factors also contribute to the increased body mass index (BMI) and weight gain [ 167 ]. Previously considered to be inactive, adipose tissue is a highly dynamic metabolically active endocrine organ, that produces a wide variety of cell-signaling molecules, namely adipocytokines or adipokines such as leptin, adiponectin, resistin, TNF-α, and IL-6, amongst others [ 168 ]. These adipokines are crucial for biochemical and metabolic homeostasis, however increased adiposity mediated adipokine dysregulation is the major culprit involved in the pathogenesis of metabolic syndrome, such as insulin resistance, diabetes mellitus, atherosclerosis, etc. [ 169 ]. CCN4 has recently been identified as a novel adipokine in humans, adding a unique functional aspect to its diverse biological repertoire [ 170 ]. Interestingly, recent studies have shown that CCN4 is also expressed and secreted by human adipocytes endowing it with the title of novel adipokine. Amongst other CCN protein members, CCN3 is also a fairly recently discovered adipokine linked to obesity [ 171 ]. Discovery of CCN4 and CCN3 as novel metabolic regulators opens new avenues for the treatment and management of obesity and associated co-morbidities.
Over the last decade, emerging evidence directly correlates systemic CCN4 levels with obesity, inflammation, and insulin-resistance. Large human cohort studies with obese and/or glucose tolerant patients revealed that circulating CCN4 is positively correlated with percent fat mass, leptin, triglyceride levels, adiposity, and BMI [ 172 , 173 ]. Another study shows that serum CCN4 levels and CCN4 mRNA expression in visceral adipose tissue were significantly higher in obese men compared to non-obese men, independent of their glycemic status [ 174 ]. CCN4 also leads to insulin resistance by impairing insulin signaling in hepatocytes and primary human skeletal muscle cells. In a dose-dependent manner, CCN4 significantly abrogated insulin-mediated phosphorylation of insulin receptor (IRβ)-Tyr1150/1151, along with decreased Akt-Ser473/Thr308, GSK3β-Ser9 phosphorylation at the lowest dose of 0.1 µg/l in both human skeletal muscle cells and murine hepatocyte cell line AML12. Insulin receptor substrate 1 (IRS1) is a key cytoplasmic adaptor protein crucial for signal transmission downstream of the receptor and treatment with 0.1 µg/l and 1 µg/l CCN4 decreased IRS1 protein expression by 50%, suggesting the direct inhibitory effect of CCN4 on insulin cascade in human skeletal muscle cells [ 174 ]. Preincubation with 0.1 µg/l and 1 µg/l of CCN4 for 24 h significantly abrogated insulin-dependent glycogen synthesis in human primary myotubes [ 174 ]. To further validate the mechanism, Woo et al. demonstrated the effect of CCN4 knockdown on insulin resistance and glucose in skeletal muscle cells of HFD-mice [ 175 ]. CCN4 knockdown significantly abrogated the inhibitory effects on insulin signaling by restoring Akt and IRS1 phosphorylation. Mechanistically, the authors also showed that CCN4 mediated insulin resistance and inflammation in murine skeletal muscle cells (C2C12 cells) and hepatocytes respectively is driven via Toll-like receptor-4 (TLR4) as TLR4 knockdown significantly abrogated CCN4-mediated JNK phosphorylation, NF-κB translocation, insulin resistance and triglyceride accumulation in hepatocytes and C2C12 cells [ 175 ]. siRNA mediated knockdown of NF-κB and JNK prevents CCN4-mediated insulin resistance, highlighting a novel mechanism for CCN4-driven impaired insulin sensitivity. In addition, siRNA-mediated CCN4 knockdown significantly ameliorates hepatic steatosis, lipogenesis and insulin resistance in HFD-fed mice suggesting that CCN4 requires TLR4 activation to drive inflammation and insulin resistance [ 175 ].
Contrary to the previously described inhibitory effect of CCN4 on insulin signaling, another study reports that it drives insulin-producing pancreatic beta (β)-cell proliferation via Akt modulation in both mouse and human cells [ 176 ]. Cell proliferation markers such as antigen kiel 67 (Ki67) and phospho-histone H3 (pHH3) were significantly reduced in CCN4 knockout mice (CCN −/− ) as compared to wild-type (CCN +/+ ). Further, CCN −/− mice treated with recombinant CCN4 exhibited twofold higher β-cell proliferation as compared to saline. Adenovirus-mediated systemic overexpression of CCN4 in streptozotocin-induced diabetes model, significantly increased plasma insulin levels by augmenting total β-cell mass and insulin positive area, however failed to reverse hyperglycemia [ 176 ]. CCN4 has also been implicated in the development and regeneration of pancreas [ 177 , 178 ]. More recently, researchers have also identified that CCN4 is highly expressed upon treatment with high concentration of glucose (30 mM) in human kidney proximal tubular cells and in renal tissue of streptozotocin-induced diabetic nephropathy (DN) mouse model [ 179 ]. Functionally, CCN4 overexpression drives cell proliferation, migration, EMT and fibrosis and these effects were partially rescued via silencing N6-adenosine methyltransferase (METTL3), which decreases DN development by decreasing CCN4 expression in-vitro [ 179 ]. Given the current body of conflicting literature on the effect of CCN4 on glucose homeostasis and rising rate of metabolic disorders, it is extremely important to decipher the functional and mechanistic consequences of CCN4 due to its profound physiological relevance.
Two independent studies have also shown that CCN4 serum level in pregnant women with gestational diabetes mellitus (GDM) is significantly higher as compared to healthy non-GDM pregnant women [ 180 , 181 ]. In addition, circulating CCN4 level in obese pregnant women with GDM is positively correlated with numerous clinical metabolic parameters such as systolic blood pressure, fasting blood glucose and aspartate aminotransferase (AST), highlighting the crucial role of CCN4 in the pathophysiology of GDM [ 180 ]. Overall, CCN4 can serve as a strong independent risk predictor and diagnostic marker and possess immense therapeutic potential in maternal-neonatal health and obstetric research. However, maternal, and neonatal safety drug assessment becomes crucial to assess the impact of possible CCN4 interventions on the fetal growth and development as CCN4 is expressed in osteoblasts and their progenitor cells during skeletogenic processes in embryonic development [ 182 ].
Obesity is also characterized as a chronic low-grade systemic inflammation due to the proinflammatory cytokine release from adipocytes and macrophages [ 183 ]. Studies show that macrophage infiltration and accumulation in adipose tissue was significantly higher in obese HFD mice as compared to normal mice [ 184 ]. Furthermore, phenotypical polarization of the infiltrated macrophages was observed in obese individuals with predominant pro-inflammatory M1 macrophages as compared to lean individuals with more anti-inflammatory M2 macrophages. The increased M1 population in obese adipose tissue overexpresses pro-inflammatory genes such as IL-6 and TNFα and lower anti-inflammatory cytokines such as IL-10, contributing to the persistent low-grade systemic inflammation and insulin resistance [ 184 , 185 ]. In addition, CCN4 protein expression is upregulated in visceral and subcutaneous adipose tissue in glucose-tolerant patients and is positively correlated with the markers of obesity, inflammation, and insulin resistance [ 170 , 172 , 174 ]. Serum CCN4 levels were also significantly elevated in obese children and adolescents with direct positive correlation to IL-18, adiponectin, and leptin [ 61 ]. Interestingly, these effects were completely reversed upon weight loss as adipose tissue CCN4 expression was significantly decreased after weight reduction, suggesting that adipocytes are the major source of circulating CCN4 [ 170 ]. These findings were further validated in another single-center randomized trial with breast cancer survivor females, where a 12-week exercise regime significantly decreased waist circumference and body fat composition accompanied by reduced serum β-catenin and CCN4 levels [ 186 ]. Furthermore, studies have shown that stimulation of macrophages with CCN4 can significantly increase pro-inflammatory cytokines such as IL-6, TNF-α and IL1B at both mRNA and protein level [ 170 , 187 ]. However, CCN4 stimulation had no significant pro-inflammatory effect on adipocytes suggesting that adipocyte-derived CCN4 does not elicit autocrine-response but rather have paracrine inflammatory effects on nearby macrophages. Additionally, stimulation of macrophages with CCN4 significantly increased the expression of pro-inflammatory M1 specific markers, such as CCR7 and COX2, whereas the expression of anti-inflammatory M2 specific markers such as CD36, CD163, MRC1 and COX1 were either markedly decreased or remained unchanged. This suggests that ‘M2 to M1’ phonotypical switch is driven at least in part due to adipocyte derived CCN4, along with other unknown mechanisms [ 170 ]. CCN4 alone does not initiate the release of inflammatory cytokines from adipocytes, however CCN4 imparts protective effects on LPS-treated adipocytes (3T3-L1) by preventing cell apoptosis and injury [ 188 ].
Murahovschi and colleagues have reported increased CCN4 expression and release during adipocyte differentiation, however no effect of CCN4 on adipocyte differentiation [ 170 ]. Yet another conflicting report suggests that CCN4 expression significantly decreases during adipocyte differentiation from preadipocytes to mature adipocytes and negatively regulates adipogenesis by physically interacting and redirecting transcriptional factor peroxisome proliferator-activated receptor gamma (PPARγ) to proteasomal degradation, which serves as a master regulator of adipocyte differentiation [ 189 ]. Potentially CCN4 does not promote new adipocyte formation, however, it can maintain and protect the pre-existing adipocytes that contribute heavily to the circulating CCN4 levels. CCN4 positively self-regulates itself by protecting the source, i.e., adipocytes, which can further aggravate systemic CCN4 levels, worsening the condition.
Increased adiposity and overexpressed CCN4 in adipocytes of obese individuals significantly contribute to the pro-inflammatory cytokine release by stimulating adipose tissue resident macrophages in a paracrine fashion and drives macrophage polarization with can further worsen the condition. Similarly, supraphysiological serum CCN4 levels also lead to insulin resistance by impairing insulin signaling. Taken together, all the evidence indicates that CCN4 is a central player and key contributor towards aggravation and perpetuation of the inflammatory response and insulin desensitization in obesity. Targeting CCN4 could have great therapeutic potential for metabolic disorders that would benefit numerous patients across the globe.
As per CDC, Arthritis is the leading cause of disability affecting nearly 1 out of 4 adults in the US. Arthritis means ‘disease of the joints’ and is usually characterized by chronic inflammation, pain, stiffness, loss of mobility and function due to progressive damage to the joint, bone and cartilage [ 190 ]. OA and RA are the most prevalent joint decaying diseases, with diverse etiologies but overlapping clinical hallmarks [ 191 ]. While there is no cure for debilitating OA and RA, treatment paradigms focus on symptomatic relief using a combination of pain management and physical therapy. A better functional and mechanistic understanding of the disease will assist in the discovery of novel diagnostic and therapeutic biomarkers for developing novel treatment strategies [ 190 ]. Given the diverse pharmacological effects of CCN4 in the human body, emerging evidence indicates the involvement of the Wnt-pathway in joint diseases.
The significance of CCN4 in the pathophysiology of OA and RA has been abundantly demonstrated by numerous researchers over the last decades. Substantial evidence implicates deleterious effects of CCN4 in the development of musculoskeletal disorders. Differential gene expression and transcriptomics analysis revealed significantly higher CCN4 expression in the cartilage of OA patients as compared to healthy controls [ 52 , 100 , 192 , 193 , 194 , 195 , 196 ]. Spatial expression profile of CCN4 reveals moderate to weak expression in the superficial layer, matrix and synovial perivascular cells of the knee and hip of RA and OA patients [ 192 ]. Another study revealed notable CCN4 upregulation in both synovium and cartilage specimens from OA-human patients and collagenase-induced OA mouse model [ 52 , 195 ]. CCN4 augmentation has been shown to stimulate chondrocytes, synovial cells, and macrophages, to induce the expression of matrix-degrading proteolytic enzymes such as MMPs that impart deleterious effects on the joint tissue of OA and RA patients. Adenovirus-mediated CCN4 overexpression in knee joints of naïve mice significantly damaged cartilage by inducing MMP13, MMP9, ADAMTS-4 and ADAMTS-5 in synovium and cartilage, exacerbating the condition [ 52 ]. In addition, treatment with recombinant human CCN4 increases MMP1, MMP2, MMP3, MMP9 and MMP13 mRNA expression in human OA synovial specimens [ 197 ]. Interestingly, CCN4 expression is directly corelated with OA severity and was densely expressed in the most damaged and degraded areas of the joint, confirming its detrimental effects, and highlighting the key role of CCN4 in OA and RA progression [ 198 ]. These findings were also confirmed in another study that demonstrated a direct role of CCN4 in the pathogenesis of OA utilizing CCN4-knockdown approach in three different experimental models of OA, that is, intra-articular collagenase induced (CIOA), anterior cruciate ligament transection (ACLT) and destabilization of the medial meniscus (DMM) model. Cartilage degradation was significantly decreased in CCN4 − / − mice in all three OA-models compared to WT (wild type). These effects were attributed to decreased expression of protease, MMP3, MMP9, ADAMTS-4 and ADAMTS-5 in the synovium of CCN4 − / − mice, suggesting CCN4 is one of the key culprits in OA-pathogenesis, [ 197 ]. Interestingly, miR-128-3p expression is notably decreased in human OA tissue, and overexpression of miR-128-3p significantly decreased CCN4 expression. Furthermore, CCN4 mediates chondrocyte apoptosis, inflammation, and ECM degradation via PI3K/Akt/ NF-κB pathway, an effect that was inhibited by miR-128-3p providing protection against the harmful effects of CCN4, emerging as a novel therapeutic target for OA [ 196 ]. Besides low miR-128-3p expression, elevated levels of TGF-β in OA drive CCN4 expression in chondrocytes [ 199 ]. CCN4 can also contribute to OA pathology by skewing TGF-β signaling in chondrocytes from protective/ non-hypertrophic ALK-5/Smad 2/3 pathway towards damaging/ hypertrophic ALK-1/ Smad 1/5/8 pathway [ 200 ].
As previously described CCN4 binds to certain integrins, predominantly αVβ5, αVβ3 and αVβ1 to mediate its functional effects in fibrosis and cancer. Similarly, researchers have also shown that CCN4 engages integrins expressed on chondrocytes and synovial fibroblasts in OA. Contrary to the previously reported degenerative effects of CCN4 on chondrocyte matrix, another study shows that CCN4 displays a protective effect on primary human OA articular chondrocytes by inhibiting senescence and apoptosis. This effect was blocked in the presence of either αVβ3 antibody or a potent small molecule PI3K inhibitor (LY294002), suggesting that CCN4 mediated protective effects are αVβ3/PI3K/Akt dependent [ 198 ]. In another study, pretreatment with αVβ5 integrin blocking antibody, but not αVβ3 or α5β1 significantly reduces CCN4 induced concentration and time dependent increase in IL-6 production in OA synovial fibroblasts. Furthermore, CCN4-dependent IL-6 production was also obliterated in the presence of PI3K (Wortmannin and LY294002), Akt (Akti) and NF-κB (TPCK and PCTC) inhibitors suggesting that CCN4 drives pro-inflammatory cytokine IL-6 release via αVβ5/PI3K/Akt/NF-κB pathway in OA [ 201 ]. Together with CCN4, the expression of integrin αV and α5 subunit was significantly higher in human OA cartilage as compared to controls and assists CCN4-dependent chondrocyte differentiation [ 199 ]. Chondrocytes are terminally differentiated cells, possessing poor self-restoring capacity leading to longer recovery time after the avascular cartilage injury. Chondrocyte dedifferentiation causes multiple phenotypical changes, that accelerates hypertrophy, matrix calcification, degradation, and fibrosis. Dedifferentiated chondrocyte markers were notably upregulated in OA cartilage, suggesting that in conjunction with other mediators, CCN4 also promotes the destructive dedifferentiation process, aggravating disease progression [ 202 ]. Contrary to the general consensus, CCN4 also promotes chondrocyte proliferation, independent of integrins [ 199 ]. Treatment with CCN4 have been shown to also drive primary human OA chondrocyte migration, however the migratory chondrocytes were not phenotypically characterized to conclude whether they are non-differentiated which could facilitate repair or dedifferentiated which can cause damage [ 203 ].
Stimulation of human-osteoblast-like cells with recombinant human CCN4 dose-dependently increases mitogenic activity assessed by BrdU incorporation and osteoblastic differentiation measured by alkaline phosphatase activity [ 49 ]. Another study reported positive influence of CCN4 on bone formation. CCN4 overexpression both in-vivo and in-vitro in osteogenic hBMSC drives osteogenesis, increased bone volume and thickness by increasing bone morphogenic protein 2 (BMP-2) expression and activity in an α5β1 integrin dependent manner [ 204 ]. Furthermore, stimulation of mesenchymal stem cells (MSC) with recombinant CCN4 stimulates proliferation in a dose-dependent manner via BMP-3 induction, as CCN4-siRNA mediated knockdown significantly reduced the mitogenic effects of BMP-3 [ 205 ]. CCN4 also promotes recruitment, adhesion, and migration of monocytes by dose-dependently increasing VCAM-1 expression in osteoarthritic synovial lining, an effect that was abolished in the presence of an α6β1 or αVβ5 integrin neutralizing antibody. CCN4 also increases activation of protein kinase C (PKCδ), JNK, AP-1 and Syk (Spleen tyrosine kinase) proteins, all of which are necessary for CCN4-mediated VCAM-1 upregulation [ 206 ]. Based on literature evidence, CCN4 elicits diverse and sometimes opposite functional effects depending on the cell-type and the spatial expression pattern within the musculoskeletal system. Another study conducted in 304 postmenopausal Japanese women indicates that genetic variations such as single nucleotide polymorphism in CCN4 gene locus has been linked with spinal osteoarthritis determined by radiographical observations such as disc space narrowing, endplate sclerosis and osteophyte formation, again highlighting its therapeutic utility as a novel diagnostic biomarker [ 207 ].
From the literature summarized herein, aberrant CCN4 expression is highly correlated with adverse clinical outcomes and demonstrates the significant role of CCN4 in diverse pathophysiological conditions, such as cancer, fibrosis, metabolic disorders, and arthritis. Altered CCN4 expression may not be the only factor controlling vast array of cellular functions, such as cell proliferation, migration, invasion, and wound healing, but it could be modulating and working in conjunction with other mitogenic signaling molecules, growth factors and inflammatory mediators in driving pathogenesis, as shown in Fig. 3 .
Functional effects of CCN4 in different diseases. CCN4 drives many cellular processes such as cell-proliferation, migration, invasion, epithelial to mesenchymal transition (EMT), apoptosis, wound healing, repair, and angiogenesis. Some of these functional effects are overlapping amongst a diverse array of pathological conditions like cancer, fibrosis, obesity, and inflammatory diseases. The image was created with BioRender.com
As more translational studies unearth the CCN4-dependent molecular mechanisms, it is highly likely that CCN4 could be involved in the progression of many more undiscovered co-morbid pathologies. However, the slow growing research on CCN family is largely due to some major challenges in the field that remains to be addressed in future research. Besides the full-length CCN4 protein, identifying the domain specific function is crucial to understand the contribution of the variable linker in CCN biology. Development of domain specific detection tools for human and murine biological tissues or fluids is crucial to understand the tissue specific degradome/cleavage pattern of CCN4 in clinical models. In conjugation with protein–protein interaction studies, researchers could possibly identify functionally active domain(s) for monoclonal antibody mediated targeted therapy. Furthermore, an indirect approach could also be utilized by targeting the key proteolytic enzyme to prevent CCN4 cleavage and subsequently the formation of functionally active single or multi-domain structures. The proportion and expression kinetics of these multi-modular truncated CCN4 variants could reveal the functional redundancy and/or diverse effects in various diseases. Novel tools and reagents are also required to carefully assess the tightly regulated spaciotemporal expression and half-life of these individual or multi-domain structures which yet remains imperative to uncover its holistic biological significance. In addition, CCN4 signaling in diverse cell/tissue specific context still remains understudied. Multi-omics-based approaches at both transcript (RNA seq) and protein level (Proteomics) could be utilized to unravel other CCN4-dependent downstream targets and/or pathways. Also, immunoassays for multi-analyte profiling could further shed light on CCN4-dependend inflammatory secretome-signature. Furthermore, homo- or hetero-multimerization within CCN family members adds to the preexisting complexities. In addition, identifying the cognate receptor/s for CCN family members is important.
Another major challenge is to study crosstalk between CCN family of proteins. One of the major gaps in the current research is how other CCN members interact and modulate CCN4 in a synergistic or antagonistic manner in a pathological context. Some CCN family members have opposing effects with respect to CCN4. A bispecific targeting approach could also be utilized to target antithetical or synergistic CCN members to attain better therapeutic outcomes. However, given the high degree of structural and sequential homology, it is of paramount importance to first understand why some CCN members have opposite functional effects in a disease specific context. Minor changes in the amino acid sequence can bring about huge variations in the overall protein folding and 3-dimensional structure, affecting the surface charge and substrate binding potency, which could be utilized for targeted strategies. Given that CCN4 drives diverse cellular processes in a tissue-specific context, a comprehensive analysis encompassing the molecular network between all the CCN family members remains indispensable. Taken together, the results from the literature reviewed here suggest that CCN4 plays a critical role in the development and progression of diverse pathologies and is emerging as a promising candidate with therapeutic potential yet untapped.
Not applicable.
Disintegrin and metalloproteinase domain-containing protein 28
Protein kinase B
Activator protein-1
Type II alveolar epithelial cells
Body mass index
Bone morphogenetic protein
Chemokine C–C motif ligand
Cellular communication network factor 4
Cluster of differentiation
Chronic kidney diseases
C-terminal cysteine knot
Connective tissue growth factor
Chemokine C-X-C motif ligand
Cysteine-rich protein 61
Diabetic nephropathy
Epidermal growth factor receptor
Epithelial to mesenchymal transition
Extracellular signal-regulated kinase
Focal adhesion kinase
Fibroblast growth factor
Fibronectin
Glucose transporter 1
Hypoxia inducible factor 1 alpha
Intracellular adhesion kinase 1
Interferon gamma
Insulin-like growth factor binding protein like domain
Interlukin-6
Idiopathic pulmonary fibrosis
Insulin receptor substrate 1
C-Jun N-terminal kinase
Low-density lipoprotein receptor-related proteins
Mitogen-activated protein kinase kinase
Matrix metalloproteases
Myocardin-related transcription factor
Mechanistic target of rapamycin
Nuclear factor kappa B
Nephroblastoma overexpressed
Osteoarthritis
Phosphoinositol 3-kinase
Protein kinase C
Peroxisome proliferator-activated receptor gamma
Post-translational modification
Rheumatoid arthritis
Transforming growth factor: β
Toll-like receptor
Thrombospondin-homology type 1 repeat
Vascular cell adhesion protein 1
Vascular endothelial growth factor
von Willebrand factor C repeat
Wnt-1 induced secreted protein-1
α-Smooth muscle actin
Bornstein P. Matricellular proteins: an overview. J Cell Commun Signal. 2009;3(3–4):163–5.
Article PubMed PubMed Central Google Scholar
Perbal B, Tweedie S, Bruford E. The official unified nomenclature adopted by the HGNC calls for the use of the acronyms, CCN1–6, and discontinuation in the use of CYR61, CTGF, NOV and WISP 1–3 respectively. J Cell Commun Signal. 2018;12(4):625–9.
Brigstock DR, Goldschmeding R, Katsube KI, Lam SCT, Lau LF, Lyons K, et al. Proposal for a unified CCN nomenclature. J Clin Pathol Mol Pathol. 2003;56(2):127–8.
Article CAS Google Scholar
Gurbuz I, Chiquet-Ehrismann R. CCN4/WISP1 (WNT1 inducible signaling pathway protein 1): A focus on its role in cancer. Int J Biochem Cell Biol. 2015;62:142–6. https://doi.org/10.1016/j.biocel.2015.03.007 .
Article CAS PubMed Google Scholar
Sun C, Zhang H, Liu X. Emerging role of CCN family proteins in fibrosis. J Cell Physiol. 2021;236(6):4195–206.
Pennica D, Swanson TA, Welsh JW, Roy MA, Lawrence DA, Lee J, et al. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A. 1998;95(25):14717–22.
Article CAS PubMed PubMed Central Google Scholar
Berschneider B, Königshoff M. WNT1 inducible signaling pathway protein 1 (WISP1): A novel mediator linking development and disease. Int J Biochem Cell Biol. 2011;43(3):306–9. https://doi.org/10.1016/j.biocel.2010.11.013 .
Walker JM. CCN proteins. In: Takigawa M, editor. Springer protocols, vol. XIV. 2nd ed. Berlin: Springer; 2017. p. 430. https://doi.org/10.1007/978-1-0716-2744-0 .
Chapter Google Scholar
Jun J-I, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov. 2011;10(12):945–63. https://doi.org/10.1038/nrd3599 .
Yoshida K, Munakata H. Connective tissue growth factor binds to fibronectin through the type I repeat modules and enhances the affinity of fibronectin to fibrin. Biochim Biophys Acta Gen Subj. 2007;1770(4):672–80.
Hoshijima M, Hattori T, Inoue M, Araki D, Hanagata H, Miyauchi A, et al. CT domain of CCN2/CTGF directly interacts with fibronectin and enhances cell adhesion of chondrocytes through integrin α5β1. FEBS Lett. 2006;580(5):1376–82.
Francischetti IMB, Kotsyfakis M, Andersen JF, Lukszo J. Cyr61/CCN1 displays high-affinity binding to the somatomedin B 1-44 domain of vitronectin. PLoS ONE. 2010;5(2):1–12.
Article Google Scholar
Nishida T, Kubota S, Fukunaga T, Kondo S, Yosimichi G, Nakanishi T, et al. CTGF/Hcs24, hypertrophic chondrocyte-specific gene product, interacts with perlecan in regulating the proliferation and differentiation of chondrocytes. J Cell Physiol. 2003;196(2):265–75.
Chen N, Leu SJ, Todorović V, Lam SCT, Lau LF. Identification of a novel integrin αvβ3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J Biol Chem. 2004;279(42):44166–76.
Kireeva ML, Lam SC, Lau LF, Biol LFMC. Adhesion of human umbilical vein endothelial cells to the immediate-early gene product Cyr61 is mediated through integrin αvβ3. J Biol Chem. 1998;273(5):3090–6. https://doi.org/10.1074/jbc.273.5.3090 .
Lin CG, Leu S-J, Chen N, Tebeau CM, Lin S-X, Yeung C-Y, et al. CCN3 ( NOV ) is a novel angiogenic regulator of the CCN protein family. J Biol Chem. 2003;278(26):24200–8. https://doi.org/10.1074/jbc.M302028200 .
Abd El Kader T, Kubota S, Anno K, Tanaka S, Nishida T, Furumatsu T, et al. Direct interaction between CCN family protein 2 and fibroblast growth factor 1. J Cell Commun Signal. 2014;8(2):157–63.
Aoyama E, Kubota S, Takigawa M. CCN2/CTGF binds to fibroblast growth factor receptor 2 and modulates its signaling. FEBS Lett. 2012;586(24):4270–5. https://doi.org/10.1016/j.febslet.2012.10.038 .
Nishida T, Kubota S, Aoyama E, Janune D, Maeda A, Takigawa M. Effect of CCN2 on FGF2-induced proliferation and MMP9 and MMP13 productions by chondrocytes. Endocrinology. 2011;152(11):4232–41.
Inoki I, Shiomi T, Hashimoto G, Enomoto H, Nakamura H, Makino K-I, et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 2002;16(2):219–21.
Abreu JG, Ketpura NI, Reversade B, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by bmp and TGF-β. Nat Cell Biol. 2002;4(8):599–604.
Bai T, Chen CC, Lau LF. The matricellular protein CCN1 activates a pro-inflammatory genetic program in murine macrophages. J Immunol. 2010;184(6):1–7.
Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin α6β1 and cell surface heparan sulfate proteoglycans. J Biol Chem. 2000;275(32):24953–61. https://doi.org/10.1074/jbc.M003040200 .
Kireeva ML, Latinkić BV, Kolesnikova TV, Chen CC, Yang GP, Abler AS, et al. Cyr61 and Fisp12 are both ECM-associated signaling molecules: activities, metabolism, and localization during development. Exp Cell Res. 1997;233(1):63–77.
Desnoyers L, Arnott D, Pennica D. WISP-1 binds to decorin and biglycan. J Biol Chem. 2001;276(50):47599–607. https://doi.org/10.1074/jbc.M108339200 .
Juric V, Chen CC, Lau LF. TNFα-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome C release. PLoS ONE. 2012;7(2):1–10.
Mercurio S, Latinkic B, Itasaki N, Krumlauf R, Smith JC. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development. 2004;131(9):2137–47.
Blalock TD, Gibson DJ, Duncan MR, Tuli SS, Grotendorst GR, Schultz GS. A connective tissue growth factor signaling receptor in corneal fibroblasts. Investig Ophthalmol Vis Sci. 2012;53(7):3387–94.
Sakamoto K, Yamaguchi S, Ando R, Miyawaki A, Kabasawa Y, Takagi M, et al. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J Biol Chem. 2002;277(33):29399–405. https://doi.org/10.1074/jbc.M203727200 .
Lau LF. Cell surface receptors for CCN proteins. J Cell Commun Signal. 2016;10:121–7. https://doi.org/10.1007/s12079-016-0324-z .
Aoyama E, Kubota S, Khattab HM, Nishida T, Takigawa M. CCN2 enhances RANKL-induced osteoclast differentiation via direct binding to RANK and OPG. Bone. 2015;73:242–8. https://doi.org/10.1016/j.bone.2014.12.058 .
Wu CL, Tsai HC, Chen ZW, Wu CM, Li TM, Fong YC, et al. Ras activation mediates WISP-1-induced increases in cell motility and matrix metalloproteinase expression in human osteosarcoma. Cell Signal. 2013;25(12):2812–22. https://doi.org/10.1016/j.cellsig.2013.09.005 .
Hou CH, Chiang YC, Fong YC, Tang CH. WISP-1 increases MMP-2 expression and cell motility in human chondrosarcoma cells. Biochem Pharmacol. 2011;81(11):1286–95. https://doi.org/10.1016/j.bcp.2011.03.016 .
Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol. 1991;114(6):1285–94.
Phanish MK, Winn SK, Dockrell MEC. Connective tissue growth factor-(CTGF, CCN2)—a marker, mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol. 2010;114(3):83–92.
Yang W, Wagener J, Wolf N, Schmidt M, Kimmig R, Winterhager E, et al. Impact of CCN3 (NOV) glycosylation on migration/invasion properties and cell growth of the choriocarcinoma cell line Jeg3. Hum Reprod. 2011;26(10):2850–60.
Soon LL, Yie TA, Shvarts A, Levine AJ, Su F, Tchou-Wong KM. Overexpression of WISP-1 down-regulated motility and invasion of lung cancer cells through inhibition of Rac activation. J Biol Chem. 2003;278(13):11465–70. https://doi.org/10.1074/jbc.M210945200 .
Neupane S, Berardinelli SJ, Cameron DC, Grady RC, Komatsu DE, Percival CJ, et al. O-fucosylation of thrombospondin type 1 repeats is essential for ECM remodeling and signaling during bone development. Matrix Biol. 2022;107:77–96.
Pendurthi UR, Tran TT, Post M, Rao LVM. Proteolysis of CCN1 by plasmin: functional implications. Cancer Res. 2005;65(21):9705–11.
Choi J, Lin A, Shrier E, Lau LF, Grant MB, Chaqour B. Degradome products of the matricellular protein CCN1 as modulators of pathological angiogenesis in the retina. J Biol Chem. 2013;288(32):23075–89. https://doi.org/10.1074/jbc.M113.475418 .
Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem. 2002;277(39):36288–95. https://doi.org/10.1074/jbc.M201674200 .
Guillon-munos A, Oikonomopoulou K, Smith CR, Canepa S, Reverdiau P, Heuze N, et al. Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors. J Biol Chem. 2011;286(29):25505–18.
Mochizuki S, Tanaka R, Shimoda M, Onuma J, Fujii Y, Jinno H, et al. Connective tissue growth factor is a substrate of ADAM28. Biochem Biophys Res Commun. 2010;402(4):651–7.
Kaasbøll OJ, Gadicherla AK, Wang JH, Monsen VT, Hagelin EMV, Dong MQ, et al. Connective tissue growth factor (CCN2) is a matricellular preproprotein controlled by proteolytic activation. J Biol Chem. 2018;293(46):17953–70.
Butler GS, Connor AR, Sounni NE, Eckhard U, Morrison CJ, Noël A, et al. Degradomic and yeast 2-hybrid inactive catalytic domain substrate trapping identifies new membrane-type 1 matrix metalloproteinase (MMP14) substrates: CCN3 (Nov) and CCN5 (WISP2). Matrix Biol. 2017;59:23–38. https://doi.org/10.1016/j.matbio.2016.07.006 .
Perbal B. Alternative splicing of CCN mRNAs… It has been upon us. J Cell Commun Signal. 2009;3(2):153–7.
Tanaka S, Sugimachi K, Saeki H, Kinoshita J, Ohga T, Shimada M, et al. A novel variant of WISP1 lacking a Von Willebrand type C module overexpressed in scirrhous gastric carcinoma. Oncogene. 2001;20(39):5525–32.
Tanaka S, Sugimachi K, Kameyama T, Maehara SI, Shirabe K, Shimada M, et al. Human WISP1v, a member of the CCN family, is associated with invasive cholangiocarcinoma. Hepatology. 2003;37(5):1122–9.
Inkson CA, Ono M, Kuznetsov SA, Fisher LW, Gehron P, Young MF. TGF-β1 and WISP-1/CCN-4 can regulate each other’s activity to cooperatively control osteoblast function. J Cell Biochem. 2009;104(5):1865–78.
Cervello M, Giannitrapani L, Labbozzetta M, Notarbartolo M, D’Alessandro N, Lampiasi N, et al. Expression of WISPs and of their novel alternative variants in human hepatocellular carcinoma cells. Ann N Y Acad Sci. 2004;1028:432–9.
Yanagita T, Kubota S, Kawaki H, Kawata K, Kondo S, Takano-Yamamoto T, et al. Expression and physiological role of CCN4/Wnt-induced secreted protein 1 mRNA splicing variants in chondrocytes. FEBS J. 2007;274(7):1655–65.
Blom AB, Brockbank SM, Van Lent PL, Van Beuningen HM, Geurts J, Takahashi N, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthr Rheum. 2009;60(2):501–12.
Chen YZ, Sun DQ, Zheng Y, Zheng GK, Chen RQ, Lin M, et al. WISP1 silencing confers protection against epithelial–mesenchymal transition of renal tubular epithelial cells in rats via inactivation of the wnt/β-catenin signaling pathway in uremia. J Cell Physiol. 2019;234(6):9673–86.
Madrigano J. Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. Occup Env Med. 2008;23(1):1–7.
Google Scholar
Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-18794-x .
Liu Y, Song Y, Ye M, Hu X, Wang ZP, Zhu X. The emerging role of WISP proteins in tumorigenesis and cancer therapy. J Transl Med. 2019. https://doi.org/10.1186/s12967-019-1769-7 .
Xi Y, LaCanna R, Ma HY, N’Diaye EN, Gierke S, Caplazi P, et al. A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis. Cell Metab. 2022;34(9):1377-1393.e8. https://doi.org/10.1016/j.cmet.2022.07.009 .
Kadam AH, Schnitzer JE. Characterization of acute lung injury in the bleomycin rat model. Physiol Rep. 2023;11(5):1–13.
Kim MS, Kim SH, Jeon D, Kim HY, Lee K. Changes in expression of cytokines in polyhexamethylene guanidine-induced lung fibrosis in mice: comparison of bleomycin-induced lung fibrosis. Toxicology. 2017;2018(393):185–92.
Königshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, Günther A, Eickelberg O. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119(4):772–87.
PubMed PubMed Central Google Scholar
Wang A-R, Yan X-Q, Zhang C, Du C-Q, Long W-J, Zhan D, et al. Characterization of Wnt1-inducible signaling pathway protein-1 in obese children and adolescents. Curr Med Sci. 2018;38(5):868–74.
Maiese K. Prospects and perspectives for WISP1 (CCN4) in diabetes mellitus. Curr Neurovasc Res. 2020;17(3):327–31.
Klee S, Lehmann M, Wagner DE, Baarsma HA, Konigshoff M. WISP1 mediates IL-6-dependent proliferation in primary human lung fibroblasts. Sci Rep. 2016;6:1–11. https://doi.org/10.1038/srep20547 .
Venkatachalam K, Venkatesan B, Valente AJ, Melby PC, Nandish S, Reusch JEB, et al. WISP1, a pro-mitogenic, pro-survival factor, mediates tumor necrosis factor-α (TNF-α)-stimulated cardiac fibroblast proliferation but inhibits TNF-α-induced cardiomyocyte death. J Biol Chem. 2009;284(21):14414–27.
Colston JT, De Rosa SD, Koehler M, Gonzales K, Mestril R, Freeman GL, et al. Wnt-induced secreted protein-1 is a prohypertrophic and profibrotic growth factor. Am J Physiol Circ Physiol. 2007;293:78229.
Wang S, Chong ZZ, Shang YC, Maiese K. WISP1 (CCN4) autoregulates its expression and nuclear trafficking of β-catenin during oxidant stress with limited effects upon neuronal autophagy. Curr Neurovasc Res. 2012;9(2):91–101.
Shang YC, Chong ZZ, Wang S, Maiese K. Wnt1 inducible signaling pathway protein 1 (WISP1) targets PRAS40 to govern β-amyloid apoptotic injury of microglia. Curr Neurovasc Res. 2012;9(4):239–49.
Maiese K. WISP1: clinical insights for a proliferative and restorative member of the CCN family. Curr Neurovasc Res. 2014;11:378.
Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU, Pienta KJ. Updating the definition of cancer. Mol Cancer Res. 2023;21(11):1142–7.
Shuel SL. Targeted cancer therapies. Can Fam Phys. 2022;68(7):515–8.
Jia Q, Xu B, Zhang Y, Ali A, Liao X. CCN family proteins in cancer: insight into their structures and coordination role in tumor microenvironment. Front Genet. 2021;12:1–13.
Yaribeygi H, Atkin SL, Sahebkar A. Wingless-type inducible signaling pathway protein-1 (WISP1) adipokine and glucose homeostasis. J Cell Physiol. 2019;234(10):16966–70.
Chen PP, Li WJ, Wang Y, Zhao S, Li DY, Feng LY, et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS ONE. 2007;2(6):1–9.
Li Y, Wang F, Liu T, Lv N, Yuan X, Li P. WISP1 induces ovarian cancer via the IGF1/αvβ3/Wnt axis. J Ovarian Res. 2022. https://doi.org/10.1186/s13048-022-01016-x .
Wu J, Long Z, Cai H, Du C, Liu X, Yu S, et al. High expression of WISP1 in colon cancer is associated with apoptosis, invasion and poor prognosis. Oncotarget. 2016;7(31):49834–47.
Zhu Y, Li W, Yang Y, Li Y, Zhao Y. WISP1 indicates poor prognosis and regulates cell proliferation and apoptosis in gastric cancer via targeting AKT/mTOR signaling pathway. Am J Transl Res. 2020;12(11):7297–311.
CAS PubMed PubMed Central Google Scholar
Chiang KC, Yeh CN, Chung LC, Feng TH, Sun CC, Chen MF, et al. WNT-1 inducible signaling pathway protein-1 enhances growth and tumorigenesis in human breast cancer. Sci Rep. 2015;5:1–12.
Zhang H, Luo H, Hu Z, Peng J, Jiang Z, Song T, et al. Targeting WISP1 to sensitize esophageal squamous cell carcinoma to irradiation. Oncotarget. 2015. https://doi.org/10.18632/oncotarget.3358 .
Jung EK, Kim S, Yoon TM, Lee KH, Kim HK, Lee DH, et al. WNT1-inducible signaling pathway protein-1 contributes to tumor progression and treatment failure in oral squamous cell carcinoma. Oncol Lett. 2017;14:1719–24.
Wang QY, Feng YJ, Ji R. High expression of WISP1 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2020;24(20):10445–51.
PubMed Google Scholar
Fernandez A, Deng W, McLaughlin SL, Pirkey AC, Rellick SL, Razazan A, et al. Cell communication network factor 4 promotes tumor-induced immunosuppression in melanoma. EMBO Rep. 2022;23(4):1–16.
Davies SR, Watkins G, Mansel RE, Jiang WG. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann Surg Oncol. 2007;14(6):1909–18.
Article PubMed Google Scholar
Taghavi A, Akbari ME, Bahremani MH. Gene expression profiling of the 8q22-24 position in human breast cancer: TSPYL5, MTDH, ATAD2 and CCNE2 genes are implicated in oncogenesis, while WISP1 and EXT1 genes may predict a risk of metastasis. Oncol Lett. 2016;12:3845–55.
Zhang H, Li W, Huang P, Lin L, Ye H, Lin D, et al. Expression of CCN family members correlates with the clinical features of hepatocellular carcinoma. Oncol Rep. 2015;33(3):1481–92.
Shao H, Cai L, Grichnik JM, Livingstone AS, Velazquez OC, Liu ZJ. Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene. 2011;30(42):4316–26.
Anderson NM, Simon MC. The tumor microenvironment. Curr Biol. 2020;30(16):R921-5. https://doi.org/10.1016/j.cub.2020.06.081 .
Tao W, Chu C, Zhou W, Huang Z, Zhai K, Fang X, et al. Dual Role of WISP1 in maintaining glioma stem cells and tumor-supportive macrophages in glioblastoma. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-16827-z .
Zimmer AM, Pan YK, Chandrapalan T, Kwong RWM, Perry SF. Loss-of-function approaches in comparative physiology: is there a future for knockdown experiments in the era of genome editing ? J Exp Biol. 2019;222(7): jeb175737.
Prelich G. Gene overexpression: uses, mechanisms, and interpretation. Genetics. 2012;190:841–54.
Beltrao P, Bork P, Krogan NJ, Van NV. Evolution and functional cross-talk of protein post-translational modifications. Mol Syst Biol. 2013;9(714):1–13.
Tai H-C, Chang A-C, Yu H-J, Huang C-Y, Lai Y-W, Sun H-L, et al. Osteoblast-derived WISP-1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget. 2014;5(17):7589.
Chang A-C, Lien M-Y, Tsai M-H, Hua C-H. WISP-1 promotes epithelial-mesenchymal transition in oral squamous cell carcinoma cells via the miR-153–3p/Snail axis. Cancers. 2019;11(1903):1–16.
Chuang JY, Chang AC, Chiang IP, Tsai MH, Tang CH. Apoptosis signal-regulating kinase 1 is involved in WISP-1-promoted cell motility in human oral squamous cell carcinoma cells. PLoS ONE. 2013;8(10): e78022.
Chuang JY, Chen PC, Tsao CW, Chang AC, Lein MY, Lin CC, et al. WISP-1, a novel angiogenic regulator of the CCN family, promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression. Oncotarget. 2015;6(6):4239–52.
Lin CC, Chen PC, Lein MY, Tsao CW, Huang CC, Wang SW, et al. WISP-1 promotes VEGF-C-dependent lymphangiogenesis by inhibiting miR-300 in human oral squamous cell carcinoma cells. Oncotarget. 2016;7(9):9993–10005.
Lee H-L, Chiou H-L, Wang S-S, Hung S-C, Chou M-C, Yang S-F, et al. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma. Urol Oncol Semin Orig Investig. 2018;36(4):160.e15-160.e21. https://doi.org/10.1016/j.urolonc.2017.11.023 .
Chen CT, Lee HL, Chiou HL, Chou CH, Wang PH, Yang SF, et al. Impacts of wnt1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development. PLoS ONE. 2018;13(6):1–15.
He J, Wang Z, Wang Y, Zou T, Li XP, Cao L, et al. The effects of WISP1 polymorphisms on the prognosis of lung cancer patients with platinum-based chemotherapy. Pharmgenomics Pers Med. 2021;14:1193–203.
Chen J, Yin J, Li X, Wang Y, Zheng Y, Qian C, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int J Mol Sci. 2014;15:21011–27.
Van Den Bosch MHJ, Ramos YFM, Den Hollander W, Bomer N, Nelissen RGHH, Bovée JVMG, et al. Increased WISP1 expression in human osteoarthritic articular cartilage is epigenetically regulated and decreases cartilage matrix production. Rheumatology. 2019;58(6):1065–74.
Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP. Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features 1. Cancer Res. 2001;61:8917–23.
CAS PubMed Google Scholar
Fang F, Xu W, Zhang J, Gu J, Yang G. Ultrasound microbubble-mediated RNA interference targeting WNT1 inducible signaling pathway protein 1 (WISP1) suppresses the proliferation and metastasis of breast cancer cells. Bioengineered. 2022;13(4):11050–60. https://doi.org/10.1080/21655979.2022.2068738 .
Ii DJK. Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity : a retrospective study. PLoS Comput Biol. 2014;10(1): e1003409.
Mirza Z, Ansari S, Iqbal S, Ahmad N, Alganmi N, Banjar H, et al. Identification of novel diagnostic and prognostic gene signature biomarkers for breast cancer using artificial intelligence and machine learning assisted transcriptomics analysis. Cancers. 2023. https://doi.org/10.3390/cancers15123237 .
Jia H, Janjanam J, Wu SC, Wang R, Pano G, Celestine M, et al. The tumor cell - secreted matricellular protein WISP 1 drives pro-metastatic collagen linearization. FASEB J. 2019. https://doi.org/10.1096/fj.202000713RR .
Liu S, Wu D, Sun X, Fan Y, Zha R, Jalali A, et al. Mechanical stimulations can inhibit local and remote tumor progression by downregulating WISP1. FASEB J. 2020;34(9):12847–59.
Li Y, Zhu Z, Hou X, Sun Y. LncRNA AFAP1-AS1 promotes the progression of colorectal cancer through miR-195–5p and WISP1. J Oncol. 2021;2021:1–10.
Nagai Y, Watanabe M, Ishikawa S, Karashima R, Kurashige J, Iwagami S, et al. Clinical significance of Wnt-induced secreted protein-1 ( WISP-1/CCN4) in esophageal squamous cell carcinoma. Anticancer Res. 2011;998:991–7.
Yang C, Li F, Zhou W, Huang J. Knockdown of long non-coding RNA CCAT2 suppresses growth and metastasis of esophageal squamous cell carcinoma by inhibiting the β-catenin/WISP1 signaling pathway. J Int Med Res. 2021;49(5):030006052110199.
Jing D, Zhang Q, Yu H, Zhao Y, Shen L. Identification of WISP1 as a novel oncogene in glioblastoma. Int J Oncol. 2017;51:1261–70.
Wang L, Sun J, Gao P, Su K, Wu H, Junli L, et al. Wnt1-inducible signaling protein 1 regulates laryngeal squamous cell carcinoma glycolysis and chemoresistance via the YAP1/TEAD1/GLUT1 pathway. J Cell Physiol. 2019. https://doi.org/10.1002/jcp.28253 .
Wang L, Sun J, Cao H. MicroRNA-384 regulates cell proliferation and apoptosis through directly targeting WISP1 in laryngeal cancer. J Cell Biochem. 2018;2019:3018–26.
Yan J, Lei J, Chen L, Deng H, Dong D, Jin T, et al. Human leukocyte antigen F locus adjacent transcript 10 overexpression disturbs WISP1 protein and mRNA expression to promote hepatocellular carcinoma progression. Hepatology. 2018;68(6):2268–84.
Margalit O, Eisenbach L, Amariglio N, Kaminski N, Harmelin A, Pfeffer R, et al. Overexpression of a set of genes, including WISP-1, common to pulmonary metastases of both mouse D122 Lewis lung carcinoma and B16-F10.9 melanoma cell lines. Br J Cancer. 2003;89(2):314–9.
Clausen MJAM, Melchers LJ, Mastik MF, Slagter-menkema L. Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinoma. Genes Chromosom Cancer. 2016;59:45–59.
Tsai H-C, Tzeng H-E, Huang C-Y, Huang Y-L, Tsai C-H, Wang S-W, et al. WISP-1 positively regulates angiogenesis by controlling VEGF-A expression in human osteosarcoma. Cell Death Dis. 2017;8(4):e2750-11. https://doi.org/10.1038/cddis.2016.421 .
Graumann J, Finkernagel F, Reinartz S, Stief T, Brödje D, Renz H, et al. Multi-platform affinity proteomics identify proteins linked to metastasis and immune suppression in ovarian cancer plasma. Front Oncol. 2019;9:1–12.
Ono M, Inkson CA, Sonn R, Kilts TM, de Castro LF, Maeda A, et al. WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS ONE. 2013;8(8): e71709.
Mao A, Tang J, Tang D, Wang F, Liao S, Yuan H, et al. MicroRNA-29b-3p enhances radiosensitivity through modulating WISP1-mediated mitochondrial apoptosis in prostate cancer cells. J Cancer. 2020;11:6356.
Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, et al. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncoimmunology. 2019;8(5):1–18. https://doi.org/10.1080/2162402X.2019.1581545 .
Chang AC, Chen PC, Lin YF, Su CM, Liu JF, Lin TH, et al. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018;426:47–56. https://doi.org/10.1016/j.canlet.2018.03.050 .
Chang KS, Chen ST, Sung HC, Hsu SY, Lin WY, Hou CP, et al. WNT1 inducible signaling pathway protein 1 is a stroma-specific secreting protein inducing a fibroblast contraction and carcinoma cell growth in the human prostate. Int J Mol Sci. 2022;23(19):1–18.
Chang AC, Lin LW, Chen YC, Chen PC, Liu SC, Tai HC, et al. The ADAM9/WISP-1 axis cooperates with osteoblasts to stimulate primary prostate tumor growth and metastasis. Int J Biol Sci. 2023;19(3):760–71.
Zheng Y, Chen CJ, Lin ZY, Li JX, Liu J, Lin FJ, et al. Circ_KATNAL1 regulates prostate cancer cell growth and invasiveness through the mir-145-3p/WISP1 pathway. Biochem Cell Biol. 2020;98(3):396–404.
Deng W, Fernandez A, McLaughlin SL, Klinke DJ. WNT1-inducible signaling pathway protein 1 (WISP1/CCN4) stimulates melanoma invasion and metastasis by promoting the epithelial mesenchymal transition. J Biol Chem. 2019;294(14):5261–80.
Deng W, Fernandez A, McLaughlin SL, Klinke DJ. Cell communication network factor 4 (CCN4/WISP1) shifts melanoma cells from a fragile proliferative state to a resilient metastatic state. Cell Mol Bioeng. 2020;13(1):45–60.
Pirkey AC, Deng W, Norman D, Razazan A, Klinke DJ. Head-to-head comparison of CCN4, DNMT3A, PTPN11, and SPARC as suppressors of anti-tumor immunity. Cell Mol Bioeng. 2023;16(5–6):431–42. https://doi.org/10.1007/s12195-023-00787-7 .
Plikus MV, Wang X, Sinha S, Forte E, Thompson SM. Fibroblasts: origins, definitions, and functions in health and disease. Cell. 2021;184(15):3852–72. https://doi.org/10.1016/j.cell.2021.06.024 .
Kendall RT, Feghali-bostwick CA, Rauch BH. Fibroblasts in fibrosis: novel roles and mediators. Front Pharmacol. 2014;5:1–13.
Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.
Abuserewa ST, Duff R, Becker G. Treatment of idiopathic pulmonary fibrosis. Cureus. 2021;13(5):1–10.
Liu J, Lv S, Ma W, Yang D, Zhang X. Effect of WISP1 on paraquat-induced EMT. Toxicol Vitro. 2023;93:105693. https://doi.org/10.1016/j.tiv.2023.105693 .
Sun Z, Yang Z, Wang M, Huang C, Ren Y, Zhang W, et al. Paraquat induces pulmonary fibrosis through Wnt/β-catenin signaling pathway and myofibroblast differentiation. Toxicol Lett. 2020;333(June):170–83. https://doi.org/10.1016/j.toxlet.2020.08.004 .
Berschneider B, Ellwanger DC, Baarsma HA, Thiel C, Shimbori C, White ES, et al. MiR-92a regulates TGF-β1-induced WISP1 expression in pulmonary fibrosis. Int J Biochem Cell Biol. 2014;53:432–41. https://doi.org/10.1016/j.biocel.2014.06.011 .
Pommier A, Varilh J, Bleuse S, Delétang K, Bonini J, Bergougnoux A, et al. miRNA repertoires of cystic fibrosis ex vivo models highlight miR-181a and miR-101 that regulate WISP1 expression. J Pathol. 2021;253(2):186–97.
Injury E, Fibrosis IP. Epithelial injury and dysfunction in the pathogenesis of idiopathic pulmonary fibrosis. Am J Med Sci. 2020;357(5):374–8.
Singh K, Teyani RL, Moniri NH. Agonists and hydrogen peroxide mediate hyperoxidation of β 2-adrenergic receptor in airway epithelial cells : implications for tachyphylaxis to β 2-agonists in constrictive airway disorders. Biomed Pharmacother. 2023;168:115763. https://doi.org/10.1016/j.biopha.2023.115763 .
Heijink IH, Kuchibhotla VNS, Roffel MP, Maes T, Knight DA, Sayers I, et al. Epithelial cell dysfunction, a major driver of asthma development. Allergy. 2020;75:1902–17.
Heise RL, Stober V, Cheluvaraju C, Hollingsworth JW, Garantziotis S. Mechanical stretch induces epithelial-mesenchymal transition in alveolar epithelia via hyaluronan activation of innate immunity. J Biol Chem. 2011;286(20):17435–44.
Stephens S, Palmer J, Konstantinova I, Pearce A, Jarai G, Day E. A functional analysis of Wnt inducible signalling pathway protein−1 (WISP-1/CCN4). J Cell Commun Signal. 2015;9(1):63–72.
Zhang C, Zhu Y, Zhang Y, Gao L, Zhang N, Feng H. Therapeutic potential of umbilical cord mesenchymal stem cells for inhibiting myofibroblastic differentiation of irradiated human lung fibroblasts. Tohoku J Exp Med. 2015;236(3):209–17.
Li X, Liu X, Deng R, Gao S, Yu H, Huang K, et al. Nintedanib inhibits Wnt3a-induced myofibroblast activation by suppressing the Src/b-catenin pathway. Front Pharmacol. 2020;11:1–11.
Lehmann M, Buhl L, Alsafadi HN, Klee S, Hermann S, Mutze K, et al. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis. Respir Res. 2018;19(1):1–12.
Huang X, Cai H, Ammar R, Zhang Y, Wang Y, Ravi K, et al. Molecular characterization of a precision-cut rat liver slice model for the evaluation of antifibrotic compounds. Am J Physiol Gastrointest Liver Physiol. 2019;316(1):G15-24.
Pivovarova-Ramich O, Loske J, Hornemann S, Markova M, Seebeck N, Rosenthal A, et al. Hepatic wnt1 inducible signaling pathway protein 1 (WISP-1/CCN4) associates with markers of liver fibrosis in severe obesity. Cells. 2021;10(5):1048.
Chen Z, Ding X, Jin S, Pitt B, Zhang L, Billiar T, et al. WISP1-αvβ3 integrin signaling positively regulates TLR-triggered inflammation response in sepsis induced lung injury. Sci Rep. 2016;6:1–11. https://doi.org/10.1038/srep28841 .
Rong X, Liu J, Yao X, Jiang T, Wang Y, Xie F. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway. Stem Cell Res Ther. 2019;10(1):1–11.
Jian YC, Wang JJ, Dong S, Hu JW, Hu LJ, Yang GM, et al. Wnt-induced secreted protein 1/CCN4 in liver fibrosis both in vitro and in vivo. Clin Lab. 2014;60(1):29–35.
Li X, Chen Y, Ye W, Tao X, Zhu J, Wu S, et al. Blockade of CCN4 attenuates CCl4-induced liver fibrosis. Arch Med Sci. 2015;11(3):647–53.
Ono M, Masaki A, Maeda A, Kilts TM. CCN4 / WISP1 controls cutaneous wound healing by modulating proliferation, migration and ECM expression in dermal fibroblasts via α 5 β 1 and TNF α. Matrix Biol. 2018;68–69:533–46. https://doi.org/10.1016/j.matbio.2018.01.004 .
Tank J, Lindner D, Wang X, Stroux A, Gilke L, Gast M, et al. Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts. J Mol Cell Cardiol. 2014;66:141–56.
Green LC, Slone S, Anthony SR, Guarnieri AR, Parkins S, Shearer SM, et al. HuR-dependent expression of Wisp1 is necessary for TGFβ-induced cardiac myofibroblast activity. J Mol Cell Cardiol. 2022;2023(174):38–46.
Zhong X, Tu YJ, Li Y, Zhang P, Wang W, Chen SS, et al. Serum levels of WNT1-inducible signaling pathway protein-1 (WISP-1): a noninvasive biomarker of renal fibrosis in subjects with chronic kidney disease. Am J Transl Res. 2017;9(6):2920–32.
Zhou Y, Chai P, Wang J, Li L, Chen MH. Wingless/int-1induced secreted protein-1: a new biomarker for renal fibrosis. J Biol Regul Homeost Agents. 2021;35(1):33480221.
Hennemeier I, Humpf HU, Gekle M, Schwerdt G. The food contaminant and nephrotoxin ochratoxin A enhances Wnt1 inducible signaling protein 1 and tumor necrosis factor-α expression in human primary proximal tubule cells. Mol Nutr Food Res. 2012;56(9):1375–84.
Yang X, Wang H, Tu Y, Li Y, Zou Y, Li G, et al. WNT1-inducible signaling protein-1 mediates TGF-β1-induced renal fibrosis in tubular epithelial cells and unilateral ureteral obstruction mouse models via autophagy. J Cell Physiol. 2020;235(3):2009–22.
Wang B, Ding C, Ding X, Tesch G, Zheng J, Tian PY, et al. WNT1-inducible signaling pathway protein 1 regulates kidney inflammation through the NF-κB pathway. Clin Sci. 2022;136(1):29–44.
Ai K, Yi L, Wang Y, Li Y. CircRNA_33702 promotes renal fibrosis by targeting the miR-29b-3p/WNT1-inducible signaling pathway protein 1 pathway. J Pharmacol Exp Ther. 2023;384(1):225–6.
Liang J-N, Zou X, Fang X-H, Xu J-D, Xiao Z, Zhu J-N, et al. The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosis. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2441–50. https://doi.org/10.1016/j.bbadis.2019.06.004 .
Gong X, Wang X, Zhou F. Liver microRNA-29b-3p positively correlates with relative enhancement values of magnetic resonance imaging and represses liver fibrosis. J Biochem. 2020;168(6):603–9.
Xue Y, Fan X, Yang R, Jiao Y, Li Y. miR-29b-3p inhibits post-infarct cardiac fibrosis by targeting FOS. Biosci Rep. 2020;40(9):1–11.
Fan X, Gao Y, Zhang X, Lughmani HY, Kennedy DJ, Haller ST, et al. A strategic expression method of miR-29b and its anti-fibrotic effect based on RNA-sequencing analysis. PLoS ONE. 2020;15:1–16. https://doi.org/10.1371/journal.pone.0244065 .
Chen H, Fan Y, Jing H, Tang S, Huang Z, Liao M, et al. LncRNA Gm12840 mediates WISP1 to regulate ischemia-reperfusion-induced renal fibrosis by sponging miR-677-5p. Epigenomics. 2020;12(24):2205–18.
Abd El-Kader T, Kubota S, Janune D. Anti-fibrotic effect of CCN3 accompanied by altered gene expression profile of the CCN family. J Cell Commun Signal. 2013;7:11–8.
Leask A. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic? J Cell Commun Signal. 2015;9(1):97–8.
Leask A. CCN3: a novel anti-fibrotic treatment in end-stage renal disease? J Cell Commun Signal. 2012;6(2):115–6.
Lin X, Li H. Obesity: epidemiology, pathophysiology, and therapeutics. Front Endocrinol. 2021;12(September):1–9.
Coelho M, Oliveira T, Fernandes R. Biochemistry of adipose tissue: an endocrine organ. Arch Med Sci. 2013;9(2):191–200.
Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11:85–97.
Murahovschi V, Pivovarova O, Ilkavets I, Dmitrieva RM, Döcke S, Keyhani-Nejad F, et al. WISP1 Is a novel adipokine linked to inflammation in obesity. Diabetes. 2015;64(3):856–66.
Martinerie C, Garcia M, Do TTH, Antoine B, Moldes M, Dorothee G, et al. NOV/CCN3: A new adipocytokine involved in obesity-associated insulin resistance. Diabetes. 2016;65(9):2502–15.
Tacke C, Aleksandrova K, Rehfeldt M, Murahovschi V, Markova M, Kemper M, et al. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP-1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal. 2018;12(3):539–48.
Barchetta I, Cimini FA, Capoccia D, De Gioannis R, Porzia A, Mainiero F, et al. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc. 2017;1:660–70.
Hörbelt T, Tacke C, Markova M, de Wiza DH, Van de Velde F, Bekaert M, et al. The novel adipokine WISP1 associates with insulin resistance and impairs insulin action in human myotubes and mouse hepatocytes. Diabetologia. 2018;61(9):2054–65.
Jung TW, Kang C, Goh J, Chae SI, Kim HC, Lee TJ, et al. WISP1 promotes non-alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol. 2018;233(8):6077–87.
Fernandez-ruiz R, García-alamán A, Esteban Y, Mir-coll J, Serra-navarro B, Fontcuberta-pisunyer M, et al. Wisp1 is a circulating factor that stimulates proliferation of adult mouse and human beta cells. Nat Commun. 2020. https://doi.org/10.1038/s41467-020-19657-1 .
Seong JK, Park J. Identification of differentially expressed mRNA during pancreas regeneration of rat by mRNA differential display. Biochem Biophys Res Commun. 2002;299:806–12.
Kapasa M, Sera I, Gavalas A, Kossida S. Genomics identification of phylogenetically conserved enhancer elements implicated in pancreas development in the WISP1 and CTGF orthologs. Genomics. 2008;92:301–8.
Chen Y, Li P, Lin M, Jiang Y, Tan G, Huang L, et al. Silencing of METTL3 prevents the proliferation, migration, epithelial-mesenchymal transition, and renal fibrosis of high glucose-induced HK2 cells by mediating WISP1 in m6A-dependent manner. Aging. 2024;16(2):1237–48.
Liu L, Hu J, Yang L, Wang N, Liu Y, Wei X, et al. Association of WISP1/CCN4 with risk of overweight and gestational diabetes mellitus in Chinese pregnant women. Dis Markers. 2020;2020:1–10.
CAS Google Scholar
Sahin Ersoy G, Altun Ensari T, Subas S, Giray B, Simsek EE, Cevik O. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Neonatal Med. 2017;30(8):942–6.
French DM, Kaul RJ, Souza ALD, Crowley CW, Bao M, Frantz GD, et al. WISP-1 is an osteoblastic regulator expressed during skeletal development and fracture repair. Am J Pathol. 2004;165(3):855–67.
Khanna D, Khanna S, Khanna P, Kahar P, Patel BM. Obesity: a chronic low-grade inflammation and its markers. Cureus. 2022;14(2): e2271.
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Investig. 2007;117(1):175–84.
Lacy P, Murray RZ, Moraes-vieira PM. The macrophage switch in obesity. Development. 2016;6(Jan):1–11.
Chang JS, Kim TH, Kong ID. Exercise intervention lowers aberrant serum WISP-1 levels with insulin resistance in breast cancer survivors : a randomized controlled trial. Sci Rep. 2020;10(2):1–9. https://doi.org/10.1038/s41598-020-67794-w .
Yu Z, Wang T, Zhang L, Yang X, Li Q, Ding X. WISP1 and TLR4 on macrophages contribute to ventilator-induced lung injury. Inflammation. 2020;43(2):425–32.
Liu L, Xu S, Li P, Li L. A novel adipokine WISP1 attenuates lipopolysaccharide-induced cell injury in 3T3-L1 adipocytes by regulating the PI3K/Akt pathway. Obes Res Clin Pract. 2022;16(2):122–9. https://doi.org/10.1016/j.orcp.2022.03.001 .
Ferrand N, Béreziat V, Moldes M, Zaoui M, Larsen AK, Sabbah M. WISP1/CCN4 inhibits adipocyte differentiation through repression of PPAR γ activity. Sci Rep. 2017;7:1–12.
Senthelal S, Li J, Ardeshirzadeh S, Thomas MA. Arthritis. StatPearls: Treasure Island; 2023.
Eakin GS, Amodeo KL, Kahlon RS. Arthritis and its public health burden. Del J Public Heal. 2017;3(1):36–44.
Komatsu M, Nakamura Y, Maruyama M, Abe K, Watanapokasin R, Kato H. Expression profiles of human CCN genes in patients with osteoarthritis or rheumatoid arthritis. J Orthop Sci. 2015;20(4):708–16.
Macsai CE, Georgiou KR, Foster BK, Zannettino ACW, Xian CJ. Microarray expression analysis of genes and pathways involved in growth plate cartilage injury responses and bony repair. Bone. 2012;50(5):1081–91. https://doi.org/10.1016/j.bone.2012.02.013 .
Geyer M, Grässel S, Straub RH, Schett G, Dinser R, Grifka J, et al. Differential transcriptome analysis of intraarticular lesional vs intact cartilage reveals new candidate genes in osteoarthritis pathophysiology. Osteoarthr Cartil. 2009;17(3):328–35.
Chou CH, Wu CC, Song IW, Chuang HP, Lu LS, Chang JH, et al. Genome-wide expression profiles of subchondral bone in osteoarthritis. Arthr Res Ther. 2013;15(6):R190.
Chen S, Li B. MiR-128-3p post-transcriptionally inhibits WISP1 to suppress apoptosis and inflammation in human articular chondrocytes via the PI3K/AKT/NF-κB signaling pathway. Cell Transpl. 2020;29(8):1–13.
van den Bosch MH, Blom AB, Kram V, Maeda A, Sikka S, Gabet Y, et al. WISP1/CCN4 aggravates cartilage degeneration in experimental osteoarthritis. Osteoarthr Cartil. 2017;25(11):1900–11. https://doi.org/10.1016/j.joca.2017.07.012 .
Cheng C, Tian J, Zhang F, Deng Z, Tu M, Li L, et al. WISP1 protects against chondrocyte senescence and apoptosis by regulating αvβ3 and PI3K/Akt pathway in osteoarthritis. DNA Cell Biol. 2021;40(4):629–37.
Zhang M, Meng QC, Yang XF, Mu WD. TGF-β1/WISP1/Integrin-α interaction mediates human chondrocytes dedifferentiation. Eur Rev Med Pharmacol Sci. 2020;24(17):8675–84.
Van den Bosch MH, Blom AB, van Lent PL, van Beuningen HM, Blaney Davidson EN, van der Kraan PM, et al. Canonical Wnt signaling skews TGF-β signaling in chondrocytes towards signaling via ALK1 and smad 1/5/8. Cell Signal. 2014;26(5):951–8. https://doi.org/10.1016/j.cellsig.2014.01.021 .
Hou CH, Tang CH, Hsu CJ, Hou SM, Liu JF. CCN4 induces IL-6 production through αvβ5 receptor, PI3K, Akt, and NF-κB singling pathway in human synovial fibroblasts. Arthr Res Ther. 2013;15(1):R19.
Charlier E, Deroyer C, Ciregia F, Malaise O, Neuville S, Plener Z, et al. Chondrocyte dedifferentiation and osteoarthritis (OA). Biochem Pharmacol. 2019;165(Feb):49–65. https://doi.org/10.1016/j.bcp.2019.02.036 .
Timmermans RGM, Blom AB, Bloks NGC, Nelissen RGHH, van der Linden EHMJ, van der Kraan PM, et al. CCN4/WISP1 promotes migration of human primary osteoarthritic chondrocytes. Cartilage. 2023;14(1):67–75.
Ono M, Inkson CA, Kilts TM, Young MF. WISP-1/CCN4 regulates osteogenesis by enhancing BMP-2 activity. J Bone Miner Res. 2011;26(1):193–208.
Cernea M, Tang W, Guan H, Yang K. Wisp1 mediates Bmp-3 stimulated mesenchymal stem cell proliferation. J Mol Endocrinol. 2016;56(1):39–46.
Liu JF, Hou SM, Tsai CH, Huang CY, Hsu CJ, Tang CH. CCN4 induces vascular cell adhesion molecule-1 expression in human synovial fibroblasts and promotes monocyte adhesion. Biochim Biophys Acta Mol Cell Res. 2013;1833(5):966–75. https://doi.org/10.1016/j.bbamcr.2012.12.023 .
Urano T, Narusawa K, Shiraki M, Usui T, Sasaki N, Hosoi T, et al. Association of a single nucleotide polymorphism in the WISP1 gene with spinal osteoarthritis in postmenopausal Japanese women. J Bone Miner Metab. 2007;25(4):253–8.
Download references
The authors wish to acknowledge Dr. Kannan Thirunavukkarasu and Dr. Marta A. Witek for providing critical feedback on the manuscript. The authors would also like to thank the Department of Biotherapeutic Enabling Biology for all the help and support.
The work was supported and funded by Eli Lilly and Company.
Authors and affiliations.
Biotherapeutic Enabling Biology, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46225, USA
Kirti Singh & Sunday S. Oladipupo
You can also search for this author in PubMed Google Scholar
KS conceptualized, compiled, reviewed literature, edited, designed figures, tables and wrote the manuscript. SSO supervised, reviewed, edited, and provided critical feedback on the manuscript. All the authors read and approved the final manuscript.
Correspondence to Sunday S. Oladipupo .
Ethics approval and consent to participate.
Not Applicable.
Competing interests.
The authors have no competing interests related to this work.
Publisher's note.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ . The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/ ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Reprints and permissions
Cite this article.
Singh, K., Oladipupo, S.S. An overview of CCN4 (WISP1) role in human diseases. J Transl Med 22 , 601 (2024). https://doi.org/10.1186/s12967-024-05364-8
Download citation
Received : 02 April 2024
Accepted : 01 June 2024
Published : 27 June 2024
DOI : https://doi.org/10.1186/s12967-024-05364-8
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
ISSN: 1479-5876
COMMENTS
Step 1: Restate the problem. The first task of your conclusion is to remind the reader of your research problem. You will have discussed this problem in depth throughout the body, but now the point is to zoom back out from the details to the bigger picture. While you are restating a problem you've already introduced, you should avoid phrasing ...
Write your research paper conclusion 2x faster with Paperpal. Try it now! Remember that a well-crafted research paper conclusion is a reflection of the strength of your research and your ability to communicate its significance effectively. It should leave a lasting impression on your readers and tie together all the threads of your paper.
Step 1: Return to your thesis. To begin your conclusion, signal that the essay is coming to an end by returning to your overall argument. Don't just repeat your thesis statement —instead, try to rephrase your argument in a way that shows how it has been developed since the introduction. Example: Returning to the thesis.
Highlight the "so what". At the beginning of your paper, you explain to your readers what's at stake—why they should care about the argument you're making. In your conclusion, you can bring readers back to those stakes by reminding them why your argument is important in the first place. You can also draft a few sentences that put ...
Research Paper Conclusion. Definition: A research paper conclusion is the final section of a research paper that summarizes the key findings, significance, and implications of the research. It is the writer's opportunity to synthesize the information presented in the paper, draw conclusions, and make recommendations for future research or ...
The point of a conclusion to a research paper is to summarize your argument for the reader and, perhaps, to call the reader to action if needed. 5. Make a call to action when appropriate. If and when needed, you can state to your readers that there is a need for further research on your paper's topic.
Step 1: Answer your research question. Step 2: Summarize and reflect on your research. Step 3: Make future recommendations. Step 4: Emphasize your contributions to your field. Step 5: Wrap up your thesis or dissertation. Full conclusion example. Conclusion checklist. Other interesting articles.
Begin your conclusion by restating your thesis statement in a way that is slightly different from the wording used in the introduction. Avoid presenting new information or evidence in your conclusion. Just summarize the main points and arguments of your essay and keep this part as concise as possible. Remember that you've already covered the ...
The conclusion is intended to help the reader understand why your research should matter to them after they have finished reading the paper. A conclusion is not merely a summary of the main topics covered or a re-statement of your research problem, but a synthesis of key points derived from the findings of your study and, if applicable based on your analysis, explain new areas for future research.
Begin with a clear statement of the principal findings. This will reinforce the main take-away for the reader and set up the rest of the discussion. Explain why the outcomes of your study are important to the reader. Discuss the implications of your findings realistically based on previous literature, highlighting both the strengths and ...
Research paper conclusion examples. Below, we've created basic templates showing the key parts of a research paper conclusion. Keep in mind that the length of your conclusion will depend on the length of your paper. The order of the parts may vary, too; these templates only demonstrate how to tie them together. 1. Empirical research paper ...
Step 1: Restate the problem. Always begin by restating the research problem in the conclusion of a research paper. This serves to remind the reader of your hypothesis and refresh them on the main point of the paper. When restating the problem, take care to avoid using exactly the same words you employed earlier in the paper.
This article provides an effective technique for writing a conclusion adapted from Erika Eby's The College Student's Guide to Writing a Good Research Paper: 101 Easy Tips & Tricks to Make Your Work Stand Out.. While the thesis introduction starts out with broad statements about the topic, and then narrows it down to the thesis statement, a thesis conclusion does the same in the opposite order.
Make sure your research paper conclusions stand on solid ground. Avoid vague platitudes in your conclusion. Your goal should be reaching strong, sound judgments, firmly grounded in your readings and research. Better to claim too little than too much. Best of all, claim what you've earned the right to say: what your research really means. ...
Writing a Conclusion. A conclusion is an important part of the paper; it provides closure for the reader while reminding the reader of the contents and importance of the paper. It accomplishes this by stepping back from the specifics in order to view the bigger picture of the document. In other words, it is reminding the reader of the main ...
The conclusion is where you describe the consequences of your arguments by justifying to your readers why your arguments matter (Hamilton College, 2014). Derntl (2014) also describes conclusion as the counterpart of the introduction. Using the Hourglass Model (Swales, 1993) as a visual reference, Derntl describes conclusion as the part of the ...
A conclusion is the final paragraph of a research paper and serves to help the reader understand why your research should matter to them. The conclusion of a conclusion should: Restate your topic and why it is important. Restate your thesis/claim. Address opposing viewpoints and explain why readers should align with your position.
Offer a Fresh Perspective: Use the conclusion as an opportunity to provide a fresh perspective or offer insights that go beyond the main body of the paper. This will leave the reader with something new to consider. Leave a Lasting Impression: End your conclusion with a thought-provoking statement or a call to action.
1. Remember about the main topic. The statement must be written clearly and concisely to be effective, just one sentence. Remember that your conclusion should be concise and precise, expressing only the most important elements. 2. Reaffirm your thesis. Restate the research paper's thesis after that.
1. New Data: In a research paper conclusion, avoid presenting new data or evidence that wasn't discussed earlier in the paper. It's the time to summarize, analyze, or explain the significance of data already provided, not to introduce new material. 2. Irrelevant Details: The conclusion is not the spot for extraneous details not directly ...
To write a conclusion for a research paper, begin by summarizing the main findings or results of your study. Restate your thesis statement or research question and briefly recap the key points discussed in the paper. Reflect on the significance of your findings and discuss their implications for the broader field of study or real-world ...
The conclusion of a research paper has several key objectives. It should: Restate your research problem addressed in the introduction section. Summarize your main arguments, important findings, and broader implications. Synthesize key takeaways from your study. The specific content in the conclusion depends on whether your paper presents the ...
To demonstrate how to write a conclusion, I will be using WPS Office, a tool designed to be convenient for students, thanks to its easy-to-use interface and free features. You can also utilize WPS AI, as I am in these simple 4 steps, to make the entire process smoother for yourself. ... So if you are stuck with a conclusion or a research paper ...
A second element of structure is the nature of conclusions or calls to action in messages and culturally based preferences in the nature ... The studies using community-based participatory research principles focused on making health messages and interventions culturally centered and relevant for target audiences by engaging directly with the ...
Research paper conclusion examples. Below, we've created basic templates showing the key parts of a research paper conclusion. Keep in mind that the length of your conclusion will depend on the length of your paper. The order of the parts may vary, too; these templates only demonstrate how to tie them together. 1. Empirical research paper ...
Background: The demand for complex home care is increasing with the growing aging population and the ongoing COVID-19 pandemic. Family and hired caregivers play a critical role in providing care for individuals with complex home care needs. However, there are significant gaps in research informing the design of complex home care technologies that consider the experiences of family and hired ...
Online Surveys and Market Research. Participating in online surveys and market research can be an easy way to make some extra cash. Websites like Swagbucks, Survey Junkie, and Vindale Research pay users for their opinions on various products and services. While this won't make you rich, it's a simple way to earn money in your spare time ...
This review emphasizes the need for future eHealth self-management research to address the digital divide, especially with the aging liver transplant recipient population, and ensure more inclusive studies across diverse ethnicities and regions. ... Conclusions: This scoping review maps the current literature on eHealth-based self-management ...
The central component in impactful healthcare decisions is evidence. Understanding how nurse leaders use evidence in their own managerial decision making is still limited. This mixed methods systematic review aimed to examine how evidence is used to solve leadership problems and to describe the measured and perceived effects of evidence-based leadership on nurse leaders and their performance ...
CCN4 (cellular communication network factor 4), a highly conserved, secreted cysteine-rich matricellular protein is emerging as a key player in the development and progression of numerous disease pathologies, including cancer, fibrosis, metabolic and inflammatory disorders. Over the past two decades, extensive research on CCN4 and its family members uncovered their diverse cellular mechanisms ...